中生北控生物科技股份有限公司

BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION *

(Incorporated in the People's Republic of China with limited liability) (Stock Code : 8247)

2018
Annual Report

* For identification purpose only

CHARACTERISTICS OF THE GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the "Directors" and each a "Director") of Biosino Bio-Technology and Science Incorporation (the "Company", together with its subsidiaries, the "Group") collectively and individually accept full responsibilities, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this report is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this report misleading.*

CONTENTS

CORPORATE INFORMATION

PRC OFFICE

No. 27 Chaoqian Road
Science and Technology Industrial Park
Changping District
Beijing, PRC

HONG KONG OFFICE

66th Floor
Central Plaza, 18 Harbour Road
Wanchai, Hong Kong

WEBSITE

http://www.zhongsheng.com.cn

BOARD OF DIRECTORS

Executive Directors
Mr. Wu Lebin *(Chairman)*
Mr. Chen Jintian *(Vice chairman)*
Dr. Xu Cunmao
Mr. Chen Jianhua

Non-executive Directors
Dr. Sun Zhe *(Vice chairman)*
Ms. Cheng Yali

Independent Non-executive Directors
Dr. Zheng Yongtang
Mr. Wang Daixue
Mr. Pan Chunyu

SUPERVISORS

Mr. Zhou Jie
Ms. Huang Aiyu
Dr. Shen Sheng

AUDIT COMMITTEE

Dr. Zheng Yongtang *(Chairman)*
Mr. Wang Daixue
Mr. Pan Chunyu

REMUNERATION COMMITTEE

Dr. Zheng Yongtang *(Chairman)*
Mr. Wang Daixue
Mr. Pan Chunyu

NOMINATION COMMITTEE

Mr. Pan Chunyu *(Chairman)*
Dr. Zheng Yongtang
Mr. Wu Lebin
Mr. Wang Daixue

COMPANY SECRETARY

Mr. Tung Woon Cheung Eric CPA, CPA (U.S.)

QUALIFIED ACCOUNTANT

Mr. Cheung Yeung CPA

AUTHORISED REPRESENTATIVES

Mr. Wu Lebin
Mr. Tung Woon Cheung Eric

COMPLIANCE OFFICER

Mr. Wu Lebin

AUDITORS

Ernst & Young

LEGAL ADVISERS

As to Hong Kong law:
Loong & Yeung Solicitors

HONG KONG H SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Investor Services Limited
Level 22, Hopewell Centre
183 Queen's Road East
Hong Kong

PRINCIPAL BANKERS

Bank of Beijing
Industrial and Commercial Bank of China
Bank of China (Hong Kong) Limited

INFORMATION OF H SHARES

Place of listing:	GEM
Stock code:	8247
Number of H shares issued:	64,286,143 H shares
Nominal value:	RMB1.00 per H share
Stock short name:	Biosino Bio-Tec

GROUP PROFILE

GROUP STRUCTURE

As at 19 March 2019



* The H shares of Biosino Bio-Technology and Science Incorporation (the "Company" or "Bio-Tech") are listed on the GEM

\# The shares of Beijing Enterprises Holdings Limited ("Beijing Enterprises") are listed on the Main Board of the Stock Exchange

△ Mr. Chen Jintian holds 16.93% and 4.69% of Biosino Bio-Tech via Beijing Shuoze Health Industry Investment Company Limited ("Beijing Shuoze") and HK Future Investment Group Limited ("HK Future") respectively, totalling 21.62% shareholding.

FINANCIAL HIGHLIGHTS

- Revenue for the year amounted to approximately RMB303 million, representing an increase of 2.7% from that of last year.
- The Board has proposed a final dividend of RMB0.1 per share for the year ended 31 December 2018.

1. REVENUE FOR THE YEAR

(RMB hundred million)



CHAIRMAN'S STATEMENT

Unity, Regulated, Courage, Efficiency, Win-Win

Dear shareholders,

It is with great pleasure that, on behalf of the board of directors (collectively referred to as the "Board") of Biosino Bio-Technology and Science Corporation (the "Company"), I hereby present to you the annual report of the Company together with its subsidiaries (collectively referred to as the "Group") for the year ended 31 December 2018 (hereinafter referred to the "Year" or "Reporting Period").

The Group, in upholding the principle of "enrichment of living standards through the use of science and technologies", earnestly implemented the resolutions of the Board and actively carried out various business activities focusing on its principal business. During the Reporting Period, the Group continued to focus on constructing our sales team and market expansion, faced intensifying fierce competition, overcame challenges due to various unfavourable factors, and vigorously explored new commercial opportunities and new mechanism. The Group and certain of its subsidiaries developed smoothly, and while continued to enhance the daily operation management methods and promoted the reinforced execution ability, and actively improved the internal mechanism in an effort to increase the core competitiveness. During the Reporting Period, the Group adjusted our deployment for some institutions and personnel, rationalised its organizational structure and completed the recruitment of competitive mid-level managerial staff smoothly, strived to optimize the personnel structure with a view to promote the overall execution ability and achieve a healthy development.

DIVIDENDS

Taking into account of the Group's financial condition, cash flow, operating and capital requirements as well as maintaining a sustainable business development in the future, the Board recommended the payment of a final dividend of RMB0.1 per share for the financial year ended 31 December 2018. During the Reporting Period, there was no arrangement under which any shareholder had waived or agreed to waive any dividends.

BUSINESS REVIEW

In 2018, the Group, in upholding the principle of "enrichment of living standards through the use of science and technologies", will pursue the enterprise culture of "Unity, Regulated, Courage, Efficiency, Win-win", and through "year of increasing income and reducing expenditure, quality, and entrepreneurship" activities, we actively carried out various business activities focusing on its principal business. During the reporting period, the Group continued to focus on constructing our sales team and market expansion, faced intensifying fierce competition, overcame challenges due to various unfavourable factors, and vigorously explored new commercial opportunities and new mechanism. The Group and certain of its subsidiaries developed smoothly, and while continued to enhance the daily operation management methods and promoted the reinforced execution ability, and actively improved the internal mechanism in an effort to increase the core competitiveness. During the Reporting Period, the Group adjusted our deployment for some institutions and personnel, rationalised its organizational structure and completed the recruitment of competitive mid-level managerial staff smoothly, strived to optimize the personnel structure with a view to promote the overall execution ability and achieve a healthy development.

During the Reporting Period, the Group aggressively and relentlessly expanded its sales channels and pushed forward product sales in segmented markets and regions through employing more sales talents, close cooperation with distributors and ultimate hospitals, and innovation of business model, and preliminary results were seen. The Company focused on increasing our investments in sales team performance orientation and realignment in terms of marketing management and introduced new employees to make the age structure younger and more efficient. The Company enhanced its budget-based performance appraisal and strived to improve the rough measures in sales work. During 2017, the Company set up 5 offices in Eastern China, Northern China, North-eastern China, Southern China and Western China in the PRC market, which not only had strengthened the close relationship with end-users, but also facilitated operational prudence and excellence in regional market with an aim to seek for regional growth and breakthrough in sales revenue.

During the Reporting Period, under the requirements of overall development strategy, the Group increased the registered capital of Beijing Biosino Medical Lab Company Limited to RMB50 million.

FUTURE PROSPECTS

In-vitro diagnostic ("IVD") is a one-time disposable consumer goods and its market demand will not shrink as there are still many unsaturated markets to be developed. Therefore, the industry will maintain a stable and rapid development trend, and is one of the fastest growing sub-sectors in the domestic medical biology segment in recent years. IVD supports the more than 70% decisive information of clinical diagnosis with its only 2% investments in the entire medical system. Thus, the in-vitro diagnostic ("IVD") has become an increasingly important component of disease prevention, diagnosis and treatment for human. In 2017, the global market size of IVD was US$79.3 billion and approximately RMB60.4 billion in China in 2018. According to the deduction of the foreign matured diagnosis market standard, China's potential market potential for IVD exceeds RMB200 billion. In China, approximately 90% of IVD reagent products market is clustered at hospitals. With increasing homogenization of diagnostic reagents, diversification in client selection and other changes, strong customer loyalty has become the key of enterprise differentiation and competitiveness.

The traditional IVD manufacturing enterprises mainly focus on distribution. During the operating process, the agents have strong bargaining power. The "hierarchical medical system" and "two-invoice system" which are being proactively pushed forward will certainly trigger a substantial change to operation channel, even business model, whereby leading to a significant change to business ecology in the industry. The agents with terminal resources become more important. At present, in the domestic IVD reagents market, biochemical diagnostic reagents and immune diagnostic reagents represented over 50% of total market size. Technically speaking, for the items broadly used in clinical application with vast market prospect (such as enzymes, lipids, liver function, blood glucose, urine test and immune reagent series in clinical biochemistry), technology standard of domestic major manufacturers has basically reached the current international level. The biochemical diagnostic market has the characteristics of higher demand and high stock level, relatively low in technology barrier and market concentration. Also, 70% of the domestic clinical biochemistry is operating under an open system. The IVD instrument and reagents have basically achieved localization and some domestic manufacturers promote the sales of their self-produced reagents through marketing high-end foreign-branded instrument as an agency. Thus, industry competition is increasingly fierce. However, the application of new technology and the development of new projects are far less active than immune diagnosis and molecular diagnosis sectors, thus industry growth is gradually going down. However, biochemistry diagnosis has its obvious advantages in terms of cost and time and are still the preference for certain qualitative examination items during initial inspection. It is expected that it will grow slowly at 5-7% in 5 next years. Instrument isolation and assembly line will be the future development trend of biochemistry diagnosis. Automatic assembly line includes automatic code scanning, sample sorting, centrifugation, capping off, analysis, capping, storage, results transmission, confirmation and sample reinspection, which will drastically shorten the time of "sample pre-treatment" and will save the entire measuring time and enhance detection efficiency immensely. In addition, automatic assembly line accelerates the turnover of sample inspection, cuts down the number of medical workers needed, and decreases the risk of biological pollution and cost. The Company will pay close attention and take active measures to adapt to changes to further strengthen the cooperation with downstream sectors through regional strategies tailored made to local conditions, with a view to improve its product sales volume or market share in diversified methods including consolidation.

The gradual implementation of the new medical reform, medical insurance and health sector policies substantively benefit the pharmaceutical sector. In particular, the influence of the medical reform has led to a steady increase in the number of domestic medical visits. The government encourages private capital investment in medical service industry, further improving the business sentiment and market environment of the industry. It is expected that as driven by social capital, the medical service market, in particular basic level medical market and high-end medical service, will increase substantially. The demand for diagnostic reagents and general consumables will continue to increase, which are beneficial to the continuous growth of the size of our business and will increase the sales of our products. However, with the gradual implementation of new medical reform, the charges of medical services begin to draw public attention. In terms of the criterion for medical service pricing issued for provinces and cities, reduction in the proportion of inspection fee and lowering inspection and testing pricing begins to take shape.

With increasing market participants, market competition for IVD reagent sector is becoming more and more intense. Enterprises are also facing on-going challenges in product quality enhancement and product-mix optimisation. With more stringent product registration and regulatory policies, drop-out rate of vulnerable companies and industry concentration rate will have obvious increase. Under the adjustment and optimisation of the sales team, the Company will take more incentive measures to explore new marketing mode actively, continue intensifying its marketing efforts, accelerate the progress in research and development, launch new products and new instruments compatible with each other or with new functionalities one after another, increase its investment in immune diagnosis and molecular diagnosis, and strive to adapt to new market changes and new demand. In 2019, the Group will further foster in-depth development of the "year of increasing income and reducing expenditure, quality, and entrepreneurship" activities, and pursue the spirit of "Unity, Regulated, Courage, Efficiency, Win-win", initiate all employees to be proactive in establishing entrepreneurial awareness, enhancing occupation quality, improving product quality in all directions and means, and increasing the momentum in marketing efforts to increase the revenue of the Group and reduce unnecessary spending in all directions and means. Through solidifying its business foundation and adjusting its operation directives and increasing income and reducing expenditure, the Group is striving to forge ahead under adverse conditions in order to become a respectable enterprise. With years of hard work and established foundation, the Board directs the Company to step towards the objective of being the "Legend Group" in China's health industry with independent intellectual property rights and international competitiveness, and achieve the best performance and bring satisfactory returns for our shareholders.

ACKNOWLEDGEMENT

On behalf of the Board, I would like to take this opportunity to express our sincere appreciation towards all of our shareholders for their guidance and support, and to thank all of our employees for their invaluable long-term contribution and dedication.

By order of the Board

Wu Lebin
Chairman

Beijing, the People's Republic of China
19 March 2019

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS ENVIRONMENT

The People's Republic of China (the "PRC") has turned into an aged society and it is expected that with intensifying aging issue and improvement in people's health consciousness, total medical visits will maintain at a growth rate of over 5% in the next five years. It is also expected that medical expenditure per capita will maintain a growth rate of 5%-7%. With diagnosis as the first step of medical treatment and IVD as a foundation inspection and testing measure, about 30% of outpatient medical expenditure will be attributable to the clinical application of IVD products. At present, under the overall background of citizens' increasing awareness in disease prevention and health consciousness, as well as drug price reduction and removal of medicine markup policies, the medical treatment service will become the main income source for hospitals. Furthermore, with the advancement of the hierarchical medical system, the improved strength of the PRC enterprises in research and development and the increase in examination and testing volume in primary hospitals, under the combined influence of the medical insurance expense control policy and the need of hospital inspection fee adjustment and a decrease on reagent consumables cost, as well as the implementation of centralized procurement policy for medical consumables (including tender procurement, network procurement, negotiation procurement and joint procurement), hospitals (especially those at the county level and below) will tend to use more domestic reagents, especially the biochemical diagnosis with relatively high price-performance, which will be beneficial to domestic reagent and instruments enterprises.

At present, the biochemical diagnostic reagent has become the most developed segment in IVD industry in the PRC. The overall technological standard is basically on par with current international standard and product quality and independent innovation capacity has improved substantially. However, such segment recorded a flat growth which is expected to be lower than 10%, in which the key growth sector is at primary hospitals. As a result of the relatively low technological barrier of the biochemical reagent industry as well as the opening up of biochemical analyzers market, domestic enterprises entered the market by taking track and imitating foreign technologies and producing reagent products supporting imported biochemical analyzers, thereby forming a batch of sizable IVD enterprises which mainly manufacture biochemical reagents. Through the traceability of diagnostic products, the accuracy, consistency and comparability of examination and testing results were improved, the room of import substitution is continuously expanding, hence import substitution had basically completed and met the domestic hospital demand at all levels. However, the high-end biochemical analyzers are still dominated by foreign brands due to higher technological barriers. The characteristics of IVD industry is the focus of primary importance in determining the research and development of analyzers. Sales of analyzers can drive up high sales of reagents due to the resulted higher barrier in research and development of analyzers. The high-end instruments are mostly run in closed operation, that is, such instruments are only compatible with special reagents from specific manufacturers. As the quality of domestic biochemical diagnostic reagents are homogenized seriously, along with fierce price competition, the growth rate of the sales declined year by year. It is urgently necessary to increase our competitiveness with new technologies and new products. The research and development is the core competition barrier for IVD instrument and reagents.

With the development of diagnostic technology, from the stages of screening, definite diagnosis to treatment, the diagnostic technology has begun to be professionally segmented. The government is promoting hierarchical diagnosis and treatment as well as the construction of regional medical complex, which will further develop the regional inspection centers, and thus bring more changes to the selling of IVD products. Furthermore, attention should be given to the cooperation model between manufacturers and distributors. The emergence of several major domestic biochemical diagnostic companies is supported by strong sales channels and distributors, and their interests have been strengthened by way of capital ties and intensified bonding, which will become an important trend in market competition in the future.

BUSINESS REVIEW

Revenue

During the Reporting Period, the Group basically achieved the revenue target set by the Board last year and recorded revenue of RMB 303 million, up by 2.7% as compared to last year.

Gross Profit and Gross Profit Margin

The gross profit during the Reporting Period was RMB120 million, down by 12.3% as compared to last year, and gross profit margin was 39.7% (2017: 46.4%).

Selling and Distribution Expenses

During the Reporting Period, selling and distribution expenses were RMB56.50 million, down by 14.2% as compared to last year. The decrease in such expenses was primarily attributable to the strengthening of cost control during the Year.

Research and Development Costs

During the Reporting Period, the Company obtained 21 new filing products such as nucleic acid extraction reagents, sample extracts, sample dilutions, and substrate disinfection solution for automatic immunoassay systems (全自動免疫檢驗系統用底物消液), and 3 authorized invention patents as follows:

- kit for detecting Klebsiella pneumoniae (肺炎克雷伯氏菌的試劑盒);
- a reduced coenzyme reagent (一種還原型輔酶試劑) and its application; and
- a thio-oxidized coenzyme I reagent (一種硫代氧化型輔酶I試劑) and its application.

Total research and development costs for the Year amounted to RMB25.40 million, down by 5.4% as compared to that of last year.

Loss for the Year

Loss for the Year amounted to RMB16.73 million, as compared with a profit of RMB21.20 million in 2017.

Loss Attributable to Owners of the Parent

During the Reporting Period, loss attributable to owners of the parent of the Company was RMB2.05 million, as compared with a profit attributable to owners of the parent of RMB25.17 million for the year ended 31 December 2017, which was mainly attributable to an increase in the cost of sales as well as an increase in financing cost resulting from the change in product portfolio during the Year.

PRODUCTION FACILITIES

The Company possesses 2 self-constructed plants complexes covering a total area of 37.17 mu, in which both complexes have passed the examination and acceptance and repair and reconstruction stages, and are in normal use. Among the aforesaid two plants, Plant Complex No. 1, with a gross floor area of 11,000 square metres, is mainly used for office, research and development, production of biochemical reagents and other purposes. On the other hand, plant Complex No. 2, with a gross floor area of 5,000 square metres (with five stories above ground), is mainly used as the production facilities for diagnostic reagents, comprising warehouse, workshops, laboratories and offices. The production facilities of each of its subsidiaries are either leased for use or constructed pursuant to relevant laws and regulations, and those facilities currently are all in normal operating conditions.

FUTURE PROSPECTS

IVD is a one-time disposable consumer goods and its market demand will not shrink as there are still many unsaturated markets to be developed. Therefore, the industry is one of the fastest growing sub-sectors in the domestic medical biology segment in recent years, and will also maintain a stable and rapid development trend in the future. IVD supports more than 70% decisive information of clinical diagnosis with its 2% investments in the entire medical system. Thus, the IVD has become a component of disease prevention, diagnosis and treatment for human. In 2017, the global market size of IVD was US$79.3 billion and approximately RMB60.4 billion in the PRC in 2018. According to the deduction of the foreign matured diagnosis market standard, the PRC's potential market for IVD exceeds RMB200 billion. In the PRC, approximately 90% of IVD reagent products market is clustered at hospitals. With increasing homogenization of diagnostic reagents, diversification in client selection and other changes, strong customer loyalty has become the key of enterprise differentiation and competitiveness.

The traditional IVD manufacturing enterprises mainly focus on distribution. During the operating process, the agents have strong bargaining power. The "hierarchical medical system" and "two-invoice system" which are being proactively pushed forward will certainly trigger a substantial change to operation channel, even business model, whereby leading to a significant change to business ecology in the industry. The agents with terminal resources become more important. At present, in the domestic IVD reagents market, biochemical diagnostic reagents and immune diagnostic reagents represented over 50% of total market size. Technically speaking, for the items broadly used in clinical application with vast market prospect (such as enzymes, lipids, liver function, blood glucose, urine test and immune reagent series in clinical biochemistry), technology standard of domestic major manufacturers has basically reached the current international level. The biochemical diagnostic market has the characteristics of higher demand and high stock level, relatively low in technology barrier and market concentration. Also, 70% of the domestic clinical biochemistry is operating under an open system. The IVD instrument and reagents have basically achieved localization and some domestic manufacturers promote the sales of their self-produced reagents through marketing high-end foreign-branded instrument as an agency. Thus, industry competition is increasingly fierce. However, the application of new technology and the development of new projects are far less active than immune diagnosis and molecular diagnosis sectors, thus industry growth is gradually going down. However, biochemistry diagnosis has its obvious advantages in terms of cost and time and are still the preference for certain qualitative examination items during initial inspection. It is expected that it will grow slowly at 5-7% in next five years. Instrument isolation and assembly line will be the future development trend of biochemistry diagnosis. Automatic assembly line includes automatic code scanning, sample sorting, centrifugation, capping off, analysis, capping, storage, results transmission, confirmation and sample reinspection, which will drastically shorten the time of "sample pre-treatment" and will save the entire measuring time and enhance detection efficiency immensely. In addition, automatic assembly line accelerates the turnover of sample inspection, cuts down the number of medical workers needed, and decreases the risk of biological pollution and cost. The Company will pay close attention and take active measures to adapt to changes to further strengthen the cooperation with downstream sectors through regional strategies tailored made to local conditions, with a view to improve its product sales volume or market share in diversified methods including consolidation.

The gradual implementation of the new medical reform, medical insurance and health sector policies substantively benefit the pharmaceutical sector. In particular, the influence of the medical reform has led to a steady increase in the number of domestic medical visits. The government encourages private capital investment in medical service industry, further improving the business sentiment and market environment of the industry. It is expected that as driven by social capital, the medical service market, in particular basic level medical market and high-end medical service, will increase substantially. The demand for diagnostic reagents and general consumables will continue to increase, which are beneficial to the continuous growth of the size of our business and will increase the sales of our products. However, with the gradual implementation of new medical reform, the charges of medical services begin to draw public attention. In terms of the criterion for medical service pricing issued for provinces and cities, reduction in the proportion of inspection fee and lowering inspection and testing pricing begins to take shape.

With increasing market participants, market competition for IVD reagent sector is becoming more and more intense. Enterprises are also facing on-going challenges in product quality enhancement and product-mix optimisation. With more stringent product registration and regulatory policies, drop-out rate of vulnerable companies and industry concentration rate will significantly increase. Under the adjustment and optimisation of the sales team, the Company will take more incentive measures to explore new marketing mode actively, continue intensifying its marketing efforts, accelerate the progress in research and development, launch new products and new instruments compatible with each other or with new functionalities one after another, increase its investment in immune diagnosis and molecular diagnosis, and strive to adapt to new market changes and new demand. In 2019, the Group will further foster in-depth development of the "year of increasing income and reducing expenditure, quality, and entrepreneurship" activities, and pursue the spirit of "Unity, Regulated, Courage, Efficiency, Win-win", initiate all employees to be proactive in establishing entrepreneurial awareness, enhancing occupation quality, improving product quality in all directions and means, and increasing the momentum in marketing efforts to increase the revenue of the Group and reduce unnecessary spending in all directions and means. Through solidifying its business foundation and adjusting its operation directives and increasing income and reducing expenditure, the Group is striving to forge ahead under adverse conditions in order to become a respectable enterprise. With years of hard work and established foundation, the Board directs the Company to step towards the objective of being the "Legend Group" in the PRC's health industry with independent intellectual property rights and international competitiveness, and achieve the best performance and bring satisfactory returns for our shareholders.

CAPITAL STRUCTURE

During the Reporting Period, the capital structure of the Company had no significant change as compared to that of last year.

LIQUIDITY AND FINANCIAL POSITION

	2018 **RMB million**	2017 RMB million
Cash and bank balances	**25**	27
Short-term loans	**166**	135
Long-term loans	**29**	16
Net debt	**170**	124
Net debt equity ratio	**47%**	32%

The Group generally financed its operations with internally generated cash flows, bank and other borrowings and capital contributions from shareholders. As at 31 December 2018, net debt increased by approximately RMB46 million year-on-year as compared to last year, which was mainly due to an increase in the investment in property, plant and equipment during the Year.

FOREIGN CURRENCY RISK

The Group's businesses are mostly located in the PRC and most transactions are conducted in RMB, except that the Group occasionally purchases equipment and some in-vitro diagnostic reagent products from overseas countries for resale in the PRC and there are administrative expenses incurred by the Canadian subsidiary. A small amount of cash denominated in Hong Kong dollar ("HKD") is placed in bank accounts in Hong Kong for payment of miscellaneous expenses such as professional fees incurred in Hong Kong.

PLEDGE OF ASSETS OF THE GROUP

At 31 December 2018, the Group's buildings with a net carrying amount of approximately RMB27.4 million, and prepaid land lease payments with a net carrying amount of approximately RMB2.65 million were pledged to Bank of Beijing to secure the bank loans granted to the Company with a principal of RMB70 million. The loans will be due in June 2019.

At 31 December 2018, certain machineries with original cost of approximately RMB85 million were pledged to third parties to secure loans granted to the Company amounted to RMB57 million with durations of 2 to 3 years.

SIGNIFICANT INVESTMENT, MATERIAL ACQUISITIONS OR DISPOSALS OF SUBSIDIARIES AND AFFILIATED COMPANIES

On 24 July 2018, the Company, Chinese Academy of Sciences Holdings Co., Ltd ("CAS Holdings") and Beijing Biosino Medical Lab Company Limited ("Biosino Lab") entered into the capital increase agreement, pursuant to which the Company proposed to make capital contribution in the amount of RMB41,000,000 (equivalent to HK$47,560,000) to the registered capital of Biosino Lab (the "Capital Increase"). Upon the completion of the Capital Increase, the registered capital of Biosino Lab will be increased from RMB9,000,000 to RMB50,000,000 and 94% and 6% of which will be held by the Company and CAS Holdings, respectively.

SUBSEQUENT EVENT

On 13 March 2019, the Company and Beijing Hengxing Huawei Commerce Co., Ltd. ("Beijing Hengxing") entered into a disposal agreement (the "Disposal Agreement"), pursuant to which, subject to the conditions precedent set out therein, the Company conditionally agreed to sell and Beijing Hengxing conditionally agreed to purchase 51% equity interest in Zhongke (Beijing) Fund Management Company Limited ("Zhongke Fund"), at a total consideration of RMB56.1 million.

As at the date of the Disposal Agreement, the Company and Beijing Hengxing owned 51% and 49% equity interest in Zhongke Fund, respectively. The disposal constituted a major disposal for the Company and a connected transaction between the Company and a connected person at the subsidiary level of the Company under Chapter 20 of the GEM Listing Rules.

The completion of this disposal is conditional upon the Company having obtained the shareholders' approval and complied with all compliance requirements under the GEM Listing Rules in respect of the Disposal Agreement and the transactions as contemplated thereunder.

Pursuant to the Disposal Agreement, Beijing Hengxing shall pay the consideration to the Company in the following manner:

1) 50% of the consideration, which is RMB28.05 million, shall be paid within 30 days from the date of the Disposal Agreement;

2) 30% of the consideration, which is RMB16.83 million, shall be paid within 180 days from the date of the Disposal Agreement; and

3) the remaining 20% of the consideration, which is RMB11.22 million shall be paid before 1 November 2019.

The transaction is estimated to be completed within 30 days upon the consideration is fully paid by Beijing Hengxing and that all the necessary registrations with the administration for the industry and commerce in respect of the transfer of Zhongke Fund's interest, amendments to the articles of the association and change of the directors and the senior management of Zhongke Fund have been completed. Upon completion, Zhongke Fund will be 100% held by Beijing Hengxing, and each of Zhongke Fund and its subsidiaries will cease to be a subsidiary of the Company.

The Company announced this major and connected transaction on 13 March 2019.

CONTINGENT LIABILITIES

At the end of the Reporting Period, contingent liabilities not provided for in the financial statements were as follows:

	2018 **RMB'000**	2017 RMB'000
Guarantee given to a bank in connection with the loans granted to an associate	**38,100**	40,200

EMPLOYEES

During the Reporting Period, the Group had a total of 479 full-time employees (2017: 490 employees) based in Hong Kong and the PRC. Total staff costs of the Group (including the Directors' and supervisors' remuneration) for the year ended 31 December 2018 amounted to approximately RMB60.36 million (2017: RMB57.75 million). The Group determines and reviews the emoluments of its staff and the Directors based on their qualifications and experience, performance and market rates, so as to maintain the remuneration of its staff and the Directors at a competitive level. The Group participates in various defined contribution retirement plans and insurance schemes in compliance with its statutory obligations under the laws and regulations of the PRC and Hong Kong. The Board believes that employees are one of the most valuable assets of the Group who contribute significantly to the success of the Group. The Group recognises the importance of training of its staff and hence provides regular training for the Group's staff members to enhance their technical and product knowledge.

Other than the company secretary and qualified accountant, all employees of the Group are stationed in the PRC.

PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES OF THE COMPANY

Neither the Company, nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities during the Year.

CORPORATE GOVERNANCE REPORT

INTRODUCTION

The Company always puts strong emphasis on the superiority, steadiness and rationality of corporate governance.

CORPORATE GOVERNANCE PRACTICE

During the Reporting Period, the Company complied with all the code provisions and, where appropriate, adopted the recommended best practices set out in the Corporate Governance Code (Appendix 15 to the GEM Listing Rules) with the exception of Code Provision A.1.8 as addressed below:

Code Provision A.1.8

Under Code Provision A.1.8, the Company should arrange appropriate insurance to cover the potential legal actions against its Directors. As at the date of this report, the Company has not arranged such insurance coverage for the Directors.

The Company is in the process of reviewing and comparing the quotations and insurance proposals provided by a number of insurers, and currently targets to purchase the relevant liability insurance for the Directors within 2019.

THE BOARD OF DIRECTORS

During the Reporting Period, the Board comprised nine Directors, including the chairman, executive Directors, non-executive Directors and independent non-executive Directors. Each of the Directors (including the non-executive Directors and independent non-executive Directors) has entered into a service contract with the Company for a term of three years, but is subject to retirement by rotation at the Company's annual general meeting in accordance with the Articles of Association of the Company. The Board is mainly accountable to the owners of the parent. It is also in charge of the management, business, strategy, annual, interim and quarterly results, risk management, major acquisitions, disposals and capital transactions and other major operational and financial aspects of the Group. Major corporate matters that are specifically delegated by the Board to the management include the preparation of annual, interim and quarterly accounts for Board approval before public reporting, execution of business strategies and initiatives adopted by the Board, implementation of adequate internal control systems and risk management procedures, and compliance with relevant statutory requirements, rules and regulations.

No corporate governance committee has been established and the Board is delegated with the corporate governance functions under Code Provision D.3.1 of the Corporate Governance Code.

The Board, in carrying out its corporate governance functions, is responsible for (a) developing and reviewing the Company's policies and practices on corporate governance; (b) reviewing and monitoring the training and continuous professional development of Directors and senior management; (c) reviewing and monitoring the Company's policies and practices on compliance with legal and regulatory requirements; (d) developing, reviewing and monitoring the code of conduct and compliance manual (if any) applicable to employees and Directors; and (e) reviewing the Company's compliance with the code and disclosure in this corporate governance report.

Details of backgrounds and qualifications of the chairman of the Board and the other Directors are set out in the Report of the Directors. All Directors have given sufficient time and attention to the affairs of the Group. Each executive Director has sufficient experience, knowledge and execution ability to hold the position so as to carry out his or her duties effectively and efficiently. There is no relationship among the members of the Board.

During the Reporting Period, the chairman of the Board kept a close relationship with all Directors to ensure steady exchange of information with them in the course of operation and decision-making.

The executive Directors are in charge of different areas of duty. One of them is always responsible for the management of the Group's day-to-day operations such as production, operation, and financial management. Another executive Director is in charge of the research and technique as well as international relations of the Company. The remaining executive Director is responsible for the daily operations of the Group.

All non-executive Directors are independent of the management and are in possession of solid experience in the business of the industry. These non-executive Directors provided significant advice and contribution to the development of the Company during the Reporting Period.

The Board fulfilled the minimum requirement of appointing at least one-third of the members of the Board as independent non-executive Directors. They have professional knowledge and extensive experience in science and technology, medical science and economics, which also conforms with the requirement of having one independent non-executive Director with appropriate qualification on professional accounting or financial management expertise. They are able to fully represent the interests of the shareholders. The Board has received an annual confirmation of independence from each of the independent non-executive Director. The Company considers all of them to be independent from the Company in accordance with the guidelines set out in Rule 5.09 of the GEM Listing Rules as at the date of this report.

During the Reporting Period, the Board held a total of six meetings. The average attendance rate of Directors and Supervisors reached 100%. The details of the attendance rate of the Board and respective Directors are as follows:

Date of meeting	Total number of Directors	Number of Directors present	Attendance rate
15 March 2018	9	9	100%
14 May 2018	9	9	100%
6 July 2018	9	9	100%
10 August 2018	9	9	100%
14 November 2018	9	9	100%
16 November 2018	9	9	100%

Name of Directors	Number of meetings attended
Mr. Wu Lebin *(Chairman and executive Director)*	6/6
Dr. Bi Lijun *(Vice chairman and non-executive Director)*	5/5
Mr. Chen Jintian *(Vice chairman and executive Director)*	6/6
Dr. Sun Zhe *(Vice chairman and non-executive Director)*	1/1
Dr. Xu Cunmao *(Executive Director)*	6/6
Mr. Hou Quanmin *(Non-executive Director)*	5/5
Ms. Cheng Yali *(Non-executive Director)*	1/1
Mr. Wang Daixue *(Independent non-executive Director)*	6/6
Dr. Hu Canwu Kevin *(Independent non-executive Director)*	6/6
Dr. Zheng Yongtang *((Independent non-executive Director)*	6/6

ANNUAL GENERAL MEETING AND EXTRAORDINARY GENERAL MEETING HELD IN 2018

The 2018 annual general meeting and extraordinary general meeting of the Company were held on 18 May 2018 and 18 September 2018 in Beijing, PRC, respectively. Details of the Directors' attendance records of the meetings are as follows:

Name of Directors	Annual general meeting 18 May 2018	Extraordinary general meeting 18 September 2018
Mr. Wu Lebin *(Chairman and executive Director)*	1/1	1/1
Mr. Chen Jintian *(Vice chairman and executive Director)*	1/1	1/1
Dr. Bi Lijun *(Vice chairman and non-executive Director)*	1/1	1/1
Mr. Zhang Haitao *(Executive Director, resigned on 19 January 2018)*	0/1	0/1
Dr. Xu Cunmao *(Executive Director)*	1/1	1/1
Mr. Hou Quanmin *(Non-executive Director)*	1/1	1/1
Dr. Zheng Yongtang *(Independent non-executive Director)*	1/1	1/1
Dr. Hu Canwu Kevin *(Independent non-executive Director)*	1/1	1/1
Mr. Wang Daixue *(Independent non-executive Director)*	1/1	1/1

CHAIRMAN AND PRESIDENT

The chairman and the chief executive officer, whose function performed by the president of the Group, are currently two separate positions held by Mr. Wu Lebin and Mr. Chen Jintian respectively with clear distinction in responsibilities.

As the chairman of the Board, Mr. Wu Lebin is responsible for the approval and supervision of the overall strategies and policies of the Group, approval of annual budgets and business plans, evaluation of the Company's performance and overseeing of the management. Other executive Directors are responsible for the day-to-day operations of the Group.

Mr. Chen Jintian, the president, is responsible for the daily operation of the Group, implementation of business strategies, targets and plans formulated and adopted by the Board, and assuming accountability to the Board for the overall operation of the Group.

DIRECTORS' SECURITIES TRANSACTIONS

The Group has adopted a model code of conduct for dealing in the Company's securities by Directors, which was formulated in accordance with Rules 5.48 to 5.67 of the GEM Listing Rules for the purpose of setting out the standards adopted by the Company for assessing the conduct of Directors in their dealings in the securities of the Company. Any violation of this code will be regarded as a violation of the GEM Listing Rules. The Company has confirmed, after making specific enquiries with the Directors, that all Directors have complied with the required standard of dealings as set out in the model code of conduct in relation to securities dealings by directors throughout the Reporting Period.

BOARD COMMITTEES

The Board has established three Board committees, namely remuneration committee (the "Remuneration Committee"), nomination committee (the "Nomination Committee") and audit committee (the "Audit Committee") to oversee the particular aspect of the Company's affairs. The Board committees are provided with sufficient resources to discharge their duties.

REMUNERATION COMMITTEE

The Remuneration Committee was established in accordance with the code provisions as set out in Appendix 15 to the GEM Listing Rules with written terms of reference. The main duties of the Remuneration Committee are the determination of specific remuneration packages of all executive Directors, including benefits in kind, pension rights and compensation payments, any compensation payable for loss or termination of their office or appointment, and making recommendations to the Board on the remuneration of non-executive Directors. The Remuneration Committee should consider factors such as salaries paid by comparable companies, time commitment and responsibilities of the Directors, employment conditions elsewhere in the Group and feasibility of performance based remuneration.

During the Reporting Period, members of the Remuneration Committee included all independent non-executive Directors, Dr. Zheng Yongtang, Dr. Hu Canwu Kevin and Mr. Wang Daixue, with Dr. Zheng Yongtang as the chairman of the Remuneration Committee. Following Dr. Hu Canwu Kevin's retirement as an independent non-executive Director on 8 January 2019, he ceased to be a member of the Remuneration Committee and was replaced by Mr. Pan Chunyu, an independent non-executive Director appointed on the same day.

The Remuneration Committee held one meeting to review and approve the remuneration packages of the Directors and senior management of the Group for the Reporting Period.

The Remuneration Committee meets regularly to determine, with delegated responsibility from the Board, the policy for the remuneration packages of individual Directors and senior management and assess the performance of executive Directors and senior management of the Company. During the year of 2018, the Remuneration Committee met once and the individual attendance of each member is set out below:

Name of Directors	**Number of meetings attended**
Dr. Zheng Yongtang	1/1
Dr. Hu Canwu Kevin	1/1
Mr. Wang Daixue	1/1

REMUNERATION OF SENIOR MANAGEMENT

The remuneration of the members of the senior management by band for the year ended 31 December 2018 is set out below:

Remuneration bands (RMB)	**Number of person**
RMB1,000,000 and under	3
RMB1,000,001 to RMB1,500,000	1
RMB1,500,001 to RMB2,000,000	Nil
RMB2,000,001 to RMB2,500,000	2

Further particulars regarding Directors' remuneration and the five highest paid employees are set out in notes 8 and 9 to the financial statements, respectively.

NOMINATION COMMITTEE

The Nomination Committee was established on 20 March 2012. The Nomination Committee is responsible for, including but not limited to, reviewing the structure, size, composition and diversity (including without limitation, gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service) of the Board and making recommendation to the Board on selection of candidates for directorships. In addition, the Nomination Committee is also responsible for (including but not limited) (i) reviewing the policy for the nomination of Directors and to make disclosure of the summary of nomination policy in annual report of the Company annually; (ii) identifying individuals suitably qualified to become Board members and select or make recommendations to the Board on the selection of individuals nominated for directorships, having due regard for the board diversity policy and nomination policy of the Company; (iii) assessing the independence of the independent non-executive Directors; (iv) making recommendations to the Board on the appointment or re-appointment of Directors and succession planning for Directors, in particular the chairman and the chief executive officer; and (v) reviewing the board diversity policy as appropriate and making recommendations on any required changes to the Board for consideration and approval, and monitor its implementation so as to ensure its effectiveness, and make disclosure of its summary and the progress of its implementation in the corporate governance report.

During the Reporting Period, the Board has adopted the board diversity policy (the "Board Diversity Policy"). All Board appointments will be based on merit, and candidates will be considered against selection criteria based on a range of diversity perspectives, which would include but not limited to gender, age, cultural and educational background, professional experience, skills, knowledge and length of service.

During the Reporting Period, the Nomination Committee comprised an executive Director, namely Mr. Wu Lebin, and three independent non-executive Directors, namely Dr. Hu Canwu Kevin, Dr. Zheng Yongtang and Mr. Wang Daixue. Dr. Hu Canwu Kevin was the chairman of the Nomination Committee. Following Dr. Hu Canwu Kevin's retirement as an independent non-executive Director on 8 January 2019, he ceased to be the chairman of the Nomination Committee and was replaced by Mr. Pan Chunyu, an independent non-executive Director appointed on the same day.

In carrying out its functions, the Nomination Committee met once during the Reporting Period. The attendance record of the said meeting is set out as follows:

Name of Directors	Number of meetings attended
Mr. Wu Lebin	1/1
Dr. Hu Canwu Kevin	1/1
Dr. Zheng Yongtang	1/1
Mr. Wang Daixue	1/1

Nomination Policy

The Board has adopted the "Nomination Policy" on 8 January 2019 in relation to the nomination, appointment, re-appointment of new Directors and the nomination procedures of the Company, which provides that in evaluating and selecting any candidate for directorship, the Nomination Committee shall consider the candidates' character and integrity, professional qualifications, skills, knowledge and experience, independence, diversity on the Board, willingness to devote adequate time to discharge duties as a Board member and such other criteria that are appropriate to the business of the Company.

Board Diversity Policy

The Board has adopted the revised "Board Diversity Policy" on 8 January 2019 in relation to the nomination and appointment of new Directors, which provides that the selection of Board candidates shall be based on a range of diversity perspectives with reference to the Company's business model and specific needs, including but not limited to gender, age, race, language, cultural background, educational background, industry experience and professional experience.

The above measurements were also reviewed and adopted when the Nomination Committee reviewed the composition of the Board. After assessing the suitability of the Directors' skills and experience to the Company's business, the Nomination Committee confirmed that the existing Board was appropriately structured and no change was required.

AUDIT COMMITTEE

The Company established the audit committee (the "Audit Committee") on 10 February 2006 in accordance with the requirements of the GEM Listing Rules.

The duties of the Audit Committee include (but not limited to):

1. supervising the accounting and financial reporting procedures and reviewing the financial statements of the Group;

2. studying carefully all the proceedings proposed by the qualified accountant, compliance officers and auditors of the Group;

3. examining and monitoring the risk management and internal control systems of the Group and other major financial matters; and

4. reviewing the relevant work of the Group's external auditors.

Members of the Audit Committee possess high sense of responsibilities. They have contributed their time and efforts to ensure efficient operation and objectivity of the Board.

The Audit Committee meets once every quarter to review the reporting of financial statements and other information to shareholders, the effectiveness and objectivity of the internal control process, and reviewed all the quarterly, half-yearly and annual results. The Audit Committee also provides an important link between the Board and the Company's auditors in matters that arise within the scope of its terms of reference and continues to review the independence and objectivity of the auditors.

During the Reporting Period, four Audit Committee meetings were held and the individual attendance of each member is set out below:

Name of Directors	Number of meetings attended
Dr. Zheng Yongtang	4/4
Dr. Hu Canwu Kevin	4/4
Mr. Wang Daixue	4/4

During the Reporting Period, the Audit Committee comprised all independent non-executive Directors, namely Dr. Zheng Yongtang, Dr. Hu Canwu Kevin and Mr. Wang Daixue, of which Dr. Zheng Yongtang is the chairman. Following Dr. Hu Canwu Kevin's retirement as an independent non-executive Director on 8 January 2019, he ceased to be a member of the Audit Committee and was replaced by Mr. Pan Chunyu, an independent non-executive Director appointed on the same day.

During the Year, the Audit Committee conducted the following activities:

(i) reviewed the Group's annual results for 2017 and the Group's interim and quarterly results for 2018;

(ii) reviewed the audit plans and findings of the external auditor;

(iii) reviewed the internal control, risk management and financial matters pursuant to its terms of reference; and

(iv) made recommendation to the Board on the re-appointment of the external auditor and its remuneration.

The Audit Committee will also meet with the auditor annually in the absence of management to discuss matters relating to any issues arising from audit and any other matters the auditor may wish to raise.

The Audit Committee has reviewed the annual results, financial position, internal control and the management issues of the Group for the Reporting Period.

COMPANY SECRETARY

Mr. Tung Woon Cheung Eric, the company secretary supports the chairman, the Board and the Board Committees by ensuring good information flow and that Board policy and procedures are followed. Mr. Tung advises the Board on governance matters and facilitates the induction and professional development of the Directors. The company secretary is an employee of the Company and is appointed by the Board. Although the company secretary reports to the chairman and the president of the Company, all Directors may call upon him for advice and assistance at any time in respect to their duties and the effective operation of the Board and Board Committees. The company secretary also plays an essential role in the relationship between the Company and its shareholders, including assisting the Board in discharging its obligations to shareholders pursuant to the GEM Listing Rules.

Mr. Tung has confirmed that he has taken not less than 15 hours of relevant professional training in the financial year.

AUDITORS' REMUNERATION

The Audit Committee is responsible for considering the appointment of the external auditors and reviewing any non-audit services performed by the external auditors, including whether such non-audit services could lead to any potential material adverse impact on the Group. For the year ended 31 December 2018, auditors' remuneration for audit services is approximately RMB845,000.

DIRECTORS' AND AUDITORS' RESPONSIBILITIES FOR THE FINANCIAL STATEMENTS

The Directors' responsibilities for the financial statements and the responsibilities of the external auditors to the shareholders are set out on pages 58 to 59.

The Directors have confirmed that the preparation of the Group's financial statements is in compliance with the relative regulations and applicable accounting standards. As at 31 December 2018, the Board was not aware of any material uncertainties relating to events or conditions which may cast significant doubt upon the Company's ability to continue as a going concern, and accordingly prepared the accounts on the going concern basis. The Directors also promise that the Group's financial statements will be distributed in due course.

DIVIDEND POLICY

The Board has adopted the "Dividend Policy" on 8 January 2019 in recommending dividends, to allow the Shareholders to participate in the Company's profits and enable the Company to retain adequate reserves for future growth, which provides that subject to the approval of the Shareholders and requirement of the relevant law, the Company shall pay annual dividends to the Shareholders if the Group is profitable, operations environment is stable and there is no significant investment or commitment made by the Group.

DIRECTORS' INDUCTION AND CONTINUOUS PROFESSIONAL DEVELOPMENT

An induction package covering the Group's businesses and the statutory and regulatory obligations of a director of a listed company will be provided to each newly appointed director, if any. The Group also provides briefings and other trainings to develop and refresh the directors' knowledge and skills, and updates all directors on the regulatory requirements as necessary.

During the year ended 31 December 2018, a memorandum on the latest amendments to the GEM Listing Rules was distributed to all Directors as part of their reading materials and training in the continuous professional development plan.

INTERNAL CONTROL AND RISK MANAGEMENT

The Board has the responsibility to maintain appropriate and effective internal control and risk management systems in order to safeguard the interest of the Group and the shareholders of the Company, review and monitor the effectiveness of the internal control and risk management systems on a regular basis to ensure that the systems in place are adequate.

The Board convenes meetings on a regular basis to discuss financial, operational and compliance controls and risk management procedures and performs quarterly review on the Group's performance and internal control and risk management systems with the Audit Committee in order to ensure effective measures are in place to protect material assets and identify potential risks. During the Year, the Board conducted a review and assessment of the effectiveness of the Group's internal control and risk management systems and procedures by way of discussions with the management of the Group and members of the Audit Committee. The Board believes that the existing internal control and risk management systems of the Group are adequate and effective. The Board has reviewed the resources, qualifications and experience of the staff of the Group's accounting and financial reporting function and their training schemes and budget and was satisfied with their adequacy.

As at 31 December 2018, the Company has not established an internal audit department. However, the Company intends to set up the said department within 2019 and have recruited relevant personnel.

RELATIONSHIP WITH THE INVESTORS

The Group has made great efforts to establish a long-term relationship with shareholders and investors with an open-mind, an adherence to the principles of integrity, regularity, high transparency and disclose the required information in compliance with GEM Listing Rules. Since the commencement of its preparation for listing, the Group has kept enhancing its transparency to provide investors precise and real-time information through various communication channels, including investor presentation, one to one conversations, road shows, seminars, press conferences, press releases, and contacts with media, analysts, and fund managers. Every year, the Directors hold the annual general meeting to meet the shareholders and respond to their questions.

CONVENING OF EXTRAORDINARY GENERAL MEETING ON REQUISITION BY SHAREHOLDERS

Any two or more shareholders holding 10% or more of the shares carrying the right to vote may, by signing one or more counterpart requisitions stating the object of the meeting, require the Board to convene an extraordinary general meeting or a class meeting. The Board shall as soon as possible proceed to do so. The relevant shareholdings of the shareholders shall be calculated as at the date of delivery of the requisitions. If the Board fails to issue a notice for such a meeting within 30 days from the date of receipt of the requisition, the requisitionists may themselves convene an extraordinary general meeting in a manner as nearly as possible to the manner in which meetings are to be convened by the Board, provided that any meeting so convened shall not be convened after the expiration of four months from the date of receipt of the requisition by the Board.

Any reasonable expenses incurred by the requisitionists by reason of the failure of the Directors duly to convene a meeting shall be borne by the Company and shall be set off against any sums owed to the Directors in default by the Company.

PROCEDURES FOR PUTTING FORWARD PROPOSALS AT GENERAL MEETINGS

Any shareholder who wishes to put forward proposals at general meetings of the Company shall submit such proposals to the Board in writing for the Board's consideration not less than 10 business days prior to the date of a general meeting through the company secretary whose contact details are set out in the paragraph "Procedures for directing shareholder' enquiries to the Board" below.

PROCEDURES FOR DIRECTING SHAREHOLDERS' ENQUIRIES TO THE BOARD

Shareholders may at any time send their enquiries and concerns to the Board in writing through the Company Secretary whose contact details are as follows:

The Company Secretary
66th Floor
Central Plaza, 18 Harbour Road
Wanchai, Hong Kong
Fax No.: (852) 2108 4001

The Company Secretary shall forward the shareholders' enquiries and concerns to the Board and/or the relevant Board Committees of the Company and where appropriate, respond to such enquiries.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Since 2016, the Company started to issue relevant information regarding the environmental, social and governance report in its annual report in accordance with relevant regulations and requirements, showing the respective data, measures and cases regarding corporate development strategy, corporate governance, environmental protection, economic responsibility, goods and service quality, occupational health and safety, employee development and social benefits to stakeholders comprehensively. The Company wishes to achieve an outstanding performance in these aspects and gains high recognition from the society.

CORPORATE GOVERNANCE

Sound corporate governance is the foundation and assurance for corporate business development. During the Reporting Period, the Company has timely revised the relevant system, further improved its corporate governance structure and optimized its internal management in accordance with the requirements of relevant laws and regulations and the regulated documents of the Company Law and Corporate Governance Code in Appendix 15 of the GEM Listing Rules of The Stock Exchange.

1. In relation to shareholders and general meeting

The general meeting is fully entitled to the highest decision making authority provided by laws and regulations and the Articles of Association, and exercises its decisions on major events of the Company. During the Reporting Period, apart from annual general meeting, we also held one special general meeting. The Company places high emphasis on the communication with shareholders and liaises with investors through various means. The substantial shareholders of the Company have not acted in a way that exceeds the limit of their authority to, directly or indirectly, intervene in the decision-making processes or production and operational activities of the Company, or have performed any acts that damage the interests of the Company and other shareholders. The substantial shareholders of the Company are mutually independent from the Company in respect of employees, assets, finance, organizations and businesses. The Boards of Directors and Supervisors and other internal authorities of the Company operate independently.

2. In relation to Directors and Board of Directors

The Company selects and appoints directors in strict compliance with the procedures stipulated in the Articles of Association, and the number of members and composition of the Board of Directors are in conformity with the laws, regulations, and the Articles of Association. The Articles of Association defines corresponding provisions on the rules of procedures for Board meetings. As at the end of Reporting Period, the Board of the Company comprised 9 Directors, 3 of which were Independent Non-executive Directors who are respectively professionals in legal, accounting, and industry sectors, and in compliance with the laws and regulations and the requirements of the Articles of Association as well as the development needs of the Group. The Board of Directors has currently established the Audit Committee, Nomination Committee, and Remuneration and Appraisal Committee. Each of the professional committees is in strict compliance with its terms of reference and implements rules when performs its responsibility.

3. In relation to Supervisors and Supervisory Committee

The Company selects and appoints Supervisors in strict compliance with the procedures stipulated in the Articles of Association. The Supervisory Committee comprises three members, of which two of them are representatives recommended by shareholders and one is employee representative recommended by workers' union. The Supervisors of the Company act independently and effectively exercise their supervision and examination rights over the Directors and senior management. The Supervisory Committee conducts meetings regularly and convenes extraordinary Meetings in a timely manner whenever necessary.

4. In relation to performance assessment and incentive mechanisms

The Group keeps on exploring, establishing and perfecting its incentive mechanism, and has formed the performance appraisal system based on KPIs and balanced scorecard. According to the responsibilities of senior management personnel, we set up evaluation indicators, sign letters of performance appraisal and conduct performance appraisal step by step according to the Group's strategic goals and budget breakdown analysis at the beginning of each year; while we evaluate employee remuneration according to the accomplishment of every performance target at the end of year. We implemented senior management's performance appraisal standards and evaluation procedures effectively, and made appropriate amendments and improvements according to the actual situation in its implementation. Meanwhile, we set up targeted and operational-friendly assessment and incentive mechanisms for each level of the Group to further improve our corporate governance structure and incentive system for all employees and to boost up the enthusiasm of the management and important personnel. The systems integrated successfully the interests of the shareholders, the Company and operating proprietors together, and enabled every party to focus on the long-term development of the Group together. The Company had already issued additional domestic shares targeted at key employees to further enhance the incentive scheme for senior management personnel and key employees, facilitating the stable development of the Group in the long run.

5. In relation to stakeholders

The Company pays full respect regarding the legitimate rights of stakeholders such as users, creditors, suppliers, employees and communities, and cooperates with them actively on the basis of equity, reasonableness and mutual benefits in accordance with the laws and regulations so as to push forward the Company's sustainable and healthy development together.

6. In relation to information disclosure

The Company fully fulfills its information disclosure obligation in strict compliance with applicable laws and regulations as well as the respective requirements of the Stock Exchange, the Articles of Association and the Regulation on Information Disclosure issued by the Company. We ensure the disclosure of information is timely, fair, accurate and complete and ensure that investors are able to obtain public information of the Company on an equitable and timely basis. During the year, it was discovered that the Company was not able to acquire and disclose information on a timely basis, but it had already communicated actively with the Stock Exchange and adopted corresponding remedial measures.

There is no material difference between the Company's governance and the requirements of the relevant regulations under CSRC and the Stock Exchange.

The Company will continue to shore up and further improve its corporate governance standard, and boost its competitive edge in the hope of generating better operating results for its investors.

ENVIRONMENTAL PROTECTION

The Group does not fall under the highly-polluted industry category stated by the Ministry of Environmental Protection of China. As at the end of the Reporting Period, the Company or controlling subsidiary and companies it invested were not included in the list of serious-polluting enterprises published by the government and local environmental protection department.

1. Construction and Implementation of Environmental Management System

The Group pays high attention to environmental protection, and emphasizes on the significance of environmental protection to corporate social responsibility and sustainable development, and actively facilitates the construction, execution and implementation of the environmental protection management system.

During the Reporting Period, the Company and relevant authorities conducted comprehensive inspection regarding the environmental management situations of all controlling subsidiaries to facilitate the improvement and promotion of controlling subsidiaries on environmental management, and demanded the completion of its construction and implementation with stipulated deadlines, ensuring effective sustainable development of the Company.

During the Reporting Period, there was no environmental pollution incident in the Company, controlling subsidiary and associate company.

2. Environmental Protection Guideline and Policy

From the strategic perspective of environmental and social sustainable development, we strictly control contamination, promote energy conservation and emission reduction and protect the ecological environment, striving to build up an environmentally friendly business community.

3. Environmental Protection Target

When screening projects, the Group focuses specifically on their potential impact on environment, and pays conscious attention to environmental protection, ensuring that the environmental impact of the Group's operation activities meet the standards and targets. The Group widely applies advanced environmental technologies into our operations actively to reduce energy consumption, advocates every stakeholder to think highly of environmental protection.

4. Utilization or consumption of resources during the Reporting Period

(1) Water utilization: 17,842 cubic meters/year; eq. standard coal: 4,333.82 kg/year; down by 36.5% as compared to last year;

(2) Power consumption: 1,363,250 kilowatt-hour/year, eq. standard coal: 184,128.6 kg/year;

(3) Other energy-consumption steam: 400 tons/year; eq. standard coals: 40 kg/year;

(4) Annual overall energy consumption: electricity + others = 188,501 kg/year;

(5) Yearly solid waste: approximately 15.12 tons/year.

There was an overall decrease in resources utilization and consumption which was mainly due to various measures to conserve energy and lower consumption adopted by the Company since 2019 and achieved obvious results. In addition, the Company gradually adjusts its product mix and increase the production of higher value-added products, thereby reduces the product volume and lower resources consumption.

5. Investments in Environmental Protection Hardware Improvement

During the Reporting Period, to enable our environmental protection works more perfect, the Group continued to invest in environmental protection, optimized its production processes, and enhanced the utilization efficiency of its production facilities and transformed part of its waste gas pollution control devices to achieve energy conservation and emission reduction and protect the environment. A fee of approximately RMB30,000 was spent on environmental management including the operation and monitoring of contamination control facilities.

6. Construction and operating conditions of environmental protection facilities

During the Reporting Period, all environmental protection facilities constructed in each of the controlling subsidiary were under normal operation, which could satisfy the needs of current production capacity of the enterprise. The waste water and air pollutants could meet the discharge standards after treatment and all hazardous wastes were being disposed of by law.

7. Categorizing pollutants discharge

(1) Sewage: It is comprised of industrial sewage and domestic sewage. The main pollutants categories include Five-day Biochemical Oxygen Demand (BOD5), Chemical Oxygen Demand (COD), Ammonia Nitrogen (NH3-N), Suspended Solids (SS) and animal and vegetable oil.

(2) Atmospheric emission: It is mainly produced by industrial waste gas, exhaust emissions of transportation. The main categories of pollutants include fumes and soot.

(3) Solid wastes: It is comprised of hazardous wastes and general wastes. Hazardous wastes include chemical raw materials, acid, alkaline and alcohol used during manufacturing, and medical wastes from laboratories. General wastes include recyclable materials (such as packaging materials and domestic waste from office operation.

8. Pollutants treatment and discharge information

(1) Sewage treatment and discharge: Piped discharge to the sewage treatment plant Class II or municipal sewage network after reaching the standard upon sewage treatment or pre-treatment by enterprise.

(2) Air pollution control and discharge: after adopting or using activated carbon to absorb or using liquid to spray or de-dust treatment on air, the exhaust is discharged in high air in strict compliance; the transportation exhaust emissions used is in compliance with the national standard transportation regulations.

(3) Disposal of solid wastes: each of the controlling subsidiaries conducts final compliance disposal such as incineration, landfill or reprocessing for use through companies that hold the disposal qualifications approved by local environmental protection bureau.

9. Any existence of serious environmental problems and improvement information during the Reporting Period

During the Reporting Period, there was no serious environmental, pollution incident in the production activities engaged by the Group and each of its controlling subsidiaries nor there was any relevant improvement information that required to be disclosed.

10. Emergency plans for environmental pollution incident

The Group has prepared corresponding emergency plans for environmental pollution incident according to its own operation characteristics, integrating with pollution control conditions and potential environmental risk identified, so as to fully response to the possible unexpected environmental pollution accident, and minimize the impact on environment.

11. Environmental protection information disclosure

The Company has disclosed its environmental protection, social and governance information in the annual report and ESG related contents to social public simultaneously and voluntarily since 2016.

SOCIAL RESPONSIBILITY

While the Group is at its continuous rapid development process, it implements its corporate social responsibility actively. In 2018, the Group continued to make progress in corporate protection, economic, environment, health and safety, product and service, employees and society, actively assuming its responsibility as a corporate citizen and repaying to the society.

During the Reporting Period, the Group continued to increase its investment in research and development, kept on improving its technology, improved its production technology process, emphasized on the construction of product quality system, extended product life cycle and lowered the costs to offer more safe, effective and affordable products and services. In order to promote member companies to improve continuously the quality management standard, we prepared the Quality Manual in 2009 for keeping annual improvement and enhancement according to the laws, regulations and the requirements of the quality management system. During the Reporting Period, it successfully passed the on-site inspection by Beijing Food and Drug Administration and Changping Food and Drug Administration.

The Group advocates learning from operation and conducts changes, actively benchmarking with domestic and overseas advanced enterprises. During the Reporting Period, it sent delegations of employees on many occasions to enterprises such as Suzhou Beckman, Mitsubishi and Furuno and several enterprises in Mainland China for learning on-site, explored new management models including lean management and reduced various kinds of costs effectively, striving to improve the overall management efficiency.

During the Reporting Period, the Group adjusted its organizational structure, integrated relevant functions and duties, achieved centralized procurement and lowered procurement costs and supplier management charges and it is going to integrate the social responsibility concept into the entire process of supplier management.

For occupational health management, as the first batch of companies meeting the foundation construction standards of occupational health in Changping District, Beijing, the Company distributes reasonable and effective labour protection gears for employees according to actual job nature of each position, ensures occupational health and implements the human-oriented operation concept. It mainly achieved the followings in terms of occupational health management: conduct an once a year inspection and testing and one assessment every three years on occupational hazards; inform employees who work in occupational hazardous position in writing the possible occupational hazards when labour contracts are signed; set up individual file for supervising occupational health for each employee who works in occupational hazardous position; arrange periodic pre-service, after-service and on-service occupational health physical examination, tracking the health conditions of employees, redeploy employee job position when occupational contraindications after physical examination are found, and firmly prevents the occurrence of occupational diseases.

For social public interests, during the Reporting Period, the Group continued to assume its social responsibility and repay the society through giving support to education, financing scientific research, health and poverty relief and disaster relief.

For safety production, the Company is a class II enterprise in safety production standardization. During the Reporting Period, the Group implemented the hierarchical accountability system for safety production, seriously took the establishment and implementation of production safety management system in the Company and its controlling subsidiaries. The management has established a periodic reviewing and decision making system in terms of performance through implementing and strengthening the all-round compliance risk assessment, team building and the construction and improvement of its professional capability, upgrading and transformation of related facilities, aperiodic independent inspection and review, reporting and rectification of hidden danger, and improving technical support of project and response, to ensure the lawful and compliance operation and continuous improvement of the Group. It organized and implemented centralized professional trainings related to safety production management and improvement activities successively, which minimized the safety risk during our operation, regulated employee operation management, and continued to deepen the safety concept and cultural construction. For resources saving and environmentally-friendly construction, the Group achieved good economic and environment effectiveness through attaching great importance to the application and promotion of advanced energy saving technology and energy contract management projects.

RISK MANAGEMENT

As an enterprise with diagnostic products as its principal business, the major risks that the Group may expose to include:

1. Industry policy risk: In engaging in the manufacturing and selling of diagnostic products (medical devices), relevant licenses granted by food and drug supervision and administration authorities must be obtained, and product quality is subject to stringent laws and regulations. Although the enterprises under the Group that engaged in the manufacturing and operation of principal diagnostic products and medical devices have already obtained the above licenses and approved documents granted by food and drug supervision and administration authorities, however, the regulations over the production and sales of diagnostic products and medical devices may be adjusted by the government. If the Group fails to make corresponding adjustments and perfection, it will cause adverse impact on its production and operation.

2. Market competition risk: Market competition is ever intensifying due to huge domestic market potential where numerous enterprises are having a foothold in the IVD business and market concentration is low. The Group adopts the mainstream model of "distribution and direct selling integration with distribution as priority" in its product sales segment, and has developed approximately 500 distributors in China's 30 provinces and regions. With the continuous increase in the number of distributors, the Group finds it more and more difficult to provide distributors proper trainings, support, management and maintenance. To establish a mutually beneficial win-win mechanism with distributors, cultivate their loyalty to the Group and achieve the overall sales targets together, the Group will closely cooperate with distributors through providing product training, technical support, marketing activities and other services to reduce the risks caused by significant reforms and violation of laws and regulations by distributors.

3. Product research and development and technology substitution risks: The IVD industry is characterized by high technological value, high personnel quality demand and long cycle for research and development as well as product registration, so it is necessary to increase investments in research and development, cultivate and introduce professionals to improve the Group's capability in scientific research. At the same time, sufficient argumentation need to be conducted on new research and development projects through external technology exchange to reduce the risk of possible replacement of currently-available know-how by the more advanced technology in the same industry, so as to remove the adverse impact on the sustainable development of the Group.

4. Quality control risk: The quality of in-vitro diagnostic reagent and in-vitro diagnostic instrument has a direct impact on the accuracy of medical diagnosis. As a result, the government sets stringent requirements on IVD products quality. With the further increase in output, quality control has always been an issue of major concern to the Group. Once the products are improperly maintained or operated during production, transportation and other aspects, it will lead quality problem incidents and affects our reputation and brands. The Group implemented an all-round quality control in product design, raw materials procurement, product manufacturing and sales as well as after-sales services according to the requirements of ISO9001: 2008 and ISO13485: 2003 quality management systems. We prepared a comprehensive quality management system with Quality Manual (《質量手冊》) as its core, and had passed the certification of third-party authority, so as to enable the entire process of our products (from raw materials incoming inspection to manufacturing and operation and after-sales service) are effectively under control. During the Reporting Period, there was no major quality problem.

5. Risk of key technical staff loss: The Group is an enterprise with the longest history in domestic IVD industry. The key factor for maintaining its competitive edge is the Group owns a stable and high quality talented team. The Group firmly believes that staff is crucial in an enterprise's development. The Group recruits and employees staff openly in strict compliance with the requirements of laws and regulations and enters into labor contracts with all employees to assure their legitimate interests in accordance with laws. While strengthening their development internally and promoting staff's skills, the Group is also actively soliciting external excellent talents to enrich the already competitive enterprise talent team. The Group provides newly-employed staff with informative induction training and offers them flexible, diversified and pragmatic business trainings. The Group sets up position and salary levels of every employee based on his/her position by comprehensively assessing job category, work nature, responsibilities, job qualifications and other factors. The salary level is determined in accordance with the staff's knowledge and skills, work performance and overall performance. The Group makes active exploration in cultural development, and creates convenient conditions in work and life, especially in physical examination, settling down and holidays and festivals, aiming at enhancing staff's sense of belongings.

6. Investment and mergers and acquisitions risk: The Group integrates its industry resources through various means such as foreign investment as well as mergers and acquisitions to enhance its core competitiveness and achieve scalable effect. Despite many investigations and argumentations are conducted on any investment object in advance, there are still many market uncertainties after implementation, making it difficult to achieve the expected target and reach a mutually-shared complementary win-win situation and may even incur huge losses. The Group will learn from lessons whole-heartedly and will strictly comply with the Measures for the Administration of Foreign Investment (《對外投資管理辦法》) to further strengthen the due diligence and research and argumentation before investing. Post investment stringent control will be strengthened to enable share-participating corporations to achieve synergy with the Group in terms of operation, management and other aspects, striving to enable target enterprises to meet the objectives within a relatively short period of time, so as to achieve the Group's strategic layout and reduce investment failure risk.

7. Account receivables risk: With the increasing efforts in market expansion and the continuous expansion of sales size, the amount in the Group's account receivables is also increasing accordingly. Hence, the bad debt risk arising therefrom is also the same. The Group has taken measures to improve the front-end control of account receivables and maintains it at a reasonable level, strengthens the daily management and collection of account receivables and takes remedial actions as early as possible when risks occurred. It turns out that risk prevention is very effective if methods are appropriate and measures are strong.

8. Force majeure risk: Serious natural disasters and sudden public health incidents will cause damages to our property and staff and may affect the Group's normal production and operation. The Group has set up corresponding emergency mechanisms and systems to cope with abrupt incidents, which can assure quick responses to make the Group's risk in production and operation activities controllable. The Company set up miniature fire station that equipped with part-time firemen as well as equipment and facilities. In 2018, the Group conducted 1 fire drill, which proved that quick response iss achievable and safeguarding the safety of corporate personnel and property.

In conclusion, in facing the above risks, the Group has three defense lines in place from top to bottom, namely, operating departments, senior management team and the Board and the Supervisory Committee, which are being set up based on corporate governance structure and according to the node of possible occurrence and development. We will fulfill the responsibilities in risk identification, response, management and supervision from different aspects and to understand in time the changes of national laws and regulation and policies, so as to earnestly control, prevent, whistle-blow and resolve all kinds of risks through measures of compliance operation, continuous monitoring and effective supervision. The dedicated internal auditors are in place in Quality Control Center, Finance Department and Engineering Department according to the actual needs of the Company. They perform their internal auditing responsibilities through measures such as important activities are subject to stringent review and approval procedures and important contracts are subject to legal advisor review. In 2018, the Company's internal auditors and externally engaged intermediaries conducted two economic accountability audits on subsidiaries. Operating risks were comprehensively audited through quarterly and half-year operation analysis meetings by the Group's members and conducting operation review meetings on respective subsidiary separately. By conducting special examination on certain high-risk segments, such as marketing, procurement, accounts receivables and instrument maintenance, we aim to promote the compliance operation of the Group's subsidiaries. We also take corresponding rectification measures in a timely manner to prevent possible risks. During the Reporting Period, no major or important omissions or defects were discovered, confirming the effectiveness of the above measures. In 2018, the Group will amend the relevant systems and establish a more reasonable internal auditing structure in accordance with the overall operation objectives and key works and based on the needs of risk management, so as to enable the internal audit and control over the risks during daily operating activities is practical and more effective.

REPORT OF THE DIRECTORS

The Directors present their report and the audited financial statements of the Company and the Group for the year ended 31 December 2018.

PRINCIPAL ACTIVITIES AND BUSINESS REVIEW

The Group is principally engaged in the manufacture, sale and distribution of IVD reagent products. Details of the principal activities of the principal subsidiaries are set out in note 1 to the financial statements.

Further discussion and analysis as required by Schedule 5 to the Companies Ordinance, including a fair review of the business and a discussion of the principal risks and uncertainties facing the Group, particulars of important events affecting the Group that have occurred since the end of the financial year 2017, and an indication of likely future development in the Group's business, are set out in the "Chairman's Statement", "Management Discussion and Analysis", "Environmental, Social and Governance Report" and "Notes to Financial Statements" sections of this report. The above sections form part of this Report of the Directors.

RESULTS AND DIVIDENDS

The Group's profit for the year ended 31 December 2018 and the state of affairs of the Group at that date are set out in the financial statements on pages 153 to 155.

The Directors recommend the payment of a final dividend of RMB0.1 per share in respect of the year to shareholders whose names appear on the register of members on 4 June 2019. Upon approval by the shareholders at the forthcoming annual general meeting of the Company, the final dividend will be paid on or before 31 July 2019. This recommendation has been incorporated in the financial statements as an allocation of retained profits within the equity of the balance sheet.

SUMMARY FINANCIAL INFORMATION

A summary of the published results and assets, liabilities and equity of the Group for the last five financial years, as extracted from the audited financial statements, is set out on page 136. This summary does not form part of the audited financial statements.

PROPERTY, PLANT AND EQUIPMENT

Details of movements in the property, plant and equipment of the Company and the Group during the year are set out in note 13 to the financial statements.

SHARE CAPITAL

The annual change in the Company's issued share capital was set out in note 32 to the financial statements.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Company's articles of association or the Company Law of the PRC which would oblige the Company to offer new shares on a pro rata basis to its existing shareholders.

PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities in the Year.

RESERVES

Details of movements in the reserves of the Company and the Group during the year are set out in note 44 to the financial statements and in the consolidated statement of changes in equity, respectively.

DISTRIBUTABLE RESERVES

Retained profits of the Company, as at 31 December 2018, amounted to approximately RMB96,880,000, of which RMB14,471,000 has been proposed as final dividend for the Year. Details of movements in the reserves of the Company during the year are set out in note 45 to the financial statements.

COMPLIANCE WITH LAWS AND REGULATIONS

As far as the Board is aware, the Group has complied with all material respects with the relevant laws and regulations that have a significant impact on the business and operations of the Group.

MAJOR CUSTOMERS AND SUPPLIERS

During the Year, sales to the Group's five largest customers of RMB123,650,000, accounted for 40% of the total revenue for the year, in which sales to the largest customer amounted to 18.7%. Purchases from the Group's five largest suppliers of RMB36,990,000, accounted for 20% of the total purchases for the year, in which purchases from the largest supplier amounted to 8%. None of the Directors or any of their close associates or any shareholders (which, to the best knowledge of the Directors, own more than 5% of the number of issued shares of the Company) had any beneficial interest in the Group's five largest customers.

DIRECTORS AND SUPERVISORS

The Directors and supervisors of the Company during the Year are as follows:

CHAIRMAN AND EXECUTIVE DIRECTOR:

Mr. Wu Lebin

VICE CHAIRMAN AND EXECUTIVE DIRECTOR:

Mr. Chen Jintian

VICE CHAIRMAN AND NON-EXECUTIVE DIRECTOR:

Dr. Sun Zhe

EXECUTIVE DIRECTORS:

Dr. Xu Cunmao
Mr. Chen Jianhua

NON-EXECUTIVE DIRECTOR:

Ms. Cheng Yali

INDEPENDENT NON-EXECUTIVE DIRECTORS:

Dr. Zheng Yongtang
Dr. Hu Canwu Kevin (retired on 8 January 2019)
Mr. Wang Daixue

SUPERVISORS:

Mr. Zhou Jie
Ms. Yan Xiyun (resigned on 8 January 2019）
Ms. Huang Aiyu

INDEPENDENT NON-EXECUTIVE DIRECTORS

The Company has received from the independent non-executive Directors annual confirmations of their independence pursuant to Rule 5.09 of the GEM Listing Rules, and as at the date of this report, the Board considers each of them to be independent.

EMOLUMENTS OF DIRECTORS AND HIGHEST PAID INDIVIDUALS

Details of emoluments of Directors and the five non-director/supervisor, highest paid individuals are set out in notes 8 and 9 to the financial statements.

DIRECTORS', SUPERVISORS' AND SENIOR MANAGEMENT'S BIOGRAPHIES

Biographical details of the Directors and supervisors of the Company and the senior management of the Group are set out on pages 51 to 55 of this report.

DIRECTORS' AND SUPERVISORS' SERVICE CONTRACTS

Each of the Directors and supervisors (including the non-executive director, the independent non-executive Directors and the supervisors) has entered into a service contract with the Company for a term of three years commencing from various dates of their respective appointments.

Apart from the foregoing, no Director or supervisor had entered into or had proposed to enter into any service contract with the Company which is not determinable by the Company within one year without payment of compensation, other than statutory compensation.

DIRECTORS' REMUNERATION

The Directors' fees are subject to shareholders' approval at the annual general meeting. Other emoluments are determined by the Board with reference to Directors' duties, responsibilities and performance and the results of the Group.

DIRECTORS' INTEREST IN CONTRACTS

No Director had a material interest, either directly or indirectly, in any contract of significance to the business of the Group to which the Company or any of its subsidiaries was a party during the Year.

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS IN SHARES AND UNDERLYING SHARES

As at 31 December 2018, the interests of the Directors, supervisors or chief executive of the Company in the shares and underlying shares of the Company or any associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO")), as recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or as otherwise required pursuant to Rules 5.46 to 5.68 of the GEM Listing Rules to be notified to the Company and the Stock Exchange, were as follows:

LONG POSITIONS IN SHARES OF THE COMPANY

Name	Number of the Company's domestic shares held	Percentage of the Company's domestic shares	Number of the Company's H shares held	Percentage of the Company's H shares	Percentage of the Company's total registered share capital
Mr. Wu Lebin	3,500,878	4.35%	–	–	2.42%
Mr. Chen Jintian *(Note)*	24,506,143	30.47%	6,780,000	10.55%	21.62%
Mr. Zhang Haitao *(resigned on 19 January 2018)*	650,000	0.81%	–	–	0.45%
Dr. Xu Cunmao	600,000	0.75%	–	–	0.41%
Mr. Hou Quanmin	300,000	0.37%	–	–	0.21%
Mr. Zhou Jie	150,000	0.19%	–	–	0.10%

Note: As at 31 December 2018, Beijing Shuoze Health Industry Investment Company Limited ("Beijing Shuoze") and Hong Kong Future Investment Group Limited ("HK Future") held 24,506,143 domestic shares and 6,780,000 H shares of the Company, respectively. Since both Beijing Shuoze and HK Future are held by Mr. Chen Jintian as to 100%, Mr. Chen Jintian is deemed to be interested in 31,286,143 shares of the Company held by Beijing Shuoze and HK Future pursuant to the SFO.

Save as disclosed above, as at 31 December 2018, none of the Directors, supervisors or chief executive of the Company had registered an interest or short position in the shares and underlying shares of the Company or any of its associated corporations that was required to be recorded pursuant to Section 352 of the SFO, or as otherwise required to be notified to the Company and the Stock Exchange pursuant to Rules 5.46 to 5.68 of the GEM Listing Rules.

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

None of the Directors or supervisors of the Company or their respective associates (as defined under the GEM Listing Rules) was granted by the Company or its subsidiaries any rights or options to acquire any shares in or debentures of the Company or had exercised any such rights as at 31 December 2018.

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS IN SHARES AND UNDERLYING SHARES

As at 31 December 2018, as far as is known to any Directors and supervisors of the Company, other than the interest of the Directors, supervisors and chief executive of the Company as disclosed under the section headed "Directors', Supervisors' and Chief Executive's Interests in Shares and Underlying Shares" above, the following persons had interests in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO, or as otherwise notified to the Company and the Stock Exchange:

LONG POSITIONS IN SHARES OF THE COMPANY

Name	Capacity and nature of interest	Number of the Company's shares held		Percentage of the Company's respective type of shares		Percentage of the Company's total registered capital
		Domestic shares	H shares	Domestic shares	H shares	
Institute of Biophysics of Chinese Academy of Sciences	Directly beneficially owned	31,308,576	–	38.93%	0.00%	21.64%
Beijing Shuoze Health Industry Investment Company Limited ("Beijing Shuoze")#	Directly beneficially owned	24,506,143	–	30.47%	0.00%	16.93%
Beijing Junfengxiang Bio-technology Company Limited	Directly beneficially owned	7,763,505	–	9.65%	0.00%	5.36%
Hong Kong Future Investment Group Limited ("HK Future")#	Directly beneficially owned	–	6,780,000	0.00%	10.55%	4.69%
Mr. Chen Jintian#	Through controlled corporations	24,506,143	6,780,000	30.47%	10.55%	21.62%
Beijing Enterprises Holdings Limited^	Directly beneficially owned	–	27,256,143	0.00%	42.40%	18.84%
Beijing Enterprises Group Company Limited^	Through controlled corporations	–	27,256,143	0.00%	42.40%	18.84%
Chung Shek Enterprises Company Limited	Directly beneficially owned	–	3,800,000	0.00%	5.91%	2.63%
K.C. Wong Education Foundation	Through controlled corporations	–	3,800,000	0.00%	5.91%	2.63%

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS IN SHARES AND UNDERLYING SHARES *(Continued)*

Each of Beijing Shuoze and HK Future is wholly owned by Mr. Chen Jintian who is therefore deemed to be interested in the domestic shares and H shares held by Beijing Shuoze and HK Future respectively pursuant to the SFO.

^ Beijing Enterprises Group Company Limited is the ultimate holding company of Beijing Enterprises Holdings Limited. Accordingly, it is deemed to be interested in the H shares owned by Beijing Enterprises Holdings Limited pursuant to the SFO.

Save as disclosed above, as far as is known to any Directors or supervisors of the Company, as at 31 December 2018, no person, other than the Directors, supervisors and chief executive of the Company, whose interests are set out in the section "Directors', Supervisors' and Chief Executive's Interests in Shares and Underlying Shares" above, had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO, or as otherwise notified to the Company and the Stock Exchange.

CORPORATE GOVERNANCE

The Company has always valued the superiority, steadiness and rationality of having a sound system of corporate governance.

For the year ended 31 December 2018, the Company complied with all code provisions and, where appropriate, adopted the recommended best practices set out in the Corporate Governance Code, with the exception of code provisions A.1.8 as addressed below.

Code Provision A.1.8

Under Code Provision A.1.8, the Company should arrange appropriate insurance to cover potential legal actions against its Directors. As at the date of this report, the Company has not arranged such insurance coverage for the Directors.

The Company is in the process of reviewing and comparing the quotations and insurance proposals from different insurers, and currently targets to purchase the relevant liability insurance for the Directors within 2019.

SUFFICIENCY OF PUBLIC FLOAT

Based on information that is publicly available to the Company and within the knowledge of the Directors, at least 25% of the Company's total issued share capital was held by the public as at the date of this report.

COMPETING INTERESTS

During the Year and up to the date of this report, none of the Directors, supervisors, the controlling shareholders of the Company and their respective close associates (as defined in the GEM Listing Rules) has an interest in any business that competes or may compete, either directly or indirectly, with the business of the Group, nor any conflicts of interest which has or may have with the Group.

MANAGEMENT CONTRACTS

During the Year, there was no contract entered into by the Company relating to the management and administration of the entire or any substantial part of the business of the Group.

PERMITTED INDEMNITY PROVISION

At no time during the Year and up to the date of this report, there was or is, any permitted indemnity provision being in force for the benefit of any of the Directors (whether made by the Company or otherwise) or an associated company (if made by the Company).

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

The Environmental, Social and Governance Report of the Company prepared in accordance with Appendix 20 to the GEM Listing Rules is set out on pages 31 to 40 of this report.

CONNECTED TRANSACTION

On 24 July 2018, the Company, CAS Holdings and Biosino Lab entered into the capital increase agreement, pursuant to which the Company proposed to make capital contribution in the amount of RMB41,000,000 (equivalent to HK$47,560,000) to the registered capital of Biosino Lab. Upon the completion of the Capital Increase, the registered capital of Biosino Lab will be increased from RMB9,000,000 to RMB50,000,000 and 94% and 6% of which will be held by the Company and CAS Holdings, respectively.

MATERIAL EVENTS AFTER THE REPORTING PERIOD

Save as disclosed in this report, there are no material events affecting the Group after the end of the Reporting Period.

AUDITORS

Ernst & Young will retire and a resolution for their reappointment as auditors of the Company will be proposed at the forthcoming AGM.

ON BEHALF OF THE BOARD

Wu Lebin
Chairman

Beijing, the People's Republic of China
19 March 2019

REPORT OF THE SUPERVISORY COMMITTEE

To all shareholders,

Since the establishment of the Company, the supervisory committee of the Company (the "Supervisory Committee") has carried out its duties in accordance with the Company's articles of association and relevant requirements. It has performed effective supervision, through the inspection of relevant documents and attending meetings of the Board, on resolutions made by the Board to ensure that they are in compliance with the relevant laws and regulations, the Company's articles of association and in the best interests of the shareholders. Such resolutions are made in a manner to ensure the shareholders' interests and long-term development of the Company.

The Supervisory Committee is in the opinion that the decision-making process of the Board is in compliance with the Company's articles of association and operating norms.

The Supervisory Committee considers that the Company's 2018 financial statements reflected a true and fair view of the financial position and operating results of the Company. The unqualified opinion expressed in the auditors' report issued by Ernst & Young is objective and fair.

The Supervisory Committee is of the opinion that the connected transactions between the Company and its connected persons were conducted at fair market prices without prejudice to the interests of the Company and its minority shareholders.

The Supervisory Committee will strictly observe the articles of association of the Company and the relevant requirements in 2019 to better discharge its duty, including securing shareholders' interests.

The Fifth Supervisory Committee of Biosino Bio-Technology and Science Incorporation
Zhou Jie
Chairman of the Supervisory Committee

Beijing, the People's Republic of China
19 March 2019

DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT

CHAIRMAN OF THE BOARD

Mr. Wu Lebin (吳樂斌先生), aged 57, is the chairman and an executive Director of the Company. Mr. Wu graduated from the Jiangxi Medical College with a bachelor's degree in medicine in 1983 and from the Graduate University of CAS with a master's degree in science in 1988. He also completed an EMBA study program jointly offered by the University of Wisconsin of the United States and the Graduate University of CAS in 2002. Prior to joining the Group, Mr. Wu served as the deputy director and the director in the CAS and the deputy director in IBP of CAS successively. He possesses over 20 years of experience in research management, technology development, administration and corporate management. Mr. Wu joined the Company in 2001. He is the president of the Company since 2003, and is chairman of the Board since 2006 and resigned the concurrent post of president on 10 July 2014. Since June 2014, he served as the secretary of the Party committee in the Corporate of CAS and as the chairman of the Board in the Chinese Academy of Sciences Holdings Co., Ltd.

VICE CHAIRMAN AND EXECUTIVE DIRECTOR

Mr. Chen Jintian (陳錦添先生), aged 41, is the vice chairman and an executive Director of the Company, president and legal representative. Mr. Chen Jintian completed a financial computerization program of The Open University of Fujian* (福建廣播電視大學) in 1999, and completed an EMBA program of University of Management and Technology in United States in 2012. He holds a master degree and is a senior economist. He was the chairman of the board of directors of Beijing Shuoze Commercial Group* (北京碩澤商業集團), HK Future Investment Group* (香港未來投資集團) and is currently the chairman of the board of Beijing Shuoze Health Industry Investment Management Company Limited* (北京碩澤健康產業投資管理有限公司). Mr. Chen joined the Company in March 2015, became the president in December and served as the legal representative of the Company in June 2016.

VICE-PRESIDENT AND NON-EXECUTIVE DIRECTOR

Dr. Sun Zhe, aged 44, currently a director and an associate researcher of the Science and Technology Cooperation and Achievement Transformation Division in IBP. Dr. Sun obtained a doctorate degree of biochemistry from the University of Heidelberg, Germany. His research works include the construction of a cellular level drug screening model and its application, transmembrane endocytosis mechanism for immune responses, cellular endocytosis transportation mechanism, structure and function of membrane protein and protein complex, precision medicine and big data application, detection of major social disease and major biosecurity issues and the construction of government standard. Dr. Sun joined the Company in September 2018.

EXECUTIVE DIRECTORS

Dr. Xu Cunmao（許存茂博士）, aged 56, is an executive Director, vice president and secretary of the Board of the Company, responsible for the overseas investment functions and the relevant matters of general meetings, board meeting and information disclosure of the Company. Dr. Xu obtained a Bachelor's Degree in Science and a Master's Degree in Science in economic geography from Northwest Normal University（西北師範大學）, and a Ph.D Degree in Science in regional economic geography from Northeast Normal University（東北師範大學）. He was an associate professor of the School of Economics in Hainan University（海南大學）, executive deputy general manager of Hainan Nanxi Industrial Co., Ltd.*（海南南希實業股份有限公司）, executive deputy general manager of Beijing Beida Nanxi Bio-Engineering Co., Ltd.*（北京北大南希生物工程有限公司）, general manager of Shanghai Guangkong Industrial Investment Co., Ltd.*（上海廣控實業投資有限公司）and general manager of PKU Weiming Diagnostics Co., Ltd.（北大未名診斷試劑有限公司）. Dr. Xu joined the Company in 2003 and was appointed as an executive Director in March 2015.

Mr. Chen Jianhua, aged 35, is an executive Director of the Company. Mr. Chen works as an assistant to the president of Zhongke (Beijing) Fund Management Co., Limited*（中科（北京）基金投資有限公司）and served as an assistant to the president of Beijing Shuoze Commercial Group*（北京碩澤商業集團）. He completed an e-commerce professionalism course*（電子商務專業）in Fujian Agriculture Forestry University Dongfang College and obtained a bachelor's degree. He has been an executive Director of the Company since May 2018.

NON-EXECUTIVE DIRECTORS

Ms. Cheng Yali（程亞利女士）, aged 57, is a non-executive Director of the Company. Since January 1993, Ms. Cheng has worked in the finance department of IBP of CAS and is now a director of the Department and senior accountant. She is mainly responsible for the fund raising, application, management, supervision and control of the capital, provides stronger capital assurance of sound development of businesses and the efficient functioning of the Institute, and the financial management of a wholly-owned subsidiary of the Institute, Beijing Pusai Asset Management Company（北京普賽資產經營公司）. Ms. Cheng joined the Company in September 2018.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Wang Daixue（王代雪先生）, aged 63, is an independent non-executive Director. He is currently the chairman of Beijing Beilu Pharmaceutical Co., Ltd.*（北京北陸藥業股份有限公司）, a company listed on the ChiNext board of the Shenzhen Stock Exchange (stock code: 300016) ("Beijing Beilu"). In October 1992, Mr. Wang founded Beijing Beilu Pharmaceutical and Chemical Co., Ltd.*（北京北陸醫藥化工公司）and was its general manager. After the restructuring of Beijing Beilu Pharmaceutical and Chemical Co., Ltd. in 1999, it became Beijing Beilu in which Mr. Wang acted as the chairman and general manager. Beijing Beilu was converted into a joint stock company in February 2001 and was one of the first batch of companies listed on the ChiNext board of the Shenzhen Stock Exchange in 2009. Mr. Wang is also the controlling shareholder of Beijing Beilu. Mr. Wang joined the Company in March 2013.

Dr. Zheng Yongtang（鄭永唐博士）, aged 57, is an independent non-executive Director. He is a research associate and a doctoral student advisor of Kunming Institute of Zoology of the CAS*（中國科學院昆明動物研究所）("KIZ"). Dr. Zheng obtained a bachelor degree in medicine from Jiangxi Medical College*（江西醫學院）in 1983, a master degree in cellular immunology and a doctoral degree in viral immunology from KIZ in 1989 and 1997, respectively. Dr. Zheng has been engaging in immunology and virology research for a long period of time. Dr. Zheng undertakes over 30 projects of various scientific research projects, such as National Science and Technology Major Project, National 973 and 863 projects and National Natural Science Foundation etc. Dr. Zheng Yongtang joined the Company in May 2015.

Mr. Pan Chunyu, aged 42, is an independent non-executive Director. Mr. Pan is currently a lawyer and the head of Beijing Yingke Law Firm Xi'an Branch（北京市盈科律師事務所西安分所）. He obtained a bachelor degree in law from Peking University in April 2002 and a master degree in law from China University of Political Science and Law in August 2017. Mr. Pan was a general manager of Beijing Tianlongzhou Economic and Trade Co., Ltd.（北京天龍州經貿有限公司）between 2002 and 2011, and a lawyer of Shaanxi Hebaohu Law Firm*（陝西賀寶虎律師事務所）between 2011 and 2016. Mr. Pan joined the Company in January 2019.

SUPERVISORS

Mr. Zhou Jie（周潔先生）, aged 57, is the chairman of the Supervisory Committee of the Company. Mr. Zhou completed a professional course in politics in Beijing Open University in 1988 and graduated from Renmin University of China with a master's degree in business administration in 2004. Mr. Zhou joined Zhong Sheng Biochemical Reagent Technology Development Corporation*（中生生化試劑技術開發公司）("Biosino Biochemical", the predecessor of the Company) in 1990 and worked in Chengdu Office, responsible for the sales of the southwestern region of the PRC. He then worked in the marketing department of the Company as a department manager, fully responsible for the sales function. In April 2001, Biosino Biochemical was transformed to become the existing Company and Mr. Zhou was recruited as vice president. Mr. Zhou was recruited as the president of the Company on 10 July 2014 and appointed as executive Director in March 2015. He was elected as Supervisor by employee representative in December 2018.

Ms. Huang Aiyu (黃愛玉女士), aged 32, the Supervisor of the Company and holds a bachelor degree in Management. She completed the financial management professional course from Beijing Technology and Business University (北京工商大學) in 2008. She was the finance manager of Beijing Shuoze Commercial Group* (北京碩澤商業集團). Ms. Huang joined the Company in March 2015.

Dr. Shen Sheng (沈勝博士), aged 34, is the Supervisor. He is currently a comprehensive affairs and business executive and business supervisor of the Science and Technology Cooperation and Achievement Transformation Division*in IBP. He obtained a doctoral degree in cell biology from the University of Chinese Academy of Sciences in July 2013. Thereafter, he worked as an assistant research associate at the Key Laboratory of Infection and Immunity* (感染與免疫院重點實驗室) in the Institute of Biophysics of the Chinese Academy of Sciences (the "IBP") of the Chinese Academy of Sciences. Dr. Shen joined the Company in January 2019.

SENIOR MANAGEMENT

Dr. Zheng Xiaowan (鄭曉婉博士), aged 36, is the vice president of the Company. Dr. Zheng graduated from Virginia Polytechnic Institute and State University in U.S.A. in 2005 with an honorable bachelor's degree, major in Biochemical and minor in management and obtained a doctoral degree in medicine from the College of Pharmacy in University of Maryland-Baltimore County in U.S.A in 2010. She published six academic papers at various national renowned academic journals during her PhD study. She conducted postdoctoral research in Roche Pharmaceutical in the New Jersey branch in the U.S.A. after graduation. She joined the Company in 2011, and served as Assistant to President and Director of International Business, responsible for the various businesses such as overseas business cooperation, import and export and products business. She was recruited as vice president in December 2015.

Dr. Jiang Lin (蔣琳博士), aged 46, is the vice president of the Company and responsible for research and development of the Company's products. Dr. Jiang Lin successively obtained a diploma degree in Pharmaceutical College of Henan University, a Master' Degree in engineering of fine chemical engineering from Shenyang University of Chemical Technology and a Ph.D Degree in Science of microbiology from Institute of Applied Ecology of CAS (中科院瀋陽應用生態研究所). Dr. Jiang Lin joined in the Company in August 2005 as head of R&D department, chief engineer, and was employed as vice president in November 2017.

Mr. Liu Jianzhong (劉建中先生), aged 54, is the finance director of the Company. Mr. Liu graduated from the Jilin Finance and Trading Institute in Accounting with a bachelor's degree. He serves as financial head of Institute of Biophysics, Chinese Academy of Sciences (中科院生物物理研究所). He had been a finance supervisor of our subsidiary, Beijing Baiao Pharmaceuticals Co., Ltd.* (北京百奧藥業有限責任公司) for several years and joined the Company in 1994. He became finance manager since 2014.

COMPANY SECRETARY

Mr. Tung Woon Cheung Eric（董渙樟先生）, aged 48, is the company secretary of the Company. Mr. Tung graduated from York University, Toronto, Canada with a honor bachelor's degree in administrative studies in 1993. Mr. Tung is a certified public accountant of Hong Kong Institute of Certified Public Accountants. He is also an U.S. certified public accountant of the American Institute of Certified Public Accountants. Mr. Tung previously worked in Ernst & Young and possesses extensive experience. Mr. Tung is currently the Assistant President and General Manager of the Capital and Finance Department of Beijing Enterprises Holdings Limited (stock code: 392), the Executive Director, Chief Financial Officer and Company Secretary of Beijing Enterprises Water Group Limited (stock code: 371), an Independent Non-executive Director of South China Financial Holdings Limited (stock code: 619) and GR Properties Limited (stock code: 108), all are companies listed on the Main Board of the Stock Exchange.

QUALIFIED ACCOUNTANT

Mr. Cheung Yeung（張洋先生）, aged 39, is the qualified accountant of the Company. Mr. Cheung graduated from The Hong Kong University of Science and Technology with a bachelor of business administration degree in accounting. Mr. Cheung is a Certified Public Accountant of Hong Kong Institute of Certified Public Accountants, and he has over ten years of experience in accounting and audit. Prior to joining the Company in December 2007, Mr. Cheung was an accounting manager of Beijing Enterprises Holdings Limited. Mr. Cheung joined the Company in December 2007.

INDEPENDENT AUDITOR'S REPORT

EY 安永

To the shareholders of Biosino Bio-Technology and Science Incorporation
(Established in the People's Republic of China with limited liability)

OPINION

We have audited the consolidated financial statements of Biosino Bio-Technology and Science Incorporation (the "Company") and its subsidiaries (the "Group") set out on pages 60 to 155, which comprise the consolidated statement of financial position as at 31 December 2018, and the consolidated statement of profit or loss, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2018, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the consolidated financial statements* section of our report. We are independent of the Group in accordance with the HKICPA's *Code of Ethics for Professional Accountants* (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have fulfilled the responsibilities described in the *Auditor's responsibilities for the audit of the consolidated financial statements* section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the consolidated financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying consolidated financial statements.

Key audit matter	How our audit addressed the key audit matter
Revenue recognition The Group recognised revenue from sales of goods amounting to RMB303 million in its consolidated statement of profit or loss for the year ended 31 December 2018. Revenue is recognised when control of goods is transferred to the customers. Since revenue is one of the key performance indicators of the Group, there is a higher risk that revenue could be recognised in the incorrect period for sales transactions occurring at and around the year end. The accounting policies and disclosures for the revenue recognition are included in notes 2 and 5 to the consolidated financial statements.	Our audit procedures included, among others, understanding the revenue recognition process, performing test of control on revenue recognition, and performing test of details by examining the occurrence and accuracy of selected revenue records based on threshold. In addition, we sent confirmations to major customers and reviewed the reconciliation of any material difference provided by the management by inspecting related documents. We performed alternative procedures for non-replied confirmations by inspecting to original documents and subsequent review. We performed substantive analytical review by comparing revenue and gross margin to previous years among the same products. We also tested the recognition of revenue transactions close to the period end to establish whether they were recorded in the correct period.

OTHER INFORMATION INCLUDED IN THE ANNUAL REPORT

The directors of the Company are responsible for the other information. The other information comprises the information included in the Annual Report, other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF THE DIRECTORS FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors of the Company are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors of the Company either intend to liquidate the Group or to cease operations or have no realistic alternative but to do so.

The directors of the Company are assisted by the Audit Committee in discharging their responsibilities for overseeing the Group's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Our report is made solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the Audit Committee, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Yee Chung Man.

Ernst & Young
Certified Public Accountants
Hong Kong
19 March 2019

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

Year ended 31 December 2018

	Notes	2018 RMB'000	2017 RMB'000
REVENUE	*5*	**303,224**	295,128
Cost of sales		**(182,821)**	(157,843)
Gross profit		**120,403**	137,285
Other income and gains	*5*	**9,313**	40,887
Selling and distribution expenses		**(56,498)**	(65,881)
Administrative expenses		**(39,266)**	(43,340)
Reversal of impairment losses on financial assets,net		**354**	–
Research and development expenses		**(25,402)**	(26,852)
Other expenses		**(11,680)**	(8,304)
Finance costs	*7*	**(14,167)**	(6,893)
Share of profits and losses of:			
A joint venture		**–**	–
Associates		**2,396**	(2,078)
(LOSS)/PROFIT BEFORE TAX	*6*	**(14,547)**	24,824
Income tax expense	*10*	**(2,184)**	(3,627)
(LOSS)/PROFIT FOR THE YEAR		**(16,731)**	21,197
Attributable to:			
Owners of the parent		**(2,049)**	25,170
Non-controlling interests		**(14,682)**	(3,973)
		(16,731)	21,197
(LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	*12*		
Basic and diluted			
– For (loss)/profit for the year		**RMB(0.014)**	RMB0.174

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Year ended 31 December 2018

	2018 RMB'000	2017 RMB'000
(LOSS)/PROFIT FOR THE YEAR	**(16,731)**	21,197
OTHER COMPREHENSIVE INCOME		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences:		
Exchange differences on translation of foreign operations	**(34)**	14
Net other comprehensive income that may be reclassified to profit or loss in subsequent periods	**(34)**	14
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:		
Equity investments designated at fair value through other comprehensive income:		
Changes in fair value	**(204)**	–
Income tax effect	**39**	–
Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods	**(165)**	–
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE YEAR, NET OF TAX	**(199)**	14
TOTAL COMPREHENSIVE (LOSS)/INCOME FOR THE YEAR	**(16,930)**	21,211
Attributable to:		
Owners of the parent	**(2,248)**	25,184
Non-controlling interests	**(14,682)**	(3,973)
	(16,930)	21,211

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

31 December 2018

	Notes	**2018 RMB'000**	2017 RMB'000
NON-CURRENT ASSETS			
Property, plant and equipment	*13*	**264,390**	251,546
Prepaid land lease payments	*14*	**2,572**	2,653
Prepayments	*15*	**600**	88,825
Goodwill	*16*	**309**	309
Other intangible assets	*17*	**20,888**	5,623
Investment in a joint venture	*18*	**–**	–
Investments in associates	*19*	**42,519**	40,123
Equity investments designated at fair value through other comprehensive income	*20*	**1,117**	–
Available-for-sale investment	*20*	**–**	1,579
Long-term receivables	*21*	**6,752**	1,359
Deferred tax assets	*30*	**4,147**	3,824
Total non-current assets		**343,294**	395,841
CURRENT ASSETS			
Inventories	*22*	**58,821**	44,844
Trade and bills receivables	*23*	**141,685**	124,821
Prepayments, other receivables and other assets	*24*	**191,145**	76,993
Financial assets at fair value through profit or loss	*25*	**16,348**	–
Pledged deposits	*26*	**6,507**	–
Cash and cash equivalents	*26*	**18,208**	26,757
Total current assets		**432,714**	273,415
CURRENT LIABILITIES			
Trade payables	*27*	**119,274**	72,914
Other payables and accruals	*28*	**84,313**	43,082
Interest-bearing bank and other borrowings	*29*	**166,437**	135,142
Tax payable		**1,074**	798
Total current liabilities		**371,098**	251,936
NET CURRENT ASSETS		**61,616**	21,479
TOTAL ASSETS LESS CURRENT LIABILITIES		**404,910**	417,320

	Notes	**2018 RMB'000**	2017 RMB'000
TOTAL ASSETS LESS CURRENT LIABILITIES		**404,910**	417,320
NON-CURRENT LIABILITIES			
Interest-bearing bank and other borrowings	*29*	**28,565**	16,067
Deferred income	*31*	**6,175**	7,527
Deferred tax liabilities	*30*	**5,707**	5,443
Total non-current liabilities		**40,447**	29,037
Net assets		**364,463**	388,283
EQUITY			
Equity attributable to owners of the parent			
Share capital	*32*	**144,707**	144,707
Reserves	*33*	**157,196**	174,984
		301,903	319,691
Non-controlling interests		**62,560**	68,592
Total equity		**364,463**	388,283

Wu Lebin
Director

Chen Jintian
Director

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Year ended 31 December 2018

Year ended 31 December 2017

	Note	Share capital RMB'000 (note 32)	Capital reserve RMB'000	Statutory reserve RMB'000	Exchange fluctuation reserve RMB'000	Retained profits RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
		Attributable to owners of the parent							
At 1 January 2017		144,707	105,090	44,436	(153)	14,898	308,978	72,565	381,543
Profit for the year		–	–	–	–	25,170	25,170	(3,973)	21,197
Other comprehensive income for the year		–	–	–	14	–	14	–	14
Total comprehensive income for the year		–	–	–	14	25,170	25,184	(3,973)	21,211
Appropriation of statutory reserve		–	–	1,630	–	(1,630)	–	–	–
Final 2016 dividend paid	11	–	–	–	–	(14,471)	(14,471)	–	(14,471)
At 31 December 2017		144,707	105,090	46,066	(139)	23,967	319,691	68,592	388,283

Year ended 31 December 2018

	Note	Share capital RMB'000 (note 32)	Capital reserve RMB'000	Statutory reserve RMB'000	Exchange fluctuation reserve RMB'000	Fair value reserve RMB'000	Retained profits RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
		Attributable to owners of the parent								
At 31 December 2017		144,707	105,090	46,066	(139)	–	23,967	319,691	68,592	388,283
Effect of adoption of HKFRS9	2.2	–	–	–	–	(212)	(857)	(1,069)	–	(1,069)
At 1 January 2018 (restated)		144,707	105,090	46,066	(139)	(212)	23,110	318,622	68,592	387,214
Loss for the year		–	–	–	–	–	(2,049)	(2,049)	(14,682)	(16,731)
Other comprehensive loss for the year:										
Change in fair value of equity investments at fair value through other comprehensive income, net of tax		–	–	–	–	(165)	–	(165)	–	(165)
Exchange differences on translation of foreign operations		–	–	–	(34)	–	–	(34)	–	(34)
Total comprehensive loss for the year		–	–	–	(34)	(165)	(2,049)	(2,248)	(14,682)	(16,930)
Capital contribution from non-controlling shareholders of subsidiaries		–	–	–	–	–	–	–	8,650	8,650
Appropriation of statutory reserve		–	–	1,929	–	–	(1,929)	–	–	–
Final 2017 dividend paid	11	–	–	–	–	–	(14,471)	(14,471)	–	(14,471)
At 31 December 2018		144,707	105,090*	47,995*	(173)*	(377)*	4,661*	301,903	62,560	364,463

* *These reserve accounts comprise the consolidated other reserves of RMB157,196,000 (2017: RMB174,984,000) in the consolidated statement of financial position.*

CONSOLIDATED STATEMENT OF CASH FLOWS

Year ended 31 December 2018

	Notes	2018 RMB'000	2017 RMB'000
CASH FLOWS FROM OPERATING ACTIVITIES			
(Loss)/profit before tax:		**(14,547)**	24,824
Adjustments for:			
Finance costs	7	**14,167**	6,893
Share of (profits)/losses of associates		**(2,396)**	2,078
Interest income	5	**(609)**	(535)
Changes in fair value of financial assets	5	**(206)**	–
Loss on disposal of items of property, plant and equipment, net	6	**80**	1,292
Depreciation	6	**23,572**	21,530
Amortisation of prepaid land lease payments	14	**81**	81
Amortisation of other intangible assets	17	**1,074**	564
Impairment of other intangible assets	17	**300**	500
(Reversal)/accrual of impairment of trade and bills receivables	23(a)	**(457)**	84
Impairment of prepayments, other receivables and other assets	6	**103**	8
Impairment of inventories, net	6	**2,120**	–
Gain on deemed disposal of shares in an associate	5	**–**	(19,953)
		23,282	37,366
(Increase)/decrease in inventories		**(16,097)**	8,804
Increase in trade and bills receivables		**(18,704)**	(29,402)
Increase in prepayments, other receivables and other assets		**(60,458)**	(26,650)
Increase in trade payables		**46,360**	32,407
Increase/(decrease) in other payables and accruals		**39,231**	(7,670)
Decrease in deferred income		**(1,352)**	(3,984)
Increase in pledged deposits		**(6,507)**	–
Cash generated from operations		**5,755**	10,871
Income tax paid		**(1,882)**	(2,195)
Interests received		**609**	535
Net cash flows from operating activities		**4,482**	9,211

CONSOLIDATED STATEMENT OF CASH FLOWS

Year ended 31 December 2018

	Notes	2018 RMB'000	2017 RMB'000
Net cash flows from operating activities		**4,482**	9,211
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchases of items of property, plant and equipment		**(37,525)**	(177,803)
Purchases of other intangible assets		**(3,524)**	(2,677)
Proceeds from disposal of items of property, plant and equipment		**1,029**	2,368
Purchase of financial assets at fair value through profit or loss		**(16,142)**	–
Increase in prepayments		**(600)**	(88,825)
Advances of loans from placement services		**–**	(30,000)
Receipt from financing services		**20,501**	206,700
Interest received		**1,378**	9,564
Net cash flows used in investing activities		**(34,883)**	(80,673)
CASH FLOWS FROM FINANCING ACTIVITIES			
New bank and other loans		**193,550**	166,209
Repayments of bank loans		**(149,757)**	(126,017)
Capital contributions from non-controlling shareholders		**8,650**	–
Dividends paid		**(14,471)**	(14,471)
Interest paid		**(14,167)**	(6,893)
Increase in amounts due to a related party		**15,000**	–
Repayments of amounts due to a related party		**(13,000)**	–
Deposits for long-term borrowings		**(3,821)**	–
Net cash flows from financing activities		**21,984**	18,828
NET DECREASE IN CASH AND CASH EQUIVALENTS		**(8,417)**	(52,634)
Cash and cash equivalents at beginning of year		**26,757**	79,567
Effect of foreign exchange rate changes, net	6	**(132)**	(176)
CASH AND CASH EQUIVALENTS AT END OF YEAR		**18,208**	26,757
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS			
Cash and bank balances	26	**18,208**	26,757

1. CORPORATE AND GROUP INFORMATION

Biosino Bio-Technology and Science Incorporation (the "Company") is a limited liability company incorporated in the People's Republic of China (the "PRC"). The registered office of the Company is located at No. 27, Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC.

During the year, the Company and its subsidiaries (collectively referred to as the "Group") principally engaged in manufacture, sale and distribution of in-vitro diagnostic reagents.

Information about subsidiaries

Particulars of the Company's principal subsidiaries are as follows:

Company name	Place of incorporation and operations	Issued ordinary/ registered share capital	Percentage of equity attributable to the Company		Principal activities
			Direct	Indirect	
Beijing Zhongsheng Jinyu Diagnostic Technology Co., Ltd. ("Zhongsheng Jinyu") (北京中生金域診斷技術股份有限公司)*	PRC/Mainland China	RMB30 million	45.9%	–	Manufacture, sale and distribution of in-vitro diagnostic reagent products
Beijing Zhongsheng Medical Laboratory Co., Ltd. ("Biosino Lab") (北京中生醫學檢驗所有限公司)	PRC/Mainland China	RMB9 million	66.67%	–	Medical service and medical inspection service
Biosino Suzhou Medical Instrument Co., Ltd. ("Biosino Suzhou") (中生(蘇州)醫療儀器有限公司)	PRC/Mainland China	RMB30 million	93.33%	–	Production of medical instruments
Canada Biosino LVD Technology Co., Ltd. ("Biosino Canada") (加拿大中生體外診斷技術有限公司)	Canada	USD3.5 million	100%	–	Research development, sale and distribution of biological reagents and instruments
Zhongke (Beijing) Hospital Investment Management Co., Ltd. ("Zhongke Investment") (中科(北京)醫院投資管理有限公司)	PRC/Mainland China	RMB13 million	100%	–	Distribution of immunodiagnostic products
Zhongke (Beijing) Fund Management Co., Ltd. ("Zhongke Fund") (中科(北京)基金管理有限公司)	PRC/Mainland China	RMB110 million	51%	–	Investment management, consultation in respect of non-securities business and equity investment management

1. CORPORATE AND GROUP INFORMATION *(Continued)*

Information about subsidiaries *(Continued)*

Company name	Place of incorporation and operations	Issued ordinary/ registered share capital	Percentage of equity attributable to the Company Direct	Indirect	Principal activities
Anhui Biosino Co., Ltd. ("Anhui Biosino") (安徽中生北控生物科技有限公司)	PRC/Mainland China	RMB5 million	51%	–	Distribution of in-vitro diagnostic reagent products
Tengxunzhongchuang Space(Beijing) Technology Co., Ltd. ("Zhongchuang Space") (騰訊眾創空間(北京)科技有限公司)	PRC/Mainland China	RMB10 million	–	100%	Lease of commercial and office buildings
Biosino Import and Export Co., Ltd. ("Zhongke Import and Export") (中科北控(北京)進出口有限公司)	PRC/Mainland China	RMB20 million	–	51%	Import and export of medical instruments
Beijing Kangbosi Diagnostic Technology Co., Ltd. ("Beijing Kangbosi") (北京康博斯診斷科技有限公司)	PRC/Mainland China	RMB20 million	–	51%	Distribution of in-vitro diagnostic reagent products

* This entity is accounted for as a subsidiary by virtue of the Company's control over it.

The above table lists the subsidiaries of the Company which, in the opinion of the directors, principally affected the results for the year or formed a substantial portion of the net assets of the Group. To give details of other subsidiaries would, in the opinion of the directors, result in particulars of excessive length.

2.1 BASIS OF PREPARATION

These financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKASs") and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"), accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for equity investments and financial assets which have been measured at fair value. These financial statements are presented in Chinese yuan and all values are rounded to the nearest thousand except when otherwise indicated.

Basis of consolidation

The consolidated financial statements include the financial statements of the Group for the year ended 31 December 2018. A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee).

When the Company has, directly or indirectly, less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

(a) the contractual arrangement with the other vote holders of the investee;

(b) rights arising from other contractual arrangements; and

(c) the Group's voting rights and potential voting rights.

The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

Profit or loss and each component of other comprehensive income are attributed to the owners of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control described above. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

If the Group loses control over a subsidiary, it derecognises (i) the assets (including goodwill) and liabilities of the subsidiary, (ii) the carrying amount of any non-controlling interest and (iii) the cumulative translation differences recorded in equity; and recognises (i) the fair value of the consideration received, (ii) the fair value of any investment retained and (iii) any resulting surplus or deficit in profit or loss. The Group's share of components previously recognised in other comprehensive income is reclassified to profit or loss or retained profits, as appropriate, on the same basis as would be required if the Group had directly disposed of the related assets or liabilities.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted the following new and revised HKFRSs for the first time for the current year's financial statements which are applicable to the Group.

HKFRS 9	*Financial Instruments*
HKFRS 15	*Revenue from Contracts with Customers*
Amendments to HKFRS 15	*Clarifications to HKFRS 15 Revenue from Contracts with Customers*
Annual Improvements 2014-2016 Cycle	Amendments to HKFRS 1 and HKAS 28

Other than as explained below regarding the impact of HKFRS 9 and HKFRS 15, the adoption of the above new and revised standards has had no significant financial effect on these financial statements.

The nature and the impact of the new and revised HKFRSs are described below:

(a) HKFRS 9 *Financial Instruments* replaces HKAS 39 *Financial Instruments: Recognition and Measurement* for annual periods beginning on or after 1 January 2018, bringing together all three aspects of the accounting for financial instruments: classification and measurement, and impairment.

The Group has recognised the transition adjustments against the applicable opening balances in equity at 1 January 2018. Therefore, the comparative information was not restated and continues to be reported under HKAS 39.

Classification and measurement

The following information sets out the impacts of adopting HKFRS 9 on the statement of financial position, including the effect of replacing HKAS 39's incurred credit loss calculations with HKFRS 9's expected credit losses ("ECLs").

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES *(Continued)*

(a) *(Continued)*

Classification and measurement *(Continued)*

A reconciliation between the carrying amounts under HKAS 39 and the balances reported under HKFRS 9 as at 1 January 2018 is as follows:

		HKAS 39 measurement					HKFRS 9 measurement	
	Note	Category	Amount RMB'000	Reclassification RMB'000	ECL RMB'000	Re-measurement RMB'000	Amount RMB'000	Category
Financial assets								
Equity investments designated at fair value through other comprehensive income		N/A	–	1,579	–	(258)	1,321	FVOCI[1] (equity)
From: Available-for-sale investments	*(i)*			1,579	–	–		
Available-for-sale investments		AFS[2]	1,579	(1,579)	–	–	–	N/A
To: Equity investments designated at fair value through other comprehensive income	*(i)*			(1,579)	–	–		
Trade and bills receivables	*(ii)*	L&R[3]	124,821	–	(857)	–	123,964	AC[4]
Financial assets included in prepayments, other receivables and other assets		L&R	48,890	–	–	–	48,890	AC
Cash and cash equivalents		L&R	26,757	–	–	–	26,757	AC
Long term receivables		L&R	1,359	–	–	–	1,359	AC
Total assets			203,406	–	(857)	(258)	202,291	

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES *(Continued)*

(a) *(Continued)*

Classification and measurement *(Continued)*

	HKAS 39 measurement				HKFRS 9 measurement	
	Category	Amount RMB'000	Re-classification RMB'000	ECL RMB'000	Amount RMB'000	Category
Other assets						
Deferred tax assets		–	46	–	46	
		203,406	46	(857)	202,595	
Financial liabilities						
Trade payables	AC	72,914	–	–	72,914	AC
Financial liabilities included in other payables and accruals	AC	5,464	–	–	5,464	AC
Interest-bearing bank and other borrowings	AC	151,209	–	–	151,209	AC
		229,587	–	–	229,587	

1 FVOCI: Financial assets at fair value through other comprehensive income
2 AFS: Available-for-sale investments
3 L&R: Loans and receivables
4 AC: Financial assets or financial liabilities at amortised cost

Note:

(i) The Group has elected the option to irrevocably designate certain of its previous available-for-sale equity investments as equity investments at fair value through other comprehensive income.

(ii) The gross carrying amounts of the trade and bills receivables under the column "HKAS 39 measurement – Amount" represent the amounts after adjustments for the adoption of HKFRS 15 but before the measurement of ECLs. Further details of the adjustments for the adoption of HKFRS 15 are included in note 2.2(b) to the financial statements.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES *(Continued)*

(a) *(Continued)*

Impairment

The following table reconciles the aggregate opening impairment allowances under HKAS 39 to the ECL allowances under HKFRS 9. Further details are disclosed in note 23 to the financial statements.

	Impairment allowances under HKAS 39 at 31 December 2017 RMB'000	Re-measurement RMB'000	ECL allowances under HKFRS 9 at 1 January 2018 RMB'000
Trade receivables	1,725	857	2,582
Financial assets included in prepayments, other receivables and other assets	1,511	–	1,511
	3,236	857	4,093

Impact on reserves and retained profits

The impact of transition to HKFRS 9 on reserves and retained profits is as follows:

	Reserves and retained profits RMB'000
Fair value reserve under HKFRS 9 (available-for-sale investment revaluation reserve under HKAS 39)	
Balance as at 31 December 2017 under HKAS 39	–
Remeasurement of equity investments designated at fair value through other comprehensive income previously measured at cost under HKAS 39	(258)
Deferred tax in relation to the above	46
Balance as at 1 January 2018 under HKFRS 9	(212)
Retained profits	
Balance as at 31 December 2017 under HKAS 39	23,967
Recognition of expected credit losses for trade and billis receivables under HKFRS 9	(857)
Balance as at 1 January 2018 under HKFRS 9	23,110

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES *(Continued)*

(b) HKFRS 15 and its amendments replace HKAS 11 *Construction Contracts*, HKAS 18 *Revenue* and related interpretations and it applies, with limited exceptions, to all revenue arising from contracts with customers. HKFRS 15 establishes a new five-step model to account for revenue arising from contracts with customers. Under HKFRS 15, revenue is recognised at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. The principles in HKFRS 15 provide a more structured approach for measuring and recognising revenue. The standard also introduces extensive qualitative and quantitative disclosure requirements, including disaggregation of total revenue, information about performance obligations, changes in contract asset and liability account balances between periods and key judgements and estimates. The disclosures are included in note 5 to the financial statements. As a result of the application of HKFRS 15, the Group has changed the accounting policy with respect to revenue recognition in note 2.4 to the financial statements.

The Group has adopted HKFRS 15 using the modified retrospective method of adoption. Under this method, the standard can be applied either to all contracts at the date of initial application or only to contracts that are not completed as at 1 January 2018.

The cumulative effect of the initial application of HKFRS 15 was recognised as an adjustment to the opening balance of retained profits as at 1 January 2018. Therefore, the comparative information was not restated and continues to be reported under HKAS 11, HKAS 18 and related interpretations.

The adoption of HKFRS 15 has not led to any adjustment to the opening balance of retained profits as at 1 January 2018. Set out below are the amounts by which each financial statement line item was affected for the year ended 31 December 2018 as a result of the adoption of HKFRS 15. The adoption of HKFRS 15 has had no impact on other comprehensive income or on the Group's operating, investing and financing cash flows. The first column shows the amounts recorded under HKFRS 15 and the second column shows what the amounts would have been had HKFRS 15 not been adopted:

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES *(Continued)*

(b) *(Continued)*

Consolidated statement of profit or loss for the year ended 31 December 2018:

		Amounts prepared under		
		HKFRS 15	**Previous HKFRS**	**Increase/ (decrease)**
	Notes	RMB'000	RMB'000	RMB'000
Revenue	*(i), (ii)*	303,224	303,224	–
Cost of sales	*(i), (ii)*	(182,821)	(166,170)	(16,651)
Gross profit		120,403	137,054	(16,651)
Loss before tax		(14,547)	(14,547)	–
Income tax credit		(2,184)	(2,184)	–
Loss for the year		(16,731)	(16,731)	–
Attributable to:				
Owners of the parent		(2,049)	(2,049)	–
Non-controlling interests		(14,682)	(14,682)	–
		(16,731)	(16,731)	–

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES *(Continued)*

The nature of the changes in the statement of profit or loss for the year ended 31 December 2018 is described below:

(i) Sales of products with provision of related instruments

The Group has provided free-of-charge instruments to certain customers or with very limited considerations in order to improve the sales volumes of in-vitro diagnostic reagent products. Before the adoption of HKFRS 15, the Group recognised revenue from such sales at the fair value of the consideration received or receivable, and recorded the depreciation expense of such instruments as parts of selling and distribution expenses. Under HKFRS 15, the Group assessed that there was an additional lease performance obligation in the sales contract, and the depreciation expenses should be reclassified as cost of sales. Based on the analysis of the historical data, the consideration to be allocated to the lease component amounted to RMB14,112,000 accounted for less than 5% of the revenue of in-vitro diagnostic reagent products for the same period, which was not material. Therefore, the Group decided not to disclose this component as a separate line item in the revenue mix in note 5 to the financial statements, but reclassified such depreciation expense from selling and distribution expenses to cost of sales.

(ii) Sale of products with transportation service

The Group has provided transportation services to certain customers to deliver products to sites designated by those customers. The Group separately engaged third-party logistics companies to deliver products and bore the inventory risks during the transportation. Before the adoption of HKFRS 15, the Group recognised revenue from such sales at the fair value of the consideration received or receivable, and recorded such freight costs as parts of selling and distribution expenses. Under HKFRS 15, the Group assessed that there was an additional performance obligation of transportation service in the sales contract, and the freight costs should be reclassified as cost of sales. Based on the analysis of the historical data, the consideration to be allocated to the transportation service component amounted to RMB2,539,000 accounted for less than 1% of the total revenue for the same period, which was not material. Therefore, the Group decided not to disclose this component as a separate line item in the revenue mix in note 5 to the financial statements, but reclassified related freight costs to cost of sales from selling and distribution expenses.

The above changes have no impact led to any adjustment to the opening balance of retained profits.

2.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS

The Group has not applied the following new and revised HKFRSs, that have been issued but are not yet effective, in these financial statements.

Amendments to HKFRS 3	*Definition of a Business*[2]
Amendments to HKFRS 9	*Prepayment Features with Negative Compensation*[1]
Amendments to HKFRS 10 and HKAS 28 (2011)	*Sale or Contribution of Assets between an Investor and its Associate or Joint Venture*[4]
HKFRS 16	*Leases*[1]
HKFRS 17	*Insurance Contracts*[3]
Amendments to HKAS 1 and HKAS 8	*Definition of Material*[2]
Amendments to HKAS 19	*Plan Amendment, Curtailment or Settlement*[1]
Amendments to HKAS 28	*Long-term Interests in Associates and Joint Ventures*[1]
HK(IFRIC)-Int 23	*Uncertainty over Income Tax Treatments*[1]
Annual Improvements 2015-2017 Cycle	Amendments to HKFRS 3, HKFRS 11, HKAS 12 and HKAS 23[1]

1 Effective for annual periods beginning on or after 1 January 2019
2 Effective for annual periods beginning on or after 1 January 2020
3 Effective for annual periods beginning on or after 1 January 2021
4 No mandatory effective date yet determined but available for adoption

Further information about those HKFRSs that are expected to be applicable to the Group is described below:

Amendments to HKFRS 3 clarify and provide additional guidance on the definition of a business. The amendments clarify that for an integrated set of activities and assets to be considered a business, it must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output. A business can exist without including all of the inputs and processes needed to create outputs. The amendments remove the assessment of whether market participants are capable of acquiring the business and continue to produce outputs. Instead, the focus is on whether acquired inputs and acquired substantive processes together significantly contribute to the ability to create outputs. The amendments have also narrowed the definition of outputs to focus on goods or services provided to customers, investment income or other income from ordinary activities. Furthermore, the amendments provide guidance to assess whether an acquired process is substantive and introduce an optional fair value concentration test to permit a simplified assessment of whether an acquired set of activities and assets is not a business. The Group expects to adopt the amendments prospectively from 1 January 2020.

2.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS *(Continued)*

Amendments to HKFRS 10 and HKAS 28 (2011) address an inconsistency between the requirements in HKFRS 10 and in HKAS 28 (2011) in dealing with the sale or contribution of assets between an investor and its associate or joint venture. The amendments require a full recognition of a gain or loss when the sale or contribution of assets between an investor and its associate or joint venture constitutes a business. For a transaction involving assets that do not constitute a business, a gain or loss resulting from the transaction is recognised in the investor's profit or loss only to the extent of the unrelated investor's interest in that associate or joint venture. The amendments are to be applied prospectively. The previous mandatory effective date of amendments to HKFRS 10 and HKAS 28 (2011) was removed by the HKICPA in January 2016 and a new mandatory effective date will be determined after the completion of a broader review of accounting for associates and joint ventures. However, the amendments are available for adoption now.

HKFRS 16 replaces HKAS 17 *Leases*, HK(IFRIC)-Int 4 *Determining whether an Arrangement contains a Lease*, HK(SIC)-Int 15 *Operating Leases – Incentives* and HK(SIC)-Int 27 *Evaluating the Substance of Transactions Involving the Legal Form of a Lease*. The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to recognise assets and liabilities for most leases. The standard includes two elective recognition exemptions for lessees – leases of low-value assets and short-term leases. At the commencement date of a lease, a lessee will recognise a liability to make lease payments (i.e., the lease liability) and an asset representing the right to use the underlying asset during the lease term (i.e., the right-of-use asset). The right-of-use asset is subsequently measured at cost less accumulated depreciation and any impairment losses unless the right-of-use asset meets the definition of investment property in HKAS 40, or relates to a class of property, plant and equipment to which the revaluation model is applied. The lease liability is subsequently increased to reflect the interest on the lease liability and reduced for the lease payments. Lessees will be required to separately recognise the interest expense on the lease liability and the depreciation expense on the right-of-use asset. Lessees will also be required to remeasure the lease liability upon the occurrence of certain events, such as change in the lease term and change in future lease payments resulting from a change in an index or rate used to determine those payments. Lessees will generally recognise the amount of the remeasurement of the lease liability as an adjustment to the right-of-use asset. Lessor accounting under HKFRS 16 is substantially unchanged from the accounting under HKAS 17. Lessors will continue to classify all leases using the same classification principle as in HKAS 17 and distinguish between operating leases and finance leases. HKFRS 16 requires lessees and lessors to make more extensive disclosures than under HKAS 17. Lessees can choose to apply the standard using either a full retrospective or a modified retrospective approach. The Group will adopt HKFRS 16 from 1 January 2019. The Group plans to adopt the transitional provisions in HKFRS 16 to recognise the cumulative effect of initial adoption as an adjustment to the opening balance of retained earnings at 1 January 2019 and will not restate the comparatives. In addition, the Group plans to apply the new requirements to contracts that were previously identified as leases applying HKAS 17 and measure the lease liability at the present value of the remaining lease payments, discounted using the Group's incremental borrowing rate at the date of initial application. The right-of-use asset will be measured at the amount of the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to the lease recognised in the statement of financial position immediately before the date of initial application. The Group plans to use the exemptions allowed by the standard on lease contracts whose lease terms end within 12 months as of the date of initial application. During 2018, the Group has performed a detailed assessment on the impact of adoption of HKFRS 16. The Group has estimated that right-of-use assets of RMB123,621,000 and lease liabilities of RMB138,329,000 will be recognised at 1 January 2019 with a corresponding adjustment to the opening balance of retained earnings.

2.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS *(Continued)*

Amendments to HKAS 1 and HKAS 8 provide a new definition of material. The new definition states that information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The amendments clarify that materiality will depend on the nature or magnitude of information. A misstatement of information is material if it could reasonably be expected to influence decisions made by the primary users. The Group expects to adopt the amendments prospectively from 1 January 2020. The amendments are not expected to have any significant impact on the Group's financial statements.

Amendments to HKAS 28 clarify that the scope exclusion of HKFRS 9 only includes interests in an associate or joint venture to which the equity method is applied and does not include long-term interests that in substance form part of the net investment in the associate or joint venture, to which the equity method has not been applied. Therefore, an entity applies HKFRS 9, rather than HKAS 28, including the impairment requirements under HKFRS 9, in accounting for such long-term interests. HKAS 28 is then applied to the net investment, which includes the long-term interests, only in the context of recognising losses of an associate or joint venture and impairment of the net investment in the associate or joint venture. The Group expects to adopt the amendments on 1 January 2019 and will assess its business model for such long-term interests based on the facts and circumstances that exist on 1 January 2019 using the transitional requirements in the amendments. The Group also intends to apply the relief from restating comparative information for prior periods upon adoption of the amendments. The amendments are not expected to have any significant impact on the Group's financial statements.

HK(IFRIC)-Int 23 addresses the accounting for income taxes (current and deferred) when tax treatments involve uncertainty that affects the application of HKAS 12 (often referred to as "uncertain tax positions"). The interpretation does not apply to taxes or levies outside the scope of HKAS 12, nor does it specifically include requirements relating to interest and penalties associated with uncertain tax treatments. The interpretation specifically addresses (i) whether an entity considers uncertain tax treatments separately; (ii) the assumptions an entity makes about the examination of tax treatments by taxation authorities; (iii) how an entity determines taxable profits or tax losses, tax bases, unused tax losses, unused tax credits and tax rates; and (iv) how an entity considers changes in facts and circumstances. The interpretation is to be applied retrospectively, either fully retrospectively without the use of hindsight or retrospectively with the cumulative effect of application as an adjustment to the opening equity at the date of initial application, without the restatement of comparative information. The Group expects to adopt the interpretation from 1 January 2019. The interpretation is not expected to have any significant impact on the Group's financial statements.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Investments in associates and a joint venture

An associate is an entity in which the Group has a long-term interest of generally not less than 20% of the equity voting rights and over which it is in a position to exercise significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies.

A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control.

The Group's investments in associates and a joint venture are stated in the consolidated statement of financial position at the Group's share of net assets under the equity method of accounting, less any impairment losses. Adjustments are made to bring into line any dissimilar accounting policies that may exist.

The Group's share of the post-acquisition results and other comprehensive income of associates and joint venture is included in the consolidated statement of profit or loss and consolidated other comprehensive income, respectively. In addition, when there has been a change recognised directly in the equity of the associate or joint venture, the Group recognises its share of any changes, when applicable, in the consolidated statement of changes in equity. Unrealised gains and losses resulting from transactions between the Group and its associates or joint venture are eliminated to the extent of the Group's investments in the associates or joint venture, except where unrealised losses provide evidence of an impairment of the asset transferred. Goodwill arising from the acquisition of any associate or joint venture is included as part of the Group's investments in associates or joint venture.

If an investment in an associate becomes an investment in a joint venture or vice versa, the retained interest is not remeasured. Instead, the investment continues to be accounted for under the equity method. In all other cases, upon loss of significant influence over the associate or joint control over the joint venture, the Group measures and recognises any retained investment at its fair value. Any difference between the carrying amount of the associate or joint venture upon loss of significant influence or joint control and the fair value of the retained investment and proceeds from disposal is recognised in profit or loss.

When an investment in an associate or a joint venture is classified as held for sale, it is accounted for in accordance with HKFRS 5 *Non-current Assets Held for Sale and Discontinued Operations.*

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Business combinations and goodwill

Business combinations are accounted for using the acquisition method. The consideration transferred is measured at the acquisition date fair value which is the sum of the acquisition date fair values of assets transferred by the Group, liabilities assumed by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange for control of the acquiree. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree that are present ownership interests and entitle their holders to a proportionate share of net assets in the event of liquidation at fair value or at the proportionate share of the acquiree's identifiable net assets. All other components of non-controlling interests are measured at fair value. Acquisition-related costs are expensed as incurred.

When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. This includes the separation of embedded derivatives in host contracts of the acquiree.

If the business combination is achieved in stages, the previously held equity interest is remeasured at its acquisition date fair value and any resulting gain or loss is recognised in profit or loss.

Any contingent consideration to be transferred by the acquirer is recognised at fair value at the acquisition date. Contingent consideration classified as an asset or liability is measured at fair value with changes in fair value recognised in profit or loss. Contingent consideration that is classified as equity is not remeasured and subsequent settlement is accounted for within equity.

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred, the amount recognised for non-controlling interests and any fair value of the Group's previously held equity interests in the acquiree over the identifiable net assets acquired and liabilities assumed. If the sum of this consideration and other items is lower than the fair value of the net assets acquired, the difference is, after reassessment, recognised in profit or loss as a gain on bargain purchase.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is tested for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired. The Group performs its annual impairment test of goodwill as at 31 December. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units, or groups of cash-generating units, that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the Group are assigned to those units or groups of units.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Business combinations and goodwill *(Continued)*

Impairment is determined by assessing the recoverable amount of the cash-generating unit (group of cash-generating units) to which the goodwill relates. Where the recoverable amount of the cash-generating unit (group of cash-generating units) is less than the carrying amount, an impairment loss is recognised. An impairment loss recognised for goodwill is not reversed in a subsequent period.

Where goodwill has been allocated to a cash-generating unit (or group of cash-generating units) and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on the disposal. Goodwill disposed of in these circumstances is measured based on the relative value of the operation disposed of and the portion of the cash-generating unit retained.

Fair value measurement

The Group measures its equity investments at fair value at the end of each reporting period. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Fair value measurement *(Continued)*

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 – based on quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly

Level 3 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by reassessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Impairment of non-financial assets

Where an indication of impairment exists, or when annual impairment testing for an asset is required (other than inventories, construction contract assets, financial assets, investment properties and non-current assets/a disposal group classified as held for sale), the asset's recoverable amount is estimated. An asset's recoverable amount is the higher of the asset's or cash-generating unit's value in use and its fair value less costs of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the cash-generating unit to which the asset belongs.

An impairment loss is recognised only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to the statement of profit and loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.

An assessment is made at the end of each reporting period as to whether there is an indication that previously recognised impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognised impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortisation) had no impairment loss been recognised for the asset in prior years. A reversal of such an impairment loss is credited to the statement of profit or loss in the period in which it arises.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Related parties

A party is considered to be related to the Group if:

(a) the party is a person or a close member of that person's family and that person

(i) has control or joint control over the Group;

(ii) has significant influence over the Group;

(iii) or is a member of the key management personnel of the Group or of a parent of the Group;

or

(b) the party is an entity where any of the following conditions applies:

(i) the entity and the Group are members of the same group;

(ii) one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);

(iii) the entity and the Group are joint ventures of the same third party;

(iv) one entity is a joint venture of a third entity and the other entity is an associate of the third entity;

(v) the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group;

(vi) the entity is controlled or jointly controlled by a person identified in (a);

(vii) a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity);

(viii) and the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the parent of the Group.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Property, plant and equipment and depreciation

Property, plant and equipment, other than construction in progress, are stated at cost less accumulated depreciation and any impairment losses. When an item of property, plant and equipment is classified as held for sale or when it is part of a disposal group classified as held for sale, it is not depreciated and is accounted for in accordance with HKFRS 5. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, is normally charged to the statement of profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalised in the carrying amount of the asset as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognises such parts as individual assets with specific useful lives and depreciates them accordingly.

Depreciation is calculated on the straight-line basis to write off the cost of each item of property, plant and equipment to its residual value over its estimated useful life. The principal annual rates used for this purpose are as follows:

Buildings	3.17%-4.75%
Leasehold improvements	Over the shorter of lease terms and 10%
Machinery	8.60%-19.40%
Furniture and fixtures	19.00%-32.33%
Motor vehicles	19.00%-24.25%

Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at each financial year end.

An item of property, plant and equipment including any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognised in the statement of profit or loss in the year the asset is derecognised is the difference between the net sales proceeds and the carrying amount of the relevant asset.

Construction in progress represents a building under construction, which is stated at cost less any impairment losses, and is not depreciated. Cost comprises the direct costs of construction and capitalised borrowing costs on related borrowed funds during the period of construction. Construction in progress is reclassified to the appropriate category of property, plant and equipment when completed and ready for use.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Intangible assets (other than goodwill)

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at each financial year end.

Patents and license

Purchased patents and license is stated at cost less any impairment losses and is amortised on the straight-line basis over an estimated useful life of 10 years.

Computer software

Computer software is stated at cost less any impairment losses and is amortised on the straight-line basis over an estimated useful life of 10 years.

Research and development costs

All research costs are charged to the statement of profit or loss as incurred.

Expenditure incurred on projects to develop new products is capitalised and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development. Product development expenditure which does not meet these criteria is expensed when incurred.

Deferred development costs are stated at cost less any impairment losses and are amortised using the straight-line basis over the commercial lives of the underlying products not exceeding five to seven years, commencing from the date when the products are put into commercial production.

Leases

Leases that transfer substantially all the rewards and risks of ownership of assets to the Group, other than legal title, are accounted for as finance leases. At the inception of a finance lease, the cost of the leased asset is capitalised at the present value of the minimum lease payments and recorded together with the obligation, excluding the interest element, to reflect the purchase and financing. Assets held under capitalised finance leases, including prepaid land lease payments under finance leases, are included in property, plant and equipment, and depreciated over the shorter of the lease terms and the estimated useful lives of the assets. The finance costs of such leases are charged to the statement of profit or loss so as to provide a constant periodic rate of charge over the lease terms.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Leases *(Continued)*

Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Where the Group is the lessor, assets leased by the Group under operating leases are included in non-current assets, and rentals receivable under the operating leases are credited to the statement of profit or loss on the straight-line basis over the lease terms. Where the Group is the lessee, rentals payable under operating leases net of any incentives received from the lessor are charged to the statement of profit or loss on the straight-line basis over the lease terms. As disclosed in note 38 to the financial statements, at 31 December 2018, the Group had future minimum lease payments under non-cancellable operating leases in aggregate of approximately RMB169,840,000.

Prepaid land lease payments under operating leases are initially stated at cost and subsequently recognised on the straight-line basis over the lease terms.

Investments and other financial assets (policies under HKFRS 9 applicable from 1 January 2018)

Initial recognition and measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through other comprehensive income, and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Group's business model for managing them. With the exception of trade receivables that do not contain a significant financing component, the Group initially measures a financial asset at its fair value, plus in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price determined under HKFRS 15 in accordance with the policies set out for "Revenue recognition (applicable from 1 January 2018)" below.

In order for a financial asset to be classified and measured at amortised cost or fair value through other comprehensive income, it needs to give rise to cash flows that are solely payments of principal and interest ("SPPI") on the principal amount outstanding.

The Group's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both.

All regular way purchases and sales of financial assets are recognised on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Investments and other financial assets (policies under HKFRS 9 applicable from 1 January 2018) *(Continued)*

Subsequent measurement

The subsequent measurement of financial assets depends on their classification as follows:

Financial assets at amortised cost (debt instruments)
The Group measures financial assets at amortised cost if both of the following conditions are met:

- The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows.

- The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets at amortised cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognised in the statement of profit or loss when the asset is derecognised, modified or impaired.

Financial assets designated at fair value through other comprehensive income (equity investments)
Upon initial recognition, the Group can elect to classify irrevocably its equity investments as equity investments designated at fair value through other comprehensive income when they meet the definition of equity under HKAS 32 *Financial Instruments:* Presentation and are not held for trading. The classification is determined on an instrument-by-instrument basis.

Gains and losses on these financial assets are never recycled to the statement of profit or loss. Dividends are recognised as other income in the statement of profit or loss when the right of payment has been established, it is probable that the economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably, except when the Group benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case such gains are recorded in other comprehensive income.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Investments and other financial assets (policies under HKFRS 9 applicable from 1 January 2018) *(Continued)*

Subsequent measurement *(Continued)*

Financial assets at fair value through profit or loss
Financial assets at fair value through profit or loss include financial assets held for trading, financial assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured at fair value. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated as effective hedging instruments. Financial assets with cash flows that are not solely payments of principal and interest are classified and measured at fair value through profit or loss, irrespective of the business model. Notwithstanding the criteria for debt instruments to be classified at amortised cost or at fair value through other comprehensive income, as described above, debt instruments may be designated at fair value through profit or loss on initial recognition if doing so eliminates, or significantly reduces, an accounting mismatch.

Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognised in the statement of profit or loss.

Investments and other financial assets (policies under HKAS 39 applicable before 1 January 2018)

Initial recognition and measurement

Financial assets are classified, at initial recognition, as financial assets at fair value through profit or loss, loans and receivables and available-for-sale financial investments, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. When financial assets are recognised initially, they are measured at fair value plus transaction costs that are attributable to the acquisition of the financial assets, except in the case of financial assets recorded at fair value through profit or loss.

All regular way purchases and sales of financial assets are recognised on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

Subsequent measurement

Financial assets at fair value through profit or loss
Financial assets at fair value through profit or loss include financial assets held for trading and financial assets designated upon initial recognition as at fair value through profit or loss. Financial assets are classified as held for trading if they are acquired for the purpose of sale in the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated as effective hedging instruments as defined by HKAS 39.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Investments and other financial assets (policies under HKAS 39 applicable before 1 January 2018) *(Continued)*

Subsequent measurement *(Continued)*

Financial assets at fair value through profit or loss (Continued)
Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with positive net changes in fair value presented as other income and gains and negative net changes in fair value presented as finance costs in the statement of profit or loss. These net fair value changes do not include any dividends or interest earned on these financial assets, which are recognised in accordance with the policies set out for "Revenue recognition (applicable before 1 January 2018)" below.

Financial assets designated upon initial recognition as at fair value through profit or loss are designated at the date of initial recognition and only if the criteria in HKAS 39 are satisfied.

Loans and receivables
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. After initial measurement, such assets are subsequently measured at amortised cost using the effective interest rate method less any allowance for impairment. Amortised cost is calculated by taking into account any discount or premium on acquisition and includes fees or costs that are an integral part of the effective interest rate. The effective interest rate amortisation is included in other income and gains in the statement of profit or loss. The loss arising from impairment is recognised in the statement of profit or loss in finance costs for loans and in other expenses for receivables.

Available-for-sale financial investments
Available-for-sale financial investments are non-derivative financial assets in listed and unlisted equity investments and debt securities. Equity investments classified as available for sale are those which are neither classified as held for trading nor designated as at fair value through profit or loss. Debt securities in this category are those which are intended to be held for an indefinite period of time and which may be sold in response to needs for liquidity or in response to changes in market conditions.

After initial recognition, available-for-sale financial investments are subsequently measured at fair value, with unrealised gains or losses recognised as other comprehensive income in the available-for-sale investment revaluation reserve until the investment is derecognised, at which time the cumulative gain or loss is recognised in the statement of profit or loss in other income, or until the investment is determined to be impaired, when the cumulative gain or loss is reclassified from the available-for-sale investment revaluation reserve to the statement of profit or loss in other gains or losses. Interest and dividends earned whilst holding the available-for-sale financial investments are reported as interest income and dividend income, respectively and are recognised in the statement of profit or loss as other income in accordance with the policies set out for "Revenue recognition (applicable before 1 January 2018)" below.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Investments and other financial assets (policies under HKAS 39 applicable before 1 January 2018) *(Continued)*

Subsequent measurement *(Continued)*

Available-for-sale financial investments (Continued)
When the fair value of unlisted equity investments cannot be reliably measured because (a) the variability in the range of reasonable fair value estimates is significant for that investment or (b) the probabilities of the various estimates within the range cannot be reasonably assessed and used in estimating fair value, such investments are stated at cost less any impairment losses.

The Group evaluates whether the ability and intention to sell its available-for-sale financial assets in the near term are still appropriate. When, in rare circumstances, the Group is unable to trade these financial assets due to inactive markets, the Group may elect to reclassify these financial assets if management has the ability and intention to hold the assets for the foreseeable future or until maturity. For a financial asset reclassified from the available-for-sale category, the fair value carrying amount at the date of reclassification becomes its new amortised cost and any previous gain or loss on that asset that has been recognised in equity is amortised to profit or loss over the remaining life of the investment using the effective interest rate. Any difference between the new amortised cost and the maturity amount is also amortised over the remaining life of the asset using the effective interest rate. If the asset is subsequently determined to be impaired, then the amount recorded in equity is reclassified to the statement of profit or loss.

For a financial asset reclassified from the available-for-sale category, the fair value carrying amount at the date of reclassification becomes its new amortised cost and any previous gain or loss on that asset that has been recognised in equity is amortised to profit or loss over the remaining life of the investment using the effective interest rate. Any difference between the new amortised cost and the maturity amount is also amortised over the remaining life of the asset using the effective interest rate. If the asset is subsequently determined to be impaired, then the amount recorded in equity is reclassified to the statement of profit or loss.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Derecognition of financial assets (policies under HKFRS 9 applicable from 1 January 2018 and policies under HKAS 39 applicable before 1 January 2018)

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e., removed from the Group's consolidated statement of financial position) when:

- the rights to receive cash flows from the asset have expired; or

- the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a "pass-through" arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership of the asset. When it has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

Impairment of financial assets (policies under HKFRS 9 applicable from 1 January 2018)

The Group recognises an allowance for ECLs for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Impairment of financial assets (policies under HKFRS 9 applicable from 1 January 2018) *(Continued)*

General approach

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

At each reporting date, the Group assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. When making the assessment, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition and considers reasonable and supportable information that is available without undue cost or effort, including historical and forward-looking information.

For debt investments at fair value through other comprehensive income, the Group applies the low credit risk simplification. At each reporting date, the Group evaluates whether the debt investments are considered to have low credit risk using all reasonable and supportable information that is available without undue cost or effort. In making that evaluation, the Group reassesses the external credit ratings of the debt investments. In addition, the Group considers that there has been a significant increase in credit risk when contractual payments are more than 30 days past due.

The Group considers a trade and bills receivable in default when contractual payments are over 360 days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Impairment of financial assets (policies under HKFRS 9 applicable from 1 January 2018) *(Continued)*

General approach *(Continued)*

Debt investments at fair value through other comprehensive income and financial assets at amortised cost are subject to impairment under the general approach and they are classified within the following stages for measurement of ECLs except for trade receivables and contract assets which apply the simplified approach as detailed below.

Stage 1 – Financial instruments for which credit risk has not increased significantly since initial recognition and for which the loss allowance is measured at an amount equal to 12-month ECLs

Stage 2 – Financial instruments for which credit risk has increased significantly since initial recognition but that are not credit-impaired financial assets and for which the loss allowance is measured at an amount equal to lifetime ECLs

Stage 3 – Financial assets that are credit-impaired at the reporting date (but that are not purchased or originated credit-impaired) and for which the loss allowance is measured at an amount equal to lifetime ECLs

Simplified approach

For trade receivables and other receivables that do not contain a significant financing component, the Group applies the simplified approach in calculating ECLs. Under the simplified approach, the Group does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

For trade receivables and other assets that contain a significant financing component and lease receivables, the Group chooses as its accounting policy to adopt the simplified approach in calculating ECLs with policies as described above.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Impairment of financial assets (policies under HKAS 39 applicable before 1 January 2018)

The Group assesses at the end of each reporting period whether there is objective evidence that a financial asset or a group of financial assets is impaired. An impairment exists if one or more events that occurred after the initial recognition of the asset have an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated. Evidence of impairment may include indications that a debtor or a group of debtors is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganisation and observable data indicating that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or economic conditions that correlate with defaults.

Financial assets carried at amortised cost

For financial assets carried at amortised cost, the Group first assesses whether impairment exists individually for financial assets that are individually significant, or collectively for financial assets that are not individually significant. If the Group determines that no objective evidence of impairment exists for an individually assessed financial asset, whether significant or not, it includes the asset in a group of financial assets with similar credit risk characteristics and collectively assesses them for impairment. Assets that are individually assessed for impairment and for which an impairment loss is, or continues to be, recognised are not included in a collective assessment of impairment.

The amount of any impairment loss identified is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not yet been incurred). The present value of the estimated future cash flows is discounted at the financial asset's original effective interest rate (i.e., the effective interest rate computed at initial recognition).

The carrying amount of the asset is reduced through the use of an allowance account and the loss is recognised in the statement of profit or loss. Interest income continues to be accrued on the reduced carrying amount using the rate of interest used to discount the future cash flows for the purpose of measuring the impairment loss. Loans and receivables together with any associated allowance are written off when there is no realistic prospect of future recovery and all collateral has been realised or has been transferred to the Group.

If, in a subsequent period, the amount of the estimated impairment loss increases or decreases because of an event occurring after the impairment was recognised, the previously recognised impairment loss is increased or decreased by adjusting the allowance account. If a write-off is later recovered, the recovery is credited to other expenses in the statement of profit or loss.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Impairment of financial assets (policies under HKAS 39 applicable before 1 January 2018) *(Continued)*

Available-for-sale financial investments

For available-for-sale financial investments, the Group assesses at the end of each reporting period whether there is objective evidence that an investment or a group of investments is impaired.

If an available-for-sale asset is impaired, an amount comprising the difference between its cost (net of any principal payment and amortisation) and its current fair value, less any impairment loss previously recognised in the statement of profit or loss, is removed from other comprehensive income and recognised in the statement of profit or loss.

In the case of equity investments classified as available for sale, objective evidence would include a significant or prolonged decline in the fair value of an investment below its cost. "Significant" is evaluated against the original cost of the investment and "prolonged" against the period in which the fair value has been below its original cost. Where there is evidence of impairment, the cumulative loss – measured as the difference between the acquisition cost and the current fair value, less any impairment loss on that investment previously recognised in the statement of profit or loss – is removed from other comprehensive income and recognised in the statement of profit or loss. Impairment losses on equity instruments classified as available for sale are not reversed through the statement of profit or loss. Increases in their fair value after impairment are recognised directly in other comprehensive income.

The determination of what is "significant" or "prolonged" requires judgement. In making this judgement, the Group evaluates, among other factors, the duration or extent to which the fair value of an investment is less than its cost.

Financial liabilities (policies under HKFRS 9 applicable from 1 January 2018 and HKAS 39 applicable before 1 January 2018)

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value though profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group's financial liabilities include trade and other payables and interest-bearing bank borrowings.

Subsequent measurement

The subsequent measurement of loans and borrowings is as follows:

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Financial liabilities (policies under HKFRS 9 applicable from 1 January 2018 and HKAS 39 applicable before 1 January 2018) *(Continued)*

Loans and borrowings

After initial recognition, interest bearing loans and borrowings are subsequently measured at amortised cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognised in the statement of profit or loss when the liabilities are derecognised as well as through the effective interest rate amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortisation is included in finance costs in the statement of profit or loss.

Derecognition of financial liabilities (policies under HKFRS 9 applicable from 1 January 2018 and HKAS 39 applicable before 1 January 2018)

A financial liability is derecognised when the obligation under the liability is discharged or cancelled, or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognised in the statement of profit or loss.

Offsetting of financial instruments (policies under HKFRS 9 applicable from 1 January 2018 and HKAS 39 applicable before 1 January 2018)

Financial assets and financial liabilities are offset and the net amount is reported in the statement of financial position if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liabilities simultaneously.

Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined on the weighted average basis and, in the case of work in progress and finished goods, comprises direct materials, direct labour and an appropriate proportion of overheads. Net realisable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Cash and cash equivalents

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise cash on hand and demand deposits, and short-term highly liquid investments that are readily convertible into known amounts of cash, are subject to an insignificant risk of changes in value, and have a short maturity of generally within three months when acquired, less bank overdrafts which are repayable on demand and form an integral part of the Group's cash management.

For the purpose of the consolidated statement of financial position, cash and cash equivalents comprise cash on hand and at banks, including time deposits, and assets similar in nature to cash, which are not restricted as to use.

Provisions

A provision is recognised when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

When the effect of discounting is material, the amount recognised for a provision is the present value at the end of the reporting period of the future expenditures expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is included in finance costs in the statement of profit or loss.

Income tax

Income tax comprises current and deferred tax. Income tax relating to items recognised outside profit or loss is recognised outside profit or loss, either in other comprehensive income or directly in equity.

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the country in which the Group operates.

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Income tax *(Continued)*

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

- in respect of taxable temporary differences associated with investments in subsidiaries, associates and joint venture, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except:

- when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

- in respect of deductible temporary differences associated with investments in subsidiaries, associates and joint venture, deferred tax assets are only recognised to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are reassessed at the end of each reporting period and are recognised to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and deferred tax liabilities are offset if and only if the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Government grants

Government grants are recognised at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the costs, which it is intended to compensate, are expensed.

Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to the statement of profit or loss over the expected useful life of the relevant asset by equal annual instalments or deducted from the carrying amount of the asset and released to the statement of profit or loss by way of a reduced depreciation charge.

Revenue recognition (applicable from 1 January 2018)

Revenue from contracts with customers

Revenue from contracts with customers is recognised when control of goods or services is transferred to the customers at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services.

When the consideration in a contract includes a variable amount, the amount of consideration is estimated to which the Group will be entitled in exchange for transferring the goods or services to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

When the contract contains a financing component which provides the customer a significant benefit of financing the transfer of goods or services to the customer for more than one year, revenue is measured at the present value of the amount receivable, discounted using the discount rate that would be reflected in a separate financing transaction between the Group and the customer at contract inception. When the contract contains a financing component which provides the Group a significant financial benefit for more than one year, revenue recognised under the contract includes the interest expense accreted on the contract liability under the effective interest method. For a contract where the period between the payment by the customer and the transfer of the promised goods or services is one year or less, the transaction price is not adjusted for the effects of a significant financing component, using the practical expedient in HKFRS 15.

Sale of diagnostic reagent products
Revenue from the sale of diagnostic reagent products is recognised at the point in time when control of the asset is transferred to the customer, generally on acceptance of the diagnostic reagent products.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Revenue recognition (applicable from 1 January 2018) *(Continued)*

Revenue from other sources

Rental income is recognised on a time proportion basis over the lease terms.

Other income

Interest income is recognised on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.

Dividend income is recognised when the shareholders' right to receive payment has been established, it is probable that the economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

Revenue recognition (applicable before 1 January 2018)

Revenue is recognised when it is probable that the economic benefits will flow to the Group and when the revenue can be measured reliably, on the following bases:

(a) from the sale of goods, when the significant risks and rewards of ownership have been transferred to the buyer, provided that the Group maintains neither managerial involvement to the degree usually associated with ownership, nor effective control over the goods sold;

(b) from the rendering of services, on the percentage of completion basis, as further explained in the accounting policy for "Contracts for services (applicable before 1 January 2018)" below;

(c) rental income, on a time proportion basis over the lease terms;

(d) interest income, on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset; and

(e) dividend income, when the shareholders' right to receive payment has been established.

Contract liabilities (applicable from 1 January 2018)

A contract liability is the obligation to transfer goods or services to a customer for which the Group has received a consideration (or an amount of consideration that is due) from the customer. If a customer pays the consideration before the Group transfers goods or services to the customer, a contract liability is recognised when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Group performs under the contract.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Employee benefits

Pension scheme

The employees of the Group's subsidiary which operates in the PRC are required to participate in a central pension scheme operated by the local municipal government. This subsidiary is required to contribute 5% of its payroll costs to the central pension scheme. The contributions are charged to the statement of profit or loss as they become payable in accordance with the rules of the central pension scheme.

Termination benefits

Termination benefits are recognised at the earlier of when the Group can no longer withdraw the offer of those benefits and when the Group recognises restructuring costs involving the payment of termination benefits.

Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, i.e., assets that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalised as part of the cost of those assets. The capitalisation of such borrowing costs ceases when the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs capitalised. All other borrowing costs are expensed in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

Dividends

Final dividends are recognised as a liability when they are approved by the shareholders in a general meeting. Proposed final dividends are disclosed in the notes to the financial statements.

Foreign currencies

These financial statements are presented in RMB, which is the Company's functional currency. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. Foreign currency transactions recorded by the entities in the Group are initially recorded using their respective functional currency rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange ruling at the end of the reporting period. Differences arising on settlement or translation of monetary items are recognised in the statement of profit or loss.

2.4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(Continued)*

Foreign currencies *(Continued)*

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. The gain or loss arising on translation of a non-monetary item measured at fair value is treated in line with the recognition of the gain or loss on change in fair value of the item (i.e., translation difference on the item whose fair value gain or loss is recognised in other comprehensive income or profit or loss is also recognised in other comprehensive income or profit or loss, respectively).

In determining the exchange rate on initial recognition of the related asset, expense or income on the derecognition of a non-monetary asset or non-monetary liability relating to an advance consideration, the date of initial transaction is the date on which the Group initially recognises the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of the advance consideration.

The functional currency of an overseas subsidiary is a currency other than RMB. As at the end of the reporting period, the assets and liabilities of the subsidiary are translated into RMB at the exchange rates prevailing at the end of the reporting period and its statement of profit or loss is translated into RMB at the weighted average exchange rates for the year.

The resulting exchange differences are recognised in other comprehensive income and accumulated in the exchange fluctuation reserve. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is recognised in the statement of profit or loss.

For the purpose of the consolidated statement of cash flows, the cash flows of overseas subsidiaries are translated into RMB at the exchange rates ruling at the dates of the cash flows. Frequently recurring cash flows of overseas subsidiaries which arise throughout the year are translated into RMB at the weighted average exchange rates for the year.

3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES

The preparation of the Group's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.

3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES *(Continued)*

Judgements

Operating lease commitments – Group as lessor

The Group has entered into commercial property leases on its investment property portfolio. The Group has determined, based on an evaluation of the terms and conditions of the arrangements, that it retains all the significant risks and rewards of ownership of these properties which are leased out on operating leases.

Consolidation of entities in which the Group holds less than a majority of voting rights

The Group considers that it controls Zhongsheng Jinyu even though it owns less than 50% of the voting rights. This is because the Group and two other shareholders entered into an Acting in Concert agreement, which constitutes 90% of the voting rights. Since the date of acquisition of Zhongsheng Jinyu, there has been no history of the other shareholders collaborating to exercise their votes collectively or to outvote the Group.

Estimation uncertainty

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.

Impairment of goodwill

The Group determines whether goodwill is impaired at least on an annual basis. This requires an estimation of the value in use of the cash-generating units to which the goodwill is allocated. Estimating the value in use requires the Group to make an estimate of the expected future cash flows from the cash-generating units and also to choose a suitable discount rate in order to calculate the present value of those cash flows. Further details are given in note 16.

Provision for expected credit losses on trade receivables

The Group uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for groupings of various customer segments that have similar loss patterns.

The provision matrix is initially based on the Group's historical observed default rates. The Group will calibrate the matrix to adjust the historical credit loss experience with forward-looking information. For instance, if forecast economic conditions (i.e., gross domestic products) are expected to deteriorate over the next year which can lead to an increased number of defaults in the manufacturing sector, the historical default rates are adjusted. At each reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

The assessment of the correlation among historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and forecast economic conditions. The Group's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the future. The information about the ECLs on the Group's trade receivables is disclosed in note 23 to the financial statements.

3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES *(Continued)*

Estimation uncertainty *(Continued)*

Impairment of non-financial assets (other than goodwill)

The Group assesses whether there are any indicators of impairment for all non-financial assets at the end of each reporting period. Indefinite life intangible assets are tested for impairment annually and at other times when such an indicator exists. Other non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. An impairment exists when the carrying value of an asset or a cash-generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The calculation of the fair value less costs of disposal is based on available data from binding sales transactions in an arm's length transaction of similar assets or observable market prices less incremental costs for disposing of the asset. When value in use calculations are undertaken, management must estimate the expected future cash flows from the asset or cash-generating unit and choose a suitable discount rate in order to calculate the present value of those cash flows.

Deferred tax assets

Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and level of future taxable profits together with future tax planning strategies. The carrying value of deferred tax assets relating to recognised tax losses at 31 December 2018 was RMB1,864,000 (2017: RMB2,092,000). The amount of unrecognised tax losses at 31 December 2018 was RMB36,478,000 (2017: RMB47,400,100).

Research and development costs

All research costs are charged to the statement of profit or loss as incurred. Expenditure incurred on projects to develop new products is capitalised and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development. Product development expenditure which does not meet these criteria is expensed when incurred. Determining the amounts of development costs to be capitalised requires the use of judgements and estimation.

Fair value of unlisted equity investments

The unlisted equity investments have been valued based on a market-based valuation technique as detailed in note 19 to the financial statements. The valuation requires the Group to determine the comparable public companies (peers) and select the price multiple. In addition, the Group makes estimates about the discount for illiquidity and size differences. The Group classifies the fair value of these investments as Level 3. The fair value of the unlisted equity investments at 31 December 2018 was RMB1,117,000 (2017: RMB1,268,000). Further details are included in note 19 to the financial statements.

3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES *(Continued)*

Estimation uncertainty *(Continued)*

Useful lives and residual values of property, plant and equipment

The Group's management determines the residual values, useful lives and related depreciation charges of the Group's property, plant and equipment. This estimate is based on the historical experience of the actual residual values and useful lives of property, plant and equipment of similar nature and functions. It could change significantly as a result of technical innovations and competitor actions in response to severe industry cycles. Management will increase the depreciation charge where residual values or useful lives are less than previously estimated, or it will write off or write down technically obsolete or non-strategic assets that have been abandoned or sold. Actual economic lives may differ from estimated useful lives. Periodic review could result in a change in depreciable lives and therefore depreciation in the future periods.

Provision for obsolete and slow-moving inventories

Management reviews the condition of inventories of the Group and makes provision for obsolete and slow-moving inventory items which are identified as no longer suitable for sale or use. Management estimates the net realisable value for such inventories based primarily on the latest invoice prices and current market conditions. The Group carries out an inventory review at the end of each reporting period and makes provision for obsolete and slow-moving items. Management reassesses the estimation at the end of each reporting period. The identification of obsolete and slow-moving inventory items requires the use of judgements and estimates. Where the expectation is different from the original estimate, such difference will impact on the carrying value of inventories and the write-down of inventories recognised in the period in which such estimate has been made.

4. OPERATING SEGMENT INFORMATION

For management purposes, the Group has one reportable operating segment: the in-vitro diagnostic reagent products segment, which manufactures, sells and distributes a variety of mono/double diagnostic reagent products.

Management monitors the operating results of the Group's business units as a whole for the purpose of making decisions about resources allocation and performance assessment. All of the Group's revenue from external customers and profits are generated from this single segment.

Geographical information

During the year ended 31 December 2018, almost all of the Group's revenue was generated from customers located in Mainland China and all of the non-current assets of the Group were located in Mainland China.

Information about major customers

Revenue of approximately RMB57,696,000 was derived from sales by the in-vitro diagnostic reagent products segment to a single customer, which amounted to more than 10% of the Group's total revenue.

5. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	2018 RMB'000	2017 RMB'000
Revenue from contracts with customers		
Sale of in-vitro diagnostic reagent products	**303,224**	295,128
Other income		
Government grants	**7,836**	2,765
Interest income	**609**	535
Income from placement services	**501**	16,048
Service income	**–**	759
Interest income from entrusted loans	**–**	613
Others	**161**	214
	9,107	20,934
Gains		
Fair value gains of financial assets, net:	**206**	–
Gain on deemed disposal on investment in an associate	**–**	19,953
	206	19,953
	9,313	40,887

6. (LOSS)/PROFIT BEFORE TAX

The Group's (loss)/profit before tax is arrived at after charging/(crediting):

	Notes	**2018 RMB'000**	2017 RMB'000
Cost of inventories sold *(i)*		**182,821**	157,843
Employee benefit expense (including directors' and supervisors' remuneration *(note 8)*):			
Wages, salaries and bonuses		**42,874**	42,048
Pension scheme contributions *(ii)*		**7,625**	6,962
Social welfare and other costs		**9,862**	8,735
		60,361	57,745
Research and development costs* *(iii)*		**25,402**	26,852
Government grants released	*5*	**(7,836)**	(2,765)
Loss on disposal of items of property, plant and equipment, net		**80**	2,368
Minimum lease payments under operating leases in respect of land and buildings		**2,211**	2,428
Auditor's remuneration		**845**	720
Depreciation	*13*	**23,572**	21,530
Amortisation of prepaid land lease payments	*14*	**81**	81
Amortisation of other intangible assets	*17*	**1,074**	564
Impairment of other intangible assets	*17*	**300**	500
(Reversal)/accrual of impairment of trade and bills receivables	*23(a)*	**(457)**	84
Impairment of prepayments, other receivables and other assets		**103**	8
Write-down of inventories to net realisable value		**2,120**	–
Fair value gains of financial assets, net	*5*	**(206)**	–
Gain on deemed disposal of an investment in an associate	*5*	**–**	(19,953)
Interest on bank and other loans	*7*	**14,167**	6,893
Foreign exchange differences, net		**132**	176

6. (LOSS)/PROFIT BEFORE TAX *(Continued)*

(i) For the year ended 31 December 2018, cost of inventories sold includes the depreciation of RMB16,283,000 (2017:RMB3,108,000), employee benefit costs of RMB13,393,000 (2017: RMB13,682,000) and rental expenditure of RMB1,548,000 (2017: RMB2,096,000).

(ii) As at 31 December 2018 and 2017, the Group had no forfeited contributions available to reduce its contributions to the pension scheme in future years.

(iii) For the year ended 31 December 2018, research and development costs include the depreciation of RMB1,269,000 (2017: RMB1,637,000), employee benefit costs of RMB11,859,000 (2017: RMB10,669,000) and rental expenditure of RMB735,000 (2017: RMB343,000).

7. FINANCE COSTS

An analysis of finance costs is as follows:

	2018 **RMB'000**	2017 RMB'000
Interest on bank and other loans	**14,167**	6,893

8. DIRECTORS' AND SUPERVISORS' REMUNERATION

Directors' and chief executive's remuneration for the year, disclosed pursuant to the Listing Rules, section 383(1)(a), (b), (c) and (f) of the Hong Kong Companies Ordinance and Part 2 of the Companies (Disclosure of Information about Benefits of Directors) Regulation, is as follows:

	Group	
	2018 **RMB'000**	2017 RMB'000
Fees	**230**	276
Other emoluments:		
Salaries, allowances and benefits in kind	**2,232**	7,384
	2,462	7,660

8. DIRECTORS' AND SUPERVISORS' REMUNERATION *(Continued)*

(a) Independent non-executive directors

The fees paid to independent non-executive directors during the year were as follows:

	2018 **RMB'000**	2017 RMB'000
Dr. Zheng Yongtang	**60**	60
Dr. Hu Canwu Kevin[1]	**60**	60
Mr. Wang Daixue	**60**	60
Mr. Pan Chunyu[2]	**–**	–
	180	180

There were no other emoluments payable to the independent non-executive directors for the years of 2018 and 2017.

1 Dr. Hu Canwu Kevin resigned as an independent non-executive director on 8 January 2019.

2 Mr. Pan Chunyu was appointed as an independent non-executive director on 8 January 2019.

8. DIRECTORS' AND SUPERVISORS' REMUNERATION *(Continued)*

(b) Executive directors, non-executive directors and supervisors

	Fees RMB'000	Salaries, allowances and benefits in kind RMB'000	Total remuneration RMB'000
2018			
Executive directors:			
Mr. Wu Lebin	–	–	–
Mr. Chen Jintian	–	780	780
Dr. Xu Cunmao	–	477	477
Mr. Chen Jianhua	–	435	435
Mr. Zhang Haitao[3]	–	64	64
	–	1,756	1,756
Non-executive directors:			
Dr. Bi Lijun[4]	12	–	12
Mr. Hou Quanmin[4]	12	–	12
Dr. Sun Zhe[5]	6	–	6
Ms. Cheng Yali[5]	6	–	6
	36	–	36
Supervisors:			
Mr. Zhou Jie	–	476	476
Ms. Yan Xiyun[6]	7	–	7
Ms. Huang Aiyu	7	–	7
Dr. Shen Sheng[7]	–	–	–
	14	476	490
	50	2,232	2,282

8. DIRECTORS' AND SUPERVISORS' REMUNERATION *(Continued)*

(b) Executive directors, non-executive directors and supervisors *(Continued)*

	Fees RMB'000	Salaries, allowances and benefits in kind RMB'000	Total remuneration RMB'000
2017			
Executive directors:			
Mr. Chen Jintian	–	2,317	2,317
Mr. Zhang Haitao[3]	–	2,237	2,237
Mr. Wu Lebin	–	1,326	1,326
Dr. Xu Cunmao	–	871	871
	–	6,751	6,751
Non-executive directors:			
Dr. Bi Lijun[4]	30	–	30
Mr. Hou Quanmin[4]	30	–	30
	60	–	60
Supervisors:			
Mr. Zhou Jie	–	633	633
Ms. Yan Xiyun[6]	18	–	18
Ms. Huang Aiyu	18	–	18
	36	633	669
	96	7,384	7,480

There was no arrangement under which a director waived or agreed to waive any remuneration during the year.

8. DIRECTORS' AND SUPERVISORS' REMUNERATION *(Continued)*

(b) Executive directors, non-executive directors and supervisors *(Continued)*

[3] Mr. Zhang Haitao was appointed as an executive director on 2 December 2015 and resigned on 19 January 2018.

[4] Dr. Bi Lijun and Mr. Hou Quanmin resigned on 18 September 2018.

[5] Dr. Sun Zhe and Ms. Cheng Yali were appointed as non-executive directors on 23 November 2018.

[6] Ms. Yan Xiyun resigned on 23 November 2018.

[7] Dr. Shen Sheng was appointed as a supervisor on 23 November 2018.

9. FIVE HIGHEST PAID EMPLOYEES

The five highest paid employees during the year included three directors and one supervisor (2017: four directors), details of whose remuneration are set out in note 8 above. Details of the remuneration for the year of the remaining one (2017: one) highest paid employee who is neither a director nor supervisor of the Company are as follows:

	2018	2017
	RMB'000	RMB'000
Salaries, allowances and benefits in kind	**444**	836
Pension scheme contributions	**23**	51
	467	887

The remuneration of the non-director and non-supervisor executive highest paid employee fell within the following band as follows:

	Number of employees	
	2018	2017
Nil to RMB1,000,000	**1**	1

10. INCOME TAX

Taxes on profits assessable in the PRC, where the Group operates, have been calculated at the rate of tax prevailing in the PRC. Under the PRC income tax laws, enterprises are subject to corporate income tax ("CIT") at a rate of 25%.

The Company and Zhongsheng Jinyu, a subsidiary of the Company, are subject to a preferential rate of 15% under the PRC income tax laws for a period of three years commencing from 1 January 2017 as they are accredited by the relevant government authorities as High and New Technology Enterprises.

Anhui Zhongsheng, a subsidiary of the Company, is subject to a preferential rate of 10% under the PRC income tax laws for a period of one year commencing from 1 January 2018 as it is accredited by the relevant government authorities as a Small and Low-profit Enterprise.

No Hong Kong profits tax has been provided because the Group did not generate any assessable profits in Hong Kong during the year.

	2018 **RMB'000**	2017 RMB'000
Current – the PRC		
Charge for the year	**1,893**	2,195
Underprovision in prior years	**265**	–
Deferred *(note 30)*	**26**	1,432
Total tax charge for the year	**2,184**	3,627

10. INCOME TAX *(Continued)*

A reconciliation of the tax expense applicable to (loss)/profit before tax at the statutory rate for the country in which the Company and the majority of its subsidiaries are domiciled to the tax expense at the effective tax rate, and a reconciliation of the applicable rate (i.e., the statutory tax rate) to the effective tax rate, are as follows:

	2018		2017	
	RMB'000	**%**	RMB'000	%
(Loss)/profit before tax	**(14,547)**		24,824	
Tax at the statutory tax rate	**(3,637)**	**25**	6,206	25
Preferential tax rate or concessions	**(1,003)**	**7**	(3,135)	(13)
Adjustments in respect of current tax of previous periods	**265**	**(2)**	–	–
(Profits)/losses attributable to associates	**(359)**	**2**	312	1
Tax incentives on eligible expenditures	**(1,750)**	**12**	(1,574)	(6)
Income not subject to tax	**–**	**–**	(6)	–
Expenses not deductible for tax	**445**	**(3)**	582	2
Tax losses utilised from previous periods	**–**	**–**	(68)	–
Tax losses not recognised	**8,223**	**(57)**	1,310	5
Tax charge at the Group's effective rate	**2,184**	**(15)**	3,627	15

There was no share of tax attributable to associates and a joint venture included in "share of profits and losses of a joint venture and associates" in the consolidated statement of profit or loss for the years 2018 and 2017.

11. DIVIDEND

	2018 RMB'000	2017 RMB'000
Proposed final dividend – RMB0.1 (2017: RMB0.1) per share	**14,471**	14,471

The proposed final dividend for the year is subject to the approval of the Company's shareholders at the forthcoming annual general meeting.

12. (LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the (loss)/earnings per share amount is based on the (loss)/profit for the year attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 144,707,176 (2017: 144,707,176) in issue during the year.

No adjustment has been made to the basic (loss)/earnings per share amounts presented for the years ended 31 December 2018 and 2017 in respect of a dilution as the Group had no potentially dilutive ordinary shares in issue during both the years ended 31 December 2018 and 2017.

The calculations of basic and diluted (loss)/earnings per share are based on:

	2018 RMB'000	2017 RMB'000
Earnings		
(Loss)/profit attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculations	**(2,049)**	25,170

	Numbers of shares	
	2018	2017
Shares		
Weighted average number of ordinary shares in issue during the year used in the basic and diluted (loss)/earnings per share calculations	**144,707,176**	144,707,176

13. PROPERTY, PLANT AND EQUIPMENT

	Buildings RMB'000	Leasehold improvements RMB'000	Machinery RMB'000	Furniture and fixtures RMB'000	Motor vehicles RMB'000	Construction in progress RMB'000	Total RMB'000
31 December 2018							
At 31 December 2017 and at 1 January 2018:							
Cost	39,933	47,636	171,578	7,573	6,904	114,447	388,071
Accumulated depreciation	(11,248)	(16,987)	(97,460)	(5,864)	(4,966)	–	(136,525)
Net carrying amount	28,685	30,649	74,118	1,709	1,938	114,447	251,546
At 1 January 2018, net of accumulated depreciation	28,685	30,649	74,118	1,709	1,938	114,447	251,546
Additions	–	868	17,360	280	60	18,957	37,525
Disposals	–	–	(920)	(52)	(137)	–	(1,109)
Depreciation provided during the year	(1,265)	(2,467)	(18,298)	(869)	(673)	–	(23,572)
Transfers	–	(16,632)	9,156	–	–	7,476	–
At 31 December 2018, net of accumulated depreciation	27,420	12,418	81,416	1,068	1,188	140,880	264,390
At 31 December 2018:							
Cost	39,933	31,872	196,846	7,514	7,095	140,880	424,140
Accumulated depreciation	(12,513)	(19,454)	(115,430)	(6,446)	(5,907)	–	(159,750)
Net carrying amount	27,420	12,418	81,416	1,068	1,188	140,880	264,390

13. PROPERTY, PLANT AND EQUIPMENT *(Continued)*

	Buildings RMB'000	Leasehold improvements RMB'000	Machinery RMB'000	Furniture and fixtures RMB'000	Motor vehicles RMB'000	Construction in progress RMB'000	Total RMB'000
31 December 2017							
At 31 December 2016 and at 1 January 2017:							
Cost	39,933	28,997	132,573	6,575	7,117	37	215,674
Accumulated depreciation	(9,984)	(14,628)	(82,694)	(4,683)	(4,310)	–	(116,741)
Net carrying amount	29,949	14,369	49,879	1,892	2,807	37	98,933
At 1 January 2017, net of accumulated depreciation	29,949	14,369	49,879	1,892	2,807	37	98,933
Additions	–	18,217	43,280	902	–	115,404	177,803
Disposals	–	–	(3,640)	(9)	(11)	–	(3,660)
Depreciation provided during the year	(1,264)	(2,360)	(15,753)	(1,295)	(858)	–	(21,530)
Transfers	–	423	352	219	–	(994)	–
At 31 December 2017, net of accumulated depreciation	28,685	30,649	74,118	1,709	1,938	114,447	251,546
At 31 December 2017:							
Cost	39,933	47,636	171,578	7,573	6,904	114,447	388,071
Accumulated depreciation	(11,248)	(16,987)	(97,460)	(5,864)	(4,966)	–	(136,525)
Net carrying amount	28,685	30,649	74,118	1,709	1,938	114,447	251,546

At 31 December 2018, the Group's buildings with a net carrying amount of approximately RMB27.4 million were pledged to Bank of Beijing to secure the bank loans granted to the Company with a principal of RMB70 million. The loans will be due in June 2019.

At 28 November 2017, the Company entered into a sale and leaseback agreement with Far Eastern Leasing Co., Ltd. ("Far Eastern") for certain machinery of the Company. Pursuant to the agreement, the Company agreed to sell certain machineries with an original cost of RMB30 million to Far Eastern with a selling price of RMB27 million and lease it back simultaneously. During the lease period, all significant risks and rewards regarding such machinery were born by the Company. At the end of the lease period, the Company was awarded with a repurchase option to buy back the aforesaid machinery with a cash consideration of RMB100. The Company will pay a monthly rental fee of RMB0.9 million to Far Eastern in 3 years with interest at an effective interest rate of 10.20%. As of 21 December 2018, the Company received all the principals from Far Eastern. The Company was of the opinion that the substance of the arrangement is to obtain a loan from Far Eastern to the Company with the Company's machinery as securities.

13. PROPERTY, PLANT AND EQUIPMENT *(Continued)*

At 31 August 2018, the Company entered into a sale and leaseback agreement with Zhongguancun Science-Tech Leasing Co., Ltd. ("Zhongguancun") for certain machineries of the Company. Pursuant to the agreement, the Company agreed to sell machinery with an original cost of RMB55 million to Zhongguancun with a selling price of RMB30 million and lease back it simultaneously. During the lease period, all significant risks and rewards regarding such machinery were born by the Company. At the end of the lease period, the Company was awarded with a repurchase option to buy back the aforesaid machinery with a cash consideration of RMB100. The Company will pay a quarterly rental fee of RMB2.8 million to Zhongguancun in 3 years with effective interest rate of 7.39%. As of 31 August 2018, the Company received all the principals from Zhongguancun. The Company was with the opinion that the substance of the leaseback arrangement is to obtain a loan from Zhongguancun to the Company with the Company's machinery as securities. In 2018, Mr. Chen Jintian, an executive director of the Group, provided guarantees to cover the loan's full amounts during the entire loan period.

14. PREPAID LAND LEASE PAYMENTS

	2018 **RMB'000**	2017 RMB'000
Carrying amount at 1 January	**2,734**	2,815
Amortisation during the year	**(81)**	(81)
Carrying amount at 31 December	**2,653**	2,734
Current portion included in prepayments, other receivables and other assets	**(81)**	(81)
Non-current portion	**2,572**	2,653

At 31 December 2018, all of the Group's prepaid land lease payments with a net carrying amount of approximately RMB2.65 million were pledged to Bank of Beijing to secure the bank loans granted to the Company with a principal of RMB70 million. The loans will be due in June 2019.

15. PREPAYMENTS

	2018 **RMB'000**	2017 RMB'000
Prepayments	**600**	88,825

As at 31 December 2018, prepayments were related to the purchase of patents and license. As at 31 December 2017, prepayment ware mainly related to purchase of constructions in progress.

16. GOODWILL

	RMB'000
At 1 January 2017, 31 December 2017 and 31 December 2018:	
Cost	309
Accumulated impairment	–
Net carrying amount	309

Impairment testing of goodwill

Goodwill acquired through business combinations has been allocated to the following cash-generating unit for impairment testing:

– Zhongsheng Jinyu

The recoverable amount of the cash-generating unit has been determined based on a value in use calculation using cash flow projections based on a financial budget covering a five-year period approved by senior management. No growth has been projected beyond the five-year period. The discount rate applied to the cash flow projections is 15% (2017: 15%).

Assumptions were used in the value in use calculation of the cash-generating unit as at 31 December 2018 and 31 December 2017. The following describes each key assumption on which management has based its cash flow projections to undertake impairment testing of goodwill:

Budgeted gross margins – The basis used to determine the value assigned to the budgeted gross margins is the average gross margins achieved in the year immediately before the budget year, increased for expected efficiency improvements.

Discount rate – The discount rate used is before tax and reflects specific risks relating to the relevant unit.

Expenses – The value assigned to the key assumptions reflects past experience and management's commitment to maintain its operating expenses at an acceptable level.

The values assigned to the key assumptions on market development of in-vitro diagnostic reagent industries, discount rates and raw material price inflation are consistent with external information sources.

17. OTHER INTANGIBLE ASSETS

	Patent and license RMB'000	Computer software RMB'000	Development cost RMB'000	Total RMB'000
31 December 2018				
At 31 December 2017 and 1 January 2018:				
Cost	9,037	2,858	1,232	13,127
Accumulated amortisation	(5,385)	(409)	–	(5,794)
Impairment	(1,710)	–	–	(1,710)
Net carrying amount	1,942	2,449	1,232	5,623
Net carrying amount:				
At 1 January 2018	1,942	2,449	1,232	5,623
Purchases/Additions	13,115	–	3,524	16,639
Amortisation provided during the year	(788)	(286)	–	(1,074)
Impairment during the year	(300)	–	–	(300)
At 31 December 2018	13,969	2,163	4,756	20,888
At 31 December 2018:				
Cost	22,152	2,858	4,756	29,766
Accumulated amortisation	(6,173)	(695)	–	(6,868)
Impairment	(2,010)	–	–	(2,010)
Net carrying amount	13,969	2,163	4,756	20,888

17. OTHER INTANGIBLE ASSETS *(Continued)*

	Patent and license RMB'000	Computer software RMB'000	Development cost RMB'000	Total RMB'000
31 December 2017				
At 31 December 2016 and 1 January 2017:				
Cost	7,499	2,182	769	10,450
Accumulated amortisation	(5,082)	(148)	–	(5,230)
Impairment	(1,210)	–	–	(1,210)
Net carrying amount	1,207	2,034	769	4,010
Net carrying amount:				
At 1 January 2017	1,207	2,034	769	4,010
Purchases/Additions	1,538	676	463	2,677
Amortisation provided during the year	(303)	(261)	–	(564)
Impairment during the year	(500)	–	–	(500)
At 31 December 2017	1,942	2,449	1,232	5,623
At 31 December 2017 and 1 January 2018:				
Cost	9,037	2,858	1,232	13,127
Accumulated amortisation	(5,385)	(409)	–	(5,794)
Impairment	(1,710)	–	–	(1,710)
Net carrying amount	1,942	2,449	1,232	5,623

18. INVESTMENT IN A JOINT VENTURE

	2018 RMB'000	2017 RMB'000
Share of net assets	**11,181**	11,181
Goodwill on acquisition	**4,282**	4,282
	15,463	15,463
Provision for impairment	**(15,463)**	(15,463)
	–	–

Particulars of the Group's joint venture are as follows:

Name	Particulars of issued shares held	Place of registration	Percentage of Ownership interest	Percentage of Voting power	Percentage of Profit sharing	Principal activity
Suzhou Otian Medical Co., Ltd. （蘇州奧潤醫療科技有限公司）	Registered capital of RMB1 each	PRC/ Mainland China	35%	35%	35%	Production of scientific instruments

The above investment is directly held by the Company.

In 2016, the joint venture was dormant according to management's decision. Based on the status and forecast of the joint venture, the investment has been fully impaired by management.

18. INVESTMENT IN A JOINT VENTURE *(Continued)*

The following table illustrates the summarised financial information adjusted for any differences in accounting policies and reconciled to the carrying amount in the financial statements:

	2018 **RMB'000**	2017 RMB'000
Share of the joint venture's assets and liabilities:		
Current assets	**402**	402
Non-current assets	**11,401**	11,401
Current liabilities	**(1,630)**	(1,630)
Non-current liabilities	**–**	–
Net assets	**10,173**	10,173
Share of the joint venture's results:		
Revenue	**–**	–
Other income	**–**	–
	–	–
Total expenses	**–**	–
Loss after tax	**–**	–

The Group has discontinued the recognition of its share of losses of the joint venture in the current period because the investment in a joint venture has been fully impaired in 2016. The total amounts of the Group's unrecognised share of losses of this joint venture for the current year and cumulatively were nil (2017: nil) and RMB1,008,000 (2017: RMB1,008,000), respectively.

19. INVESTMENTS IN ASSOCIATES

	2018 RMB'000	2017 RMB'000
Share of net assets	**42,519**	40,123

Particulars of the associates are as follows:

Name	Place of registration and business	Percentage of ownership interest attributable to the Group	Principal activities
Beijing Zhongsheng Ke Wei Technology Co., Ltd. ("Ke Wei")（北京中生科維技術有限公司，原名為"北京中生科維醫療科技有限公司"）	PRC/Mainland China	19.30%	Development, manufacture and distribution of clinical instruments
Mian Yang Hi-tech Industrial Park Zhongke Bioengineering Co., Ltd. ("Mian Yang Zhongke")（綿陽高新區中科生物工程有限公司）	PRC/Mainland China	29%	Manufacture and sale of enzyme and biological products
Beijing Zhonghe Baike Scientific Instrument and Technology Co., Ltd. ("Baike")（北京眾合百克科學儀器技術有限公司）	PRC/Mainland China	20%	Production of scientific instruments
Sinofn (Tianjin) Pharm-Tech Co., Ltd. ("Sinofn Tianjin")（中恩（天津）醫藥科技有限公司）	PRC/Mainland China	39.21%	Wholesale of prepackaged healthcare food

The Group has discontinued the recognition of its share of losses of Ke Wei and Baike because the share of losses of the associates exceeded the Group's investments in the associates. The total amounts of the Group's unrecognised share of losses of these associate for the current year and cumulatively were RMB107,000 (2017: RMB186,000) and RMB2,434,000 (2017: RMB2,327,000), respectively.

19. INVESTMENTS IN ASSOCIATES *(Continued)*

Sinofn Tianjin is considered a material associate of the Group, which is engaged in the manufacture of wholesale of prepackaged food and is accounted for using the equity method.

The following table illustrates the summarised financial information in respect of Sinofn Tianjin adjusted for any differences in accounting policies and reconciled to the carrying amount in the consolidated financial statements:

	2018 **RMB'000**	2017 RMB'000
Current assets	**127,397**	29,455
Non-current assets, excluding goodwill	**128,926**	121,665
Current liabilities	**(89,373)**	(14,643)
Non-current liabilities	**(66,199)**	(41,200)
Net assets	**100,751**	95,277
Reconciliation to the Group's interest in the associate:		
Proportion of the Group's ownership	**39.21%**	39.21%
Group's share of net assets of the associate, excluding goodwill	**39,504**	37,358
Carrying amount of the investment	**39,504**	37,358
Revenue	**64,850**	43,598
Profit/(loss) for the year	**5,474**	(5,771)
Total comprehensive income/(loss) for the year	**5,474**	(5,771)

The following table illustrates the aggregate financial information of the Group's associates that are not individually material:

	2018 **RMB'000**	2017 RMB'000
Share of the associates profit for the year	**250**	(220)
Share of the associates total comprehensive income/(loss)	**250**	(220)
Aggregate carrying amount of the Group's investments in the associates	**3,015**	2,765

20. EQUITY INVESTMENTS DESIGNATED AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME/AVAILABLE-FOR-SALE INVESTMENT

	2018	2017
	RMB'000	RMB'000
Equity investments designated at fair value through other comprehensive income		
Unlisted equity investment, at fair value		
Baichuanfeihong Co., Ltd	**227**	–
CAS Health Management Co., Ltd.	**890**	–
	1,117	–
Available for sale investments		
Unlisted equity investment, at cost	**–**	1,579

The above equity investments were irrevocably designated at fair value through other comprehensive income as the Group considers these investments to be strategic in nature.

21. LONG-TERM RECEIVABLES

	2018	2017
	RMB'000	RMB'000
Receivables from sales and other deposits	**6,752**	1,359

22. INVENTORIES

	2018	2017
	RMB'000	RMB'000
Raw materials	**19,437**	15,855
Work in progress	**3,007**	1,393
Semi-finished goods	**7,653**	5,342
Finished goods	**28,724**	22,254
	58,821	44,844

23. TRADE AND BILLS RECEIVABLES

	2018 RMB'000	2017 RMB'000
Trade receivables	**144,241**	127,086
Bills receivable	**–**	819
Impairment	**(2,125)**	(1,725)
	142,116	126,180
Less: Amounts shown as non-current	**(431)**	(1,359)
	141,685	124,821

Except for certain established customers of the Group which have been granted with payment terms ranging from two to four years in respect of certain sales of instruments, the credit periods of the Group granted to its customers generally range from 0 to 360 days. The Group closely monitors overdue balances, and provision for impairment is made when it is considered that the amounts due may not be recovered. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. The trade receivables are non-interest bearing.

An ageing analysis of the trade and bills receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	2018 RMB'000	2017 RMB'000
Within 3 months	**61,262**	76,299
4 to 6 months	**34,833**	32,197
7 to 12 months	**38,681**	14,143
1 to 2 years	**6,164**	3,446
Over 2 years	**1,176**	95
	142,116	126,180

23. TRADE AND BILLS RECEIVABLES *(Continued)*

The movement in the loss allowance for impairment of trade receivables are as follows:

	2018 RMB'000	2017 RMB'000
At beginning of year	**1,725**	1,641
Effect of adoption of HKFRS 9	**857**	–
At beginning of year (restated)	**2,582**	1,641
Impairment losses, net *(note 6)*	**(457)**	84
At end of year	**2,125**	1,725

Impairment under HKFRS 9 for the year ended 31 December 2018

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on days past due for groupings of various customer segments with similar loss patterns (i.e., customer type and rating). The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Generally, trade receivables are written off if past due for more than two to three years, depending on the customer type, and are not subject to enforcement activity.

Set out below is the information about the credit risk exposure on the Group's trade receivables using a provision matrix:

As at 31 December 2018

		Past due		
	Current RMB'000	Less than 1 year RMB'000	Over 1 year RMB'000	Total RMB'000
Expected credit loss rate	**0.03%**	**0.21%**	**53.36%**	**1.47%**
Gross carrying amount (RMB'000)	**93,772**	**46,721**	**3,748**	**144,241**
Expected credit losses (RMB'000)	**25**	**100**	**2,000**	**2,125**

23. TRADE AND BILLS RECEIVABLES *(Continued)*

Impairment under HKAS 39 for the year ended 31 December 2017

Included in the above loss allowance for impairment of trade receivables, which was measured based on incurred credit losses under HKAS 39, as at 31 December 2017 was a provision for individually impaired trade receivables of RMB1,725,000 with a carrying amount before provision of RMB126,180,000.

The individually impaired trade receivables as at 31 December 2017 related to a customer that was in financial difficulties. The Group did not hold any collateral or other credit enhancements over this balance.

The ageing analysis of the trade and bills receivables as at 31 December 2017 that were not individually nor collectively considered to be impaired under HKAS 39 is as follows:

	2017 RMB'000
Neither past due nor impaired	122,639
Less than 1 year	3,541
Over 1 year	–
	126,180

Receivables that were neither past due nor impaired relate to a large number of diversified customers for whom there was no recent history of default.

Receivables that were past due but not impaired relate to a number of independent customers that had a good track record with the Group. Based on past experience, the directors of the Company were of the opinion that no provision for impairment under HKAS 39 was necessary in respect of these balances as there had not been a significant change in credit quality and the balances were still considered fully recoverable.

24. PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS

	2018 **RMB'000**	2017 RMB'000
Deposits and other receivables	**170,751**	30,401
Prepayments	**21,970**	24,338
Loans receivable from placement services *(note (a))*	**–**	20,000
Tax recoverable	**–**	549
Due from related companies *(note (b))*	**38**	3,216
Impairment allowance	**(1,614)**	(1,511)
	191,145	76,993

The financial assets included in the above balances relate to receivables for which there was no recent history of default.

(a) The balance as at 31 December 2017 represented loans granted to independent third parties. The amounts were secured by properties of the guarantors, bore interest at 14.0% per annum and repaid in 2018.

(b) The balance as at 31 December 2018 represented receivables due from Suzhou Otian Medical Co., Ltd., a joint venture of the Group, of RMB38,000 (2017: RMB38,000).The amounts are unsecured, interest-free and have no fixed terms of repayment.

(c) Deposits and other receivables mainly represent rental deposits and deposits with suppliers. Where applicable, an impairment analysis is performed at each reporting date by considering the probability of default of comparable companies with published credit ratings. As at 31 December 2018, the probability of default applied ranged from 0.95% to 1.00% and the loss given default was estimated to be 0.95%. In the situation where no comparable companies with credit ratings can be identified, expected credit losses are estimated by applying a loss rate approach with reference to the historical loss record of the Group. The loss rate is adjusted to reflect the current conditions and forecasts of future economic conditions, as appropriate.

25. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

	2018 **RMB'000**	2017 RMB'000
Mutual fund	**14,148**	–
Wealth management products issued by banks	**2,200**	–
Financial instruments, at fair value	**16,348**	–

The above unlisted investments at 31 December 2018 were mutual fund issued by securities and wealth management products issued by banks in Mainland China. They were mandatorily classified as financial assets at fair value through profit or loss as their contractual cash flows are not solely payments of principal and interest.

26. CASH AND CASH EQUIVALENTS AND PLEDGED DEPOSITS

	2018 RMB'000	2017 RMB'000
Cash and bank balances	**24,715**	26,757
Less: Pledged deposits for bank's letters of credit	**(6,507)**	–
Cash and cash equivalents	**18,208**	26,757

At the end of the reporting period, the cash and bank balances of the Group denominated in RMB amounted to RMB22,206,000 (2017: RMB23,871,000). The RMB is not freely convertible into other currencies, however, under Mainland China's Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash at banks earns interest at floating rates based on daily bank deposit rates. The bank balances and time deposits are deposited with creditworthy banks with no recent history of default.

27. TRADE PAYABLES

An aging analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	2018 RMB'000	2017 RMB'000
Within 3 months	**36,777**	43,434
4 to 6 months	**26,662**	17,046
7 to 12 months	**53,697**	12,126
1 to 2 years	**1,881**	110
Over 2 years	**257**	198
	119,274	72,914

The trade payables are non-interest-bearing and are normally settled on credit terms ranging from 30 to 90 days.

28. OTHER PAYABLES AND ACCRUALS

	Notes	**2018 RMB'000**	2017 RMB'000
Contract Liabilities		**44,408**	–
Advance from customers		**–**	8,280
Other liabilities		**13,777**	5,464
Salaries and welfare payables		**12,131**	8,957
Accrued expenses		**8,252**	14,663
Due to an associate	*(a)*	**2,304**	–
Other tax payable		**1,510**	4,484
Due to a shareholder	*(b)*	**1,500**	1,000
Accrued interests		**431**	234
		84,313	43,082

Notes:

(a) The balance as at 31 December 2018 represented the amount due to Sinofn Tianjin. In 2018, Sinofn Tianjin lent a RMB15 million loan to the Company with the annual interest rate of 5.5% and the expiration date on May 2019. RMB13 million was repaid in the current year. The balance as at 31 December 2018 included the remaining principal of RMB2 million and accrued interests of RMB304,000. The remaining balance was repaid in January 2019.

(b) The balance as at 31 December 2018 represented the amount due to the Institute of Biophysics ("IBP"), included in which was an accrued technical service fee of RMB1,500,000 (2017: RMB1,000,000) for the right to use technical know-how held by IBP. Further details of the technical service fee arrangements are set out in note 39 to the financial statements. The amount due to IBP is unsecured, interest-free and has no fixed terms of repayment.

29. INTEREST-BEARING BANK AND OTHER BORROWINGS

	2018			2017		
	Effective interest rate (%)	**Maturity**	**RMB'000**	Effective interest rate (%)	Maturity	RMB'000
Current						
Bank loans – unsecured	**5.66 – 6.09**	**2019**	**29,154**	4.78 – 6.65	2018	77,525
Bank loans – secured	**5.00 – 5.23**	**2019**	**70,000**	4.35 – 5.00	2018	53,784
Other loans – secured	**7.39 – 10.20**	**2019**	**37,283**	10.20	2018	3,833
Other loans – unsecured	**12.00**	**2019**	**30,000**			–
			166,437			135,142
Non-current						
Other loans – secured	**7.39 – 10.20**	**2021**	**28,565**	6.50 – 10.20	2019 – 2020	16,067
			195,002			151,209

	2018 RMB'000	2017 RMB'000
Analysed into:		
Bank and other loans repayable:		
Within one year	**166,437**	135,142
In the second to third years, inclusive	**28,565**	16,067
	195,002	151,209

29. INTEREST-BEARING BANK AND OTHER BORROWINGS *(Continued)*

At 31 December 2018, the Group's buildings and prepaid land lease payments with a net carrying amount of approximately RMB30.1 million were pledged to Bank of Beijing to secure the bank loans granted to the Company with a principal of RMB70 million. The loans will be due in June 2019.

At 28 November 2017, the Company entered into a sale and leaseback agreement with Far Eastern Leasing Co., Ltd. ("Far Eastern") for certain machinery of the Company. Pursuant to the agreement, the Company agreed to sell certain machineries with an original cost of RMB30 million to Far Eastern with a selling price of RMB27 million and it lease back simultaneously. During the lease period, all significant risks and rewards regarding such machinery were born by the Company. At the end of the lease period, the Company was awarded with a repurchase option to buy back the aforesaid machinery with a cash consideration of RMB100. The Company will pay a monthly rental fee of RMB0.9 million to Far Eastern in 3 years with interest at an effective interest rate of 10.20%. As of 21 December 2018, the Company received all the principals from Far Eastern. The Company was of the opinion that the substance of the arrangement is to obtain a loan from Far Eastern to the Company with the Company's machinery as securities.

At 31 August 2018, the Company entered into a sale and leaseback agreement with Zhongguancun Science-Tech Leasing Co., Ltd. ("Zhongguancun") for certain machineries of the Company. Pursuant to the agreement, the Company agreed to sell machinery with an original cost of RMB55 million to Zhongguancun with a selling price of RMB30 million and lease back it simultaneously. During the lease period, all significant risks and rewards regarding such machinery were born by the Company. At the end of the lease period, the Company was awarded with a repurchase option to buy back the aforesaid machinery with a cash consideration of RMB100. The Company will pay a quarterly rental fee of RMB2.8 million to Zhongguancun in 3 years with effective interest rate of 7.39%. As of 31 August 2018, the Company received all the principals from Zhongguancun. The Company was with the opinion that the substance of the leaseback arrangement is to obtain a loan from Zhongguancun to the Company with the Company's machinery as securities. In 2018, Mr. Chen Jintian, an executive director of the Group, provided guarantees to cover the loan's full amounts during the entire loan period

30. DEFERRED TAX

The movements in deferred tax assets and liabilities during the year are as follows:

Deferred tax assets

	2018				
	Fair value adjustments of investments at fair value through other comprehensive income RMB'000	**Provision for impairment of assets RMB'000**	**Tax losses RMB'000**	**Others RMB'000**	**Total RMB'000**
At 31 December 2017	**–**	**696**	**2,092**	**1,036**	**3,824**
Effect of adoption of HKFRS 9	**46**	**–**	**–**	**–**	**46**
At 1 January 2018 (restated)	**46**	**696**	**2,092**	**1,036**	**3,870**
Deferred tax credited to the statement of comprehensive income during the year	**39**	**–**	**–**	**–**	**39**
Deferred tax credited to the statement of profit or loss during the year *(note 10)*	**–**	**221**	**(228)**	**245**	**238**
At 31 December 2018	**85**	**917**	**1,864**	**1,281**	**4,147**

	2017			
	Provision for impairment of assets RMB'000	Tax losses RMB'000	Others RMB'000	Total RMB'000
At 1 January 2017	611	480	262	1,353
Deferred tax credited to the statement of profit or loss during the year *(note 10)*	85	1,612	774	2,471
At 31 December 2017	696	2,092	1,036	3,824

30. DEFERRED TAX *(Continued)*

Deferred tax liabilities

	2018		
	Depreciation of assets RMB'000	**Others RMB'000**	**Total RMB'000**
At 1 January 2018	**2,414**	**3,029**	**5,443**
Deferred tax charged to the statement of profit or loss during the year *(note 10)*	**264**	**–**	**264**
At 31 December 2018	**2,678**	**3,029**	**5,707**

	2017		
	Depreciation of assets RMB'000	Others RMB'000	Total RMB'000
At 1 January 2017	1,505	35	1,540
Deferred tax charged to the statement of profit or loss during the year *(note 10)*	909	2,994	3,903
At 31 December 2017	2,414	3,029	5,443

The Group has tax losses arising in Mainland China of RMB36,478,000 (2017: RMB41,362,000) that will expire in one to ten years for offsetting against future taxable profits.

Deferred tax assets have not been recognised in respect of these losses as they have arisen in subsidiaries that have been loss-making for some time and it is not considered probable that taxable profits will be available against which the tax losses can be utilised.

31. DEFERRED INCOME

Various government grants have been received for setting up research and development activities and acquisition of required assets. Government grants received which related to assets or for which related expenditure has not yet been undertaken are included in deferred income in the statement of financial position and will be released to the statement of profit or loss over the expected useful life of the relevant asset by equal annual instalments or when the related expenses have been incurred. There are no unfulfilled conditions or contingencies relating to these grants, except that they must be used for research and development activities or acquisition of the required assets.

32. SHARE CAPITAL

	2018 RMB'000	2017 RMB'000
Registered, issued and fully paid:		
80,421,033 (2017: 80,421,033) domestic shares of RMB1 each	**80,421**	80,421
64,286,143 (2017: 64,286,143) H shares of RMB1 each	**64,286**	64,286
	144,707	144,707

No shares were issued during the year of 2018.

33. RESERVES

The amounts of the Group's reserves and the movements therein for the current and prior years are presented in the consolidated statement of changes in equity on page 64 of the financial statements.

34. PARTLY-OWNED SUBSIDIARIES WITH MATERIAL NON-CONTROLLING INTERESTS

Details of the Group's subsidiaries that have material non-controlling interests are set out below:

	2018	2017
Percentage of equity interest held by non-controlling interests:		
Zhongsheng Jinyu	**54.1%**	54.1%
Zhongke Fund	**49%**	49%

	2018 RMB'000	2017 RMB'000
Loss for the year allocated to non-controlling interests:		
Zhongsheng Jinyu	**1,725**	3,190
Zhongke Fund	**12,933**	404
Accumulated balances of non-controlling interests at the reporting dates:		
Zhongsheng Jinyu	**17,227**	15,200
Zhongke Fund	**41,518**	54,451

34. PARTLY-OWNED SUBSIDIARIES WITH MATERIAL NON-CONTROLLING INTERESTS *(Continued)*

The following tables illustrate the summarised financial information of the above subsidiaries. The amounts disclosed are before any inter-company elimination:

2018	**Zhongsheng Jinyu RMB'000**	**Zhongke Fund RMB'000**
Revenue	**31,380**	**–**
Total expenses	**(34,409)**	**(23,965)**
Loss for the year	**(3,029)**	**(23,965)**
Total comprehensive loss for the year	**(3,029)**	**(23,965)**
Current assets	**23,218**	**157,290**
Non-current assets	**17,014**	**141,778**
Current liabilities	**(11,413)**	**(211,908)**
Non-controlling interests	**(3,565)**	**2,334**
Net cash flow used in operating activities	**(3,333)**	**(2,349)**
Net cash flows used in investing activities	**(33)**	**(61,918)**
Net cash flows generated from financing activities	**3,752**	**64,200**
Net increase/(decrease) in cash and cash equivalents	**386**	**(67)**

2017	Zhongsheng Jinyu RMB'000	Zhongke Fund RMB'000
Revenue	29,455	2,191
Total expenses	(35,351)	(3,015)
Loss for the year	(5,896)	(824)
Total comprehensive loss for the year	(5,896)	(824)
Current assets	20,540	34,817
Non-current assets	14,543	203,059
Current liabilities	(6,987)	(126,751)
Net cash flow used in operating activities	(3,300)	(7,022)
Net cash flows used in investing activities	(870)	(53,997)
Net cash flows generated from financing activities	–	61,020
Net (decrease)/increase in cash and cash equivalents	(4,170)	1

35. NOTE TO THE CONSOLIDATED STATEMENT OF CASH FLOWS

(a) Major non-cash transactions

At 20 June 2017, there was a capital increment agreement signed between Sinofn Tianjin, Sinofn Tianjin's existing investors including Cangzhou Enji Biological Products Co., Ltd, Guo'en(Tianjin) Technology Development Co., Ltd., the Company, and 2 new investors, Chinese Academy of Sciences holding Company("CAS") and Shanghai Jinyu Investment Partnership(Jinyu). Pursuant to the agreement, CAS and Jinyu invested RMB30,000,000 to Sinofn Tianjin for percentage of ownership interest of 9.16%, respectively, and the total capital injection of RMB60,000,000 has been received in July 2018.

After completion of the transaction, the percentage of attributable ownership interest attributable to the Group from Sinofn Tianjin has decreased from 48% to 39.21%, however, there was a deemed disposal gain of RMB19,953,000 recognized in income statement due to the capital injection.

(b) Changes in liabilities arising from financing activities

	Bank and other loans RMB'000
At 1 January 2018	**151,209**
Changes from financing cash flows	**43,793**
At 31 December 2018	**195,002**

36. CONTINGENT LIABILITIES

At the end of the reporting period, contingent liabilities not provided for in the financial statements were as follows:

	2018 RMB'000	2017 RMB'000
Guarantees given to a bank in connection with loans granted to an associate	**38,100**	40,200

As at 31 December 2018, the banking facilities guaranteed by the Group to Sinofn (Tianjin) Pharm-Tech Co., Ltd. were utilised to the extent of approximately RMB38,100,000 (2017: RMB40,200,000).

37. PLEDGE OF ASSETS

Details of the Group's assets pledged for the Group's bank and other loans are included in Notes 13, 14 and 29 to the financial statements.

38. OPERATING LEASE ARRANGEMENTS

(a) As lessor

The Group leases out its construction in progress (note 13 to the financial statements) under operating lease arrangements with lease term for 13 years. The terms of the leases generally also provide for periodic rent adjustments according to the then prevailing market conditions.

At 31 December 2018, the Group had total future minimum lease receivables under non-cancellable operating leases with its tenants falling due as follows:

	2018	2017
	RMB'000	RMB'000
Within one year	**5,100**	–
In the second to fifth years, inclusive	**78,762**	–
After five years	**189,290**	–
	273,152	–

(b) As lessee

The Group leases certain of its office properties, factory premises and warehouses under operating lease arrangements. Leases of the properties are negotiated for terms ranging from one to five years.

At 31 December 2018, the Group had total future minimum lease payments under non-cancellable operating leases falling due as follows:

	2018	2017
	RMB'000	RMB'000
Within one year	**13,352**	12,716
In the second to fifth years, inclusive	**54,064**	60,855
After five years	**102,424**	106,100
	169,840	179,671

39. COMMITMENTS

In addition to the operating lease commitments detailed in Note 38(b) above, the Group had the following capital commitments at the end of the reporting period:

	2018 **RMB'000**	2017 RMB'000
Contracted, but not provided for:		
Construction in progress for property, plant and equipment	**2,739**	–
Know-how, patents and license	**1,400**	500
	4,139	500

On 9 December 2004, the Company and its substantial shareholder, IBP, entered into an exclusive technology licensing agreement (the "Licensing Agreement") with regard to the production of diagnostic reagents by employing the technologies owned by IBP (the "Reagent Technologies"). Pursuant to the Licensing Agreement, the Company is required to pay a fee of RMB500,000 per annum to IBP for 20 years, commencing on the effective date of the Licensing Agreement. As at 31 December 2018, the technical service fees payable by the Group of RMB1,500,000 (31 December 2017: RMB1,000,000) were included in the amount due to a shareholder *(note 28(b))*.

40. RELATED PARTY TRANSACTIONS

(a) In addition to the transactions detailed elsewhere in these financial statements, the Group had the following transaction with a related party during the year:

	2018 **RMB'000**	2017 RMB'000
Annual technical service fee to IBP*	**500**	500
Associate:		
Purchases of products from Mian Yang Zhongke	**478**	–

* The related party transaction also constitutes connected transaction as defined in Chapter 20 of the GEM Listing Rules.

40. RELATED PARTY TRANSACTIONS *(Continued)*

(b) Outstanding balances with related parties are set out in notes 24 and 28 to the financial statements.

(c) Compensation of key management personnel of the Group

	2018 **RMB'000**	2017 RMB'000
Short-term employee benefits	**3,533**	7,334
Post-employment benefits	**124**	253
Total compensation paid to key management personnel	**3,657**	7,587

Further details of directors' and supervisors' emoluments are included in note 8 to the financial statements.

(d) Mr. Chen Jintian, an executive director of the Group, guaranteed a loan granted to the Company with the principal amounting to RMB30 million in 2018, as further detailed in note 29 to the financial statements.

41. FINANCIAL INSTRUMENTS BY CATEGORY

The carrying amounts of each of the categories of financial instruments as at the end of the reporting period are as follows:

2018

Financial assets

	2018			
	Financial assets at fair value through profit or loss	Financial assets at fair value through other comprehensive income	Financial assets at amortised cost	Total
	Held for trading RMB'000	Equity investments RMB'000	RMB'000	RMB'000
Equity investments at fair value through other comprehensive income	–	1,117	–	1,117
Long-term receivables	–	–	6,752	6,752
Trade and bills receivables	–	–	141,685	141,685
Financial assets included in prepayments, other receivables and other assets	–	–	169,175	169,175
Financial assets at fair value through profit or loss	16,348	–	–	16,348
Pledged deposits	–	–	6,507	6,507
Cash and cash equivalents	–	–	18,208	18,208
	16,348	1,117	342,327	359,792

Financial liabilities

	Financial liabilities at amortised cost RMB'000
Interest-bearing bank borrowings	195,002
Trade payables	119,274
Financial liabilities included in other payables and accruals	18,012
	332,288

41. FINANCIAL INSTRUMENTS BY CATEGORY *(Continued)*

2017

Financial assets

	Available-for-sale financial assets RMB'000	Loans and receivables RMB'000	Total RMB'000
Available-for-sale investment	1,579	–	1,579
Long-term receivables	–	1,359	1,359
Trade and bills receivables	–	124,821	124,821
Financial assets included in prepayments, deposits and other receivables	–	48,890	48,890
Cash and cash equivalents	–	26,757	26,757
	1,579	201,827	203,406

Financial liabilities

	Financial liabilities at amortised cost RMB'000
Interest-bearing bank borrowings	151,209
Trade payables	72,914
Financial liabilities included in other payables and accruals	5,464
	229,587

42. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The carrying amounts and fair values of the Group's financial instruments, other than those with carrying amounts that reasonably approximate to fair values, are as follows:

	Carrying amounts		Fair values	
	2018	2017	**2018**	2017
	RMB'000	RMB'000	**RMB'000**	RMB'000
Financial assets				
Equity investments designated at fair value through other comprehensive income	**1,117**	–	**1,117**	–
Available-for-sale investments	**–**	1,579	**–**	1,579
Financial assets at fair value through profit or loss	**16,348**	–	**16,348**	–
	17,465	1,579	**17,465**	1,579

Management has assessed that the fair values of cash and cash equivalents, pledged deposits, trade and bills receivables, trade payables, financial assets included in prepayments, other receivables and other assets, financial liabilities included in other payables and accruals, and loans from associates approximate to their carrying amounts largely due to the short-term maturities of these instruments.

The Group's finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer and the audit committee. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of unlisted equity investments designated at fair value through other comprehensive income, which were previously classified as available-for-sale equity investments, have been estimated using a asset-based valuation technique based on assumptions that are not supported by observable market prices or rates. The directors believe that the estimated fair values resulting from the valuation technique, which are recorded in the consolidated statement of financial position, and the related changes in fair values, which are recorded in other comprehensive income, are reasonable, and that they were the most appropriate values at the end of the reporting period.

42. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

(Continued)

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 31 December 2018

	Fair value measurement using		
	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
Equity investments designated at fair value through other comprehensive income	–	1,117	1,117
Financial assets at fair value through profit or loss	16,348	–	16,348
	16,348	1,117	17,465

The movements in fair value measurements within Level 3 during the year are as follows:

	2018 RMB'000	2017 RMB'000
Equity investments at fair value through other comprehensive income/available-for-sale investments – unlisted:		
At 1 January	1,579	1,579
Effect of adoption of HKFRS 9	(258)	–
At 1 January (restated)	1,321	1,579
Total losses recognised in other comprehensive income	(204)	–
At 31 December	1,117	1,579

The fair value of the long-term receivables has been calculated by discounting the expected future cash flows using rates currently available for an instrument with a similar term, credit risk and remaining maturity.

There was no fair value measurement hierarchy of the Group's financial instruments in the year of 2017.

43. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The main risks arising from the Group's financial instruments are interest rate risk, foreign currency risk, credit risk, and liquidity risk. The board of directors reviews and agrees policies for managing each of these risk and they are summarised below:

Interest rate risk

In the opinion of the directors, the Group has no significant concentration of interest rate risk.

Foreign currency risk

The Group's businesses are mostly located in the PRC and most transactions are conducted in RMB, except that the Group occasionally purchases equipment and some in-vitro diagnostic reagent products from overseas countries for resale in the PRC and there are administrative expenses incurred by the Canadian subsidiary. A small amount of cash denominated in Hong Kong dollars ("HK$") is placed in bank accounts in Hong Kong for payments of miscellaneous expenses such as professional fees incurred in Hong Kong.

Credit risk

The Group trades only with recognised and creditworthy third parties. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis and the Group's exposure to bad debts is not significant.

43. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES *(Continued)*

Maximum exposure and year-end staging as at 31 December 2018

The table below shows the credit quality and the maximum exposure to credit risk based on the Group's credit policy, which is mainly based on past due information unless other information is available without undue cost or effort, and year-end staging classification as at 31 December 2018. The amounts presented are gross carrying amounts for financial assets and the exposure to credit risk for the financial guarantee contracts.

	12-months ELCs Stage 1 RMB'000	**Lifetime ECLs Simplified approach** RMB'000
Trade and bills receivables*	–	141,685
Financial assets included in prepayments, other receivables and other assets		
– Normal**	169,175	–
– Doubtful**	–	–
Pledged deposits		
– Not yet past due	6,507	–
Cash and cash equivalents		
– Not yet past due	18,207	–
	193,889	141,685

* For trade receivables to which the Group applies simplified approach for impairment, information based on the provision matrix is disclosed in note 23 to the financial statements.

** The credit quality of the financial assets included in prepayments, other receivables and other assets is considered to be "normal" when they are not past due and there is no information indicating that the financial assets had a significant increase in credit risk since initial recognition. Otherwise, the credit quality of the financial assets is considered to be "doubtful".

Maximum exposure as at 31 December 2017

The credit risk of the Group's other financial assets, which comprise cash and bank balances, time deposits and other receivables, arises from default of the counterparty, with a maximum exposure equal to the carrying amounts of these instruments.

43. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES *(Continued)*

Maximum exposure as at 31 December 2017 *(Continued)*

Since the Group trades only with recognised and creditworthy third parties, there is no requirement for collateral. Concentration of credit risk is managed by customer/counterparty, by geographical region and by industry sector. At the end of the reporting period, 62% of the Group's trade and bills receivables were due from the Group's five largest customers. As the Group's major customers are public hospitals, the Group believes that they are reliable and of high credit quality and hence, there is no significant credit risk with these customers. As the Group's exposure is spread over a diversified portfolio of customers, there is no significant concentration of credit risk.

The Group performs ongoing credit evaluations of its customers' financial conditions. The allowance for doubtful debts is based upon a review of the expected collectability of all trade receivables.

The bank balances and time deposits are deposited with creditworthy banks with no recent history of default.

Liquidity risk

The liquidity risk of the Group is primarily dependent on its ability to maintain adequate cash inflow from operations and on its ability to obtain external financing to finance the working capital of the Group.

Financial liabilities of the Group included in current liabilities as at the end of the reporting period either had no fixed terms of repayment or were due for repayment within one year.

The maturity profile of the Group's financial liabilities as at the end of the reporting period, based on the contractual undiscounted payments, is as follows:

	2018					
	On demand RMB'000	Less than 3 months RMB'000	3 to less than 12 months RMB'000	1 to 5 years RMB'000	Over 5 years RMB'000	Total RMB'000
Interest-bearing bank and other borrowings	–	50,186	122,136	33,834	–	206,156
Trade payables	119,274	–	–	–	–	119,274
Financial liabilities included in other payables and accruals	15,708	2,304	–	–	–	18,012
	134,982	52,490	122,136	33,834	–	343,442

43. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES *(Continued)*

Liquidity risk *(Continued)*

	2017					
	On demand RMB'000	Less than 3 months RMB'000	3 to less than 12 months RMB'000	1 to 5 years RMB'000	Over 5 years RMB'000	Total RMB'000
Interest-bearing bank and other borrowings	–	53,939	84,266	17,896	–	156,101
Trade payables	72,914	–	–	–	–	72,914
Financial liabilities included in other payables and accruals	–	5,464	–	–	–	5,464
	72,914	59,403	84,266	17,896	–	234,479

Capital management

The Group's objective for managing capital is to maintain a strong capital base to support the development of its business and maximise shareholders' value. The Group is not subject to any externally imposed capital requirements.

The Group has an annual capital plan which is prepared and approved by the board of directors with the objective of maintaining the optimal amount of capital and debt structure. The Group manages its own capital within the context of the approved annual capital plan, which determines the level of asset growth and the optimal amount and the ratio of capital and debt required to support its planned business growth.

44. EVENTS AFTER THE REPORTING PERIOD

On 13 March 2019, the Company and Beijing Hengxing Huawei Commerce Co., Ltd. ("Beijing Hengxing"), entered into a disposal agreement, pursuant to which, subject to the conditions precedent set out, the Company conditionally agreed to sell and Beijing Hengxing conditionally agreed to purchase 51% equity interest in Zhongke Fund, at a total consideration of RMB56.1 million.

As at the date of the disposal agreement, the Company and Beijing Hengxing owned 51% and 49% equity interest in Zhongke Fund, respectively. The disposal constituted a major disposal for the Company and a connected transaction between the Company and a connected person at the subsidiary level of the Company under Chapter 20 of the HK GEM Listing Rules.

The completion of this disposal is conditional upon the Company having obtained the Shareholders' approval and complied with all compliance requirements under the HK GEM Listing Rules in respect of the disposal agreement and the transactions as contemplated thereunder.

Pursuant to the disposal agreement, Beijing Hengxing shall pay the consideration to the Company in the following manner:

1) 50% of the consideration, which is RMB28.05 million, shall be paid within 30 days from the date of the disposal agreement;

2) 30% of the consideration, which is RMB16.83 million, shall be paid within 180 days from the date of the disposal agreement; and

3) the remaining 20% of the consideration, which is RMB11.22 million shall be paid before 1 November 2019.

The transaction is estimated to be completed within 30 days upon the consideration is fully paid by Beijing Hengxing and that all the necessary registrations with the administration for the industry and commerce in respect of the transfer of Zhongke Fund's interest, amendments to the articles of the association and change of the directors and the senior management of Zhongke Fund have been completed. Upon completion, Zhongke Fund will be 100% held by Beijing Hengxing, and Zhongke Fund and its subsidiaries will cease to be a subsidiary of the Company.

The Company announced this major and connected transaction in the Hong Kong Exchange official website on 13 March 2019.

45. STATEMENT OF FINANCIAL POSITION OF THE COMPANY

Information about the statement of financial position of the Company at the end of the reporting period is as follows:

	2018 RMB'000	2017 RMB'000
NON-CURRENT ASSETS		
Property, plant and equipment	**109,020**	109,512
Prepaid land lease payments	**2,572**	2,653
Other intangible assets	**3,357**	4,132
Investments in subsidiaries	**134,731**	134,731
Investment in a joint venture	**–**	–
Investments in associates	**37,558**	37,558
Available-for-sale investments	**–**	529
Equity investments designated at fair value through other comprehensive income	**227**	–
Long-term receivables	**4,752**	1,359
Deferred tax assets	**1,943**	1,593
Total non-current assets	**294,160**	292,067
CURRENT ASSETS		
Inventories	**39,118**	27,328
Due from subsidiaries	**230,928**	147,089
Trade and bills receivables	**134,044**	122,542
Prepayments, other receivables and other assets	**30,425**	29,790
Cash and cash equivalents	**6,128**	16,581
Total current assets	**440,643**	343,330

45. STATEMENT OF FINANCIAL POSITION OF THE COMPANY *(Continued)*

	2018 RMB'000	2017 RMB'000
CURRENT LIABILITIES		
Due to subsidiaries	**19,416**	13,404
Trade payables	**99,329**	58,859
Other payables and accruals	**45,535**	24,958
Tax payable	**124**	–
Interest-bearing bank and other borrowings	**166,437**	135,142
Total current liabilities	**330,841**	232,363
NET CURRENT ASSETS	**109,802**	110,967
TOTAL ASSETS LESS CURRENT LIABILITIES	**403,962**	403,034
NON-CURRENT LIABILITIES		
Interest-bearing bank and other borrowings	**28,565**	16,067
Deferred income	**5,627**	6,149
Deferred tax liabilities	**5,682**	5,412
Due to subsidiaries	**–**	12,630
Total non-current liabilities	**39,874**	40,258
Net assets	**364,088**	362,776
EQUITY		
Share capital	**144,707**	144,707
Reserves *(Note)*	**219,381**	218,069
Total equity	**364,088**	362,776

Wu Lebin
Director

Chen Jintian
Director

45. STATEMENT OF FINANCIAL POSITION OF THE COMPANY *(Continued)*

Note:

A summary of the Company's reserves is as follows:

	Capital reserve RMB'000	Statutory reserve RMB'000	Fair value reserve RMB'000	Retained profits RMB'000	Total RMB'000
At 1 January 2017	80,486	38,713	–	80,056	199,255
Total comprehensive income for the year	–	–	–	33,285	33,285
Appropriation of statutory reserve	–	1,630	–	(1,630)	–
2016 final dividend declared	–	–	–	(14,471)	(14,471)
At 31 December 2017	80,486	40,343	–	97,240	218,069
At 31 December 2017	80,486	40,343	–	97,240	218,069
Effect of adoption of HKFRS 9	–	–	(158)	–	(158)
At 1 January 2018 (restated)	80,486	40,343	(158)	97,240	217,911
Total comprehensive income for the year	–	–	(99)	16,040	15,941
Appropriation of statutory reserve	–	1,929	–	(1,929)	–
2017 final dividend declared	–	–	–	(14,471)	(14,471)
At 31 December 2018	80,486	42,272	(257)	96,880	219,381

46. APPROVAL OF THE FINANCIAL STATEMENTS

The financial statements were approved and authorised for issue by the board of directors on 19 March 2019.

FIVE YEAR FINANCIAL SUMMARY

A summary of the results and of the assets, liabilities and equity of the Group for the last five financial years, as extracted from the current year's published audited financial statements and annual report for the year ended 31 December 2018, is set out below. This summary does not form part of the audited financial statements.

RESULTS

	Year ended 31 December				
	2018	2017	2016	2015	2014
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
REVENUE	**303,224**	295,128	325,388	290,380	265,331
(LOSS)/PROFIT BEFORE TAX	**(14,547)**	24,824	21,615	3,402	13,842
TAX	**(2,184)**	(3,627)	(4,979)	(1,277)	(3,703)
(LOSS)/PROFIT FOR THE YEAR	**(16,731)**	21,197	16,636	2,125	10,139
ATTRIBUTABLE TO:					
Owners of the parent	**(2,049)**	25,170	15,980	588	8,485
Non-controlling interests	**(14,682)**	(3,973)	656	1,537	1,654
	(16,731)	21,197	16,636	2,125	10,139

ASSETS, LIABILITIES AND EQUITY

	31 December				
	2018	2017	2016	2015	2014
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
TOTAL ASSETS	**776,008**	669,256	597,668	383,037	381,623
TOTAL LIABILITIES	**(411,545)**	(280,973)	(216,125)	(86,912)	(67,858)
NET ASSETS	**364,463**	388,283	381,543	296,125	313,765
REPRESENTED BY:					
EQUITY ATTRIBUTABLE TO:					
OWNERS OF THE PARENT	**301,903**	319,691	308,978	274,753	287,302
NON-CONTROLLING INTERESTS	**62,560**	68,592	72,565	21,372	26,463
TOTAL EQUITY	**364,463**	388,283	381,543	296,125	313,765